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Sleep that knits up the raveled sleave of care,
The death of each day’s life, sore labor’s bath,
Balm of hurt minds, great nature’s second course,
Chief nourisher in life’s feast.












1“Birds do it, bees do it, even educated flees do it…” – Cole Porter
Sleep is an integral part of life.1 Everyone will agree that humans need sleep, judging 
from what happens when you do not get it for a night. Yet, sleep is poorly understood 
compared to other basic things you do every day, such as eating, drinking or breathing. 
We largely lack insight into what brings about sleep, what are its underlying biological 
mechanisms, and why we sleep. Even defining sleep can be difficult and may require 
long, sometimes sleep-inducing descriptions. One definition describes sleep as “a 
recurring, reversible neuro-behavioral state of relative perceptual disengagement from 
and unresponsiveness to the environment, typically accompanied by postural recumbence, 
behavioral quiescence, and closed eyes”.2 Essentially, sleep differs from ‘chilling out’ by 
sensory disconnection that cannot be achieved voluntarily.3 Yet, this neuro-behavioral 
state, in which nothing much seems to be happening, involves unique patterns of brain 
activity, and seems preserved across all animal species.1 Assuming that ‘if sleep does not 
serve an absolutely vital function, it is the biggest mistake evolution ever made’ (Allan Re-
chtschaffen, University of Chicago Sleep Laboratory, Smithsonian Institute, 1978), sleep 
research is thus empowered. Answers to questions on the mechanisms and functions 
of sleep will surely provide essential biological insights into one of the key behavioral 
experiences of everyday life. These insights are especially relevant to learn about sleep’s 
role in health and disease.
As sleep is primarily ‘by the brain, for the brain’,4 its role in brain health and disorders 
is specifically interesting. Neurodegenerative diseases in the aged, such as Alzheimer’s 
disease, other forms of dementia, and Parkinson’s disease are common and highly 
burdensome diseases.5-7 The societal impact of these diseases, in terms of healthy years 
lost and healthcare costs, is enormous.8,9 Treatment aimed at modifying these diseases 
are currently thought ineffective as too much brain damage has already accumulated 
by the time recognizable symptoms emerge. This helped fuel the search for factors that 
identify the disease earlier, or that causally contribute to its development or progression. 
In the search for such factors, sleep has gained increasing attention.10-13 Recent studies 
into the ‘nightlife’ of neurons and astrocytes have helped understand the potential 
functions of sleep, most of which are highly relevant to the study of neurodegenerative 
processes and diseases. Non-mutually exclusive hypotheses on sleep’s function include 
the synaptic homeostasis hypothesis,14,15 which states that sleep ‘is the price the brain 
pays for synaptic plasticity’.3 During wakefulness, synapses – the connections that allow 
neurons to communicate – are on average strengthened while the brain is continuously 
processing information, or learning.3 Information from experiences is continuously ma-
terialized in synaptic strength, and sleep allows going offline from the environment to 
reduce synaptic strength, sorting out the most salient information collected along the 
way. This reduction also decreases expenditure of cellular supplies and energy on costly 
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synapses.3 Another hypothesis posits that sleep is necessary for ‘housekeeping’ in the 
brain, as it drives fluid exchange in the brain which circulates signaling molecules and 
clears metabolic waste.16-18
Both aforementioned hypotheses imply that disturbed sleep, if severe or chronic 
enough, may harm the brain by dysfunction of aforementioned homeostatic pro-
cesses. Importantly, these processes overlap with the key pathological features found 
in neurodegenerative diseases in the aged, e.g. synaptic dysfunction19 or a detrimental 
accumulation of proteins.20 Against this background, observing associations of sleep 
disturbances, i.e. sleep disorders or otherwise abnormal sleep, with a higher risk of 
cognitive decline or neurodegenerative diseases in humans suggests an etiological, 
causal role of sleep disturbances.13,21 As sleep disturbances are common in the aged,22 
and have been hypothesized to be modifiable,11,23 this supposed causal relation may 
harbor a large preventive potential for these conditions. It is therefore important we try 
to further substantiate the etiological role of sleep disturbances in these diseases.
This thesis is rooted in epidemiology,24 a scientific discipline concerned with quan-
tifying (biomedical) relations through comparing groups of individuals, aimed at 
controlling health problems.25 Its principles and methods are applied by many if not all 
researchers in the biomedical field seeking to answer causal questions. This thesis uses 
observational data from the population-based, prospective Rotterdam Study cohort of 
middle-aged and elderly individuals, designed to investigate risk factors of common 
chronic diseases. The Rotterdam Study focuses among others on neurodegenerative 
diseases such as dementia, including Alzheimer’s disease, and Parkinson’s disease. 
Study participants routinely undergo measurements relevant to these conditions such 
as cognitive tests, locomotor screening, blood sampling or a brain MRI. Also, virtually all 
participants consented to provide access to their medical records, allowing continuous 
ascertainment of any neurodegenerative diseases for which any care was given. The 
study incorporated sleep measurements since 2002 and leverages over a decade of 
follow-up for neurodegenerative disease.
The aim of this thesis is to investigate the etiological role of sleep in neurodegenera-
tive diseases, specifically dementia and Parkinson’s disease, and related neurobiological 
correlates measures in middle-aged and elderly persons. First, in chapter 2, we describe 
sleep in the general population, using individual-level data from 36 national sleep 
cohorts, as well as objective and subjective sleep data from different countries. We also 
review recent studies investigating the 24-hour activity rhythm in relation to common 
age-related diseases in older adults. The 24-hour activity rhythm is a behavioral reflec-
tion of functioning of the circadian timing system, a key determinant of the sleep-wake 
cycle. In chapter 3, we investigate the relation of sleep characteristics with incident 
dementia including Alzheimer’s disease, and Parkinson’s disease. In chapter 4, we inves-
tigate associations of sleep characteristics with related aspects of brain aging: Neuronal 
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1damage indicated by neurofilament light chain in plasma, brain waste clearance indi-cated by the structural appearance of perivascular spaces on brain magnetic resonance 
imaging, and brain functional connectivity measured with resting state functional MRI. 
Lastly, the main discussion in chapter 5 synthesizes results of chapters 2-4, discusses key 
methodological considerations in appraising these findings, and discusses implications 
for current clinical and public health practices, and future research.
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We have 24 hours a day. We sleep 6 hours a day, so that 
gives you still 18 hours. Now there is probably someone 
shaking their head out there, saying “I don’t sleep 6 hours I 
sleep 8 hours!”, right? Well..... just sleep faster!


















2.1 SLEEP CHARACTERISTICS SYSTEMATIC REVIEW AND 
INDIVIDUAL PARTICIPANT META-
ANALYSIS
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The study has three main objectives: 1) to obtain reliable reference charts for sleep dura-
tion; 2) estimate the prevalence of sleep complaints in the general population across the 
lifespan; and 3) to identify risk indicators of poor sleep.
We identified studies identified through systematic literature search in Embase, 
Medline and Web of Science (August 9th 2019), and through personal contacts with 
colleagues in the UK and US. Studies were eligible if published between 2000 and 2017 
with data on sleep characteristics assessed with questionnaires, sampling at least 100 
participants from the general population of the Netherlands. Large population-based 
studies/surveys from UK and US were included for comparisons. For IPD analysis, data 
were obtained for 36 out of 47 eligible studies. Two researchers independently coded 
sleep variables: (time in bed (TIB), sleep duration (Total Sleep Time, TST), sleep efficiency 
(TST/TIB*100)), self/caregiver-reported sleep quality, insomnia symptoms and other 
sleep complaints, as well as socio-demographic characteristics (sex, age, education, 
ethnic origin, employment and partnership status) and health risk indicators (smoking 
and body mass index). All variables were coded following a standardized protocol. For 
comparison, complementary sleep data from the UK Biobank and the National Health 
Interview Survey in the USA were included. Where available, actigraphic sleep estimates 
were obtained using validated algorithms.
We assembled IPD from 200,358 persons (age range 1-100 years, 55% female) from 
the Netherlands, 471,759 persons (40 to 69 years old, 55.5% female) from the UK, and 
409,617 persons (≥18 years, 55.8% female) from the US. Age-specific percentile curves 
for TST demonstrate that overall 24.5% of the studied population slept less than age-
specific recommendations, but only 5.8% slept outside of the “acceptable range” for 
sleep duration. Short sleep duration was most prevalent in teenagers, as 51.5% reported 
TST less than the recommended 8-10 hours and 18% report daytime sleepiness. In 
adults (≥18yrs), poor sleep quality (13.3%) and insomnia symptoms (9.6-19.4%) were 
more prevalent than short sleep duration (6.5% with TST<6 hours). Insomnia symptoms 
were least frequent in 26-to-40-year-olds and most frequent in persons aged >65 years, 
and those spending 9 or more hours in bed. Poor sleep quality was most common in 
those spending <6 hours in bed. Women, persons of non-European origin, overweight 
persons and smokers were more prone to poor sleep. While habitual TST was similar in 
the different countries, insomnia symptoms were between 1.5 to 2.9 times higher in 
USA than in the Netherlands. Women (41+) reported sleeping shorter or less efficient 
than men, which was opposite to actigraphy estimates where women were estimated 
to sleep longer and more efficiently than man, both in the UK and in the Netherlands. 
In conclusion, we provide age- and sex-specific population reference charts for sleep 
duration and efficiency which can be used in research, clinical and preventive in indus-
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trialized countries. More people report poor sleep quality than short sleep duration. 
Thus, whereas most available guidelines address optimal sleep duration, our findings 




Poor sleep is common and increasingly recognized as a potentially modifiable risk factor 
for various physical and mental health problems.1,2 Yet, sleep has received little attention 
from a public health perspective. This may partly be due to the lack of valid descrip-
tions of typical sleep patterns in the general population. Estimating reference ranges for 
sleep duration can help compare an individual’s sleep characteristics with that of men 
or women of the same age in the general population and quantify the prevalence of 
insufficient sleep at a population level.
The widely used sleep duration recommendations issued by the American National 
Sleep Foundation (NSF),3,4 synthesize relevant empirical studies but partly rely on expert 
opinion, thus may differ from data-driven descriptions of sleep in the general popula-
tion.5 In addition, these recommendations target healthy populations, whereas the 
general population represents the continuum between health and disease. It is also 
unclear how the three categories of sleep duration (recommended, acceptable, not 
recommended) relate to sleep quality or other sleep complaints. Ideally, recommenda-
tions for sleep duration in the general population should be described over multiple 
physiologically and clinically relevant aspects, including age, sex, demographics, or 
lifestyle. We described variations in sleep duration and estimated the proportion that 
falls outside of the recommendations, and studied factors related to suboptimal sleep. 
Few epidemiological studies have systematically summarized sleep characteristics in 
the general population. The studies conducted to date have either collected data via 
mobile devices6 or online surveys,7,8 have focused on a particular age group such as 
children9,10 or older adults,11,12 or studied a single sleep problem such as short sleep,13 
long sleep or insomnia.14,15
We summarized available information in the general population by jointly investigat-
ing multiple sleep variables across the lifespan. Importantly, as opposed to previous 
meta-analytical efforts,16-18 also of similar sample sizes,19 we assembled individual par-
ticipant data (IPD) from 200,358 persons aged 1 to 100 years, from 36 population-based 
studies from the Netherlands. This allowed us to explore sleep characteristics in various 
subgroups as well as interrelations between sleep indices. In addition, we compared the 
available estimates with those from two large population-based adult samples from the 
UK (n=498,320) and USA (n=409,617).
This study provides reliable estimates of self-reported sleep duration, sleep timing, 
sleep efficiency, but also perceived sleep quality, insomnia symptoms and other sleep 
complaints (non-restorative sleep, sleepiness, snoring and use of sleep medication) in 
the general population. In order to obtain valuable population percentile curves and 
reference values we described sleep duration, time in bed and sleep efficiency across 
age and sex. We also explored educational level, ethnic origin, partnership and employ-
23
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ment status, as well as BMI and smoking, as potential risk indicators associated with 
these sleep variables. Where data was available, we complemented subjective data with 
objectively estimated sleep variables. Moreover, we evaluated consistency and differ-
ences in sleep parameters across populations from the Netherlands, UK and USA.
METHODS
Search strategy, eligibility and selection criteria
We conducted a systematic literature search to identify population-based cohorts from 
the Netherlands assessing sleep characteristics via questionnaires. We searched Embase, 
Medline Ovid, and Web of Science Core Collection on August 9th 2019 with a search 
strategy developed by a biomedical information specialist (WB; Supplementary Text). 
Inclusion criteria were: i) population-based sample from the Netherlands; ii) inclusion 
of at least 100 participants older than 1 year; iii) assessment of sleep with question-
naires; iv) publication in a peer-reviewed journal after the year 2000. Exclusion criteria 
and steps are outlined in a detailed flowchart (Supplementary Figure 1a and 1b). All 
5,750 identified abstracts were checked for eligibility by two independent reviewers 
(DK and either TSL, YX, MEKV or ID, references were split randomly), after which DK as-
sessed 381 full-text articles for eligibility, and TSL again assessed the excluded articles. 
From 142 publications that met our inclusion criteria, we identified 43 non-overlapping 
study populations. We additionally added 4 studies identified by personal contacts, but 
sought IPD from 47 studies (IPD was not requested from 3 studies that were published 
after data collection had been completed in early 2017), of which 36 agreed (response 
81%). From studies with repeated measurements, the baseline measurement was used 
for this IPD as it comprised the largest sample size.
All studies included in the meta-analysis (Supplementary Table 1) were approved by 
the ethics committee of the local university, institute or organization. Written informed 
consent was obtained in the original studies from all participants or caregivers (see 
publications in Supplementary Table 1). The first and corresponding authors obtained 
legal rights for access to anonymized datasets. This article follows the Preferred Report-
ing Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for Individual 
Patient Data reporting guidelines, Supplementary Text 2.20
To evaluate consistency of sleep characteristics across countries, we included two 
large population-based datasets from adults in the UK Biobank (n=498,320) and the 
National Health Interview Survey (NHIS) from the USA (n=409,617). These samples were 
not meta-analytically pooled with the data from the Netherlands, as this would further 




Patient and Public Involvement
This research is a response to public interest. In April 2015, residents of the Netherlands 
were asked to indicate which scientific questions should be addressed in the next de-
cade. Requests of 11,700 people laid the foundation for the National Science Agenda 
(https://wetenschapsagenda.nl/). Text analysis revealed that attention for sleep-related 
issues was requested 423 times; hence the current research question can be considered 
relevant by the general population. However, participants were not invited to comment 
on the study design or interpretation of the results. Participants did not contribute to 
the writing or editing of this document for readability or accuracy.
Individual Participant Data coding
To maximize internal validity, we harmonized the datasets in a three step procedure: 1) 
we agreed upon definitions for each sleep variable (described in the Coding Steps and 
Protocol, see Supplementary Text), also socio-demographic variables were classified in 
line with Statistics Netherlands21,22; 2) two independent coders (DK and TSL) coded all 
datasets according to the standardized protocol (reliability statistics reported in Coding 
Steps and Protocol); and 3) coding disagreements were resolved by consensus super-
vised by a senior sleep researcher (HT). 
Sleep variables
We distinguished the following 10 sleep variables:
- Time in bed (TIB, hours) was calculated as the difference between bedtime and wake 
up time in hours, for weekdays and weekends separately. Bedtimes between 12:00 
and 17:00, and wake up times between 17:00 and 02:00 were excluded (N=97). 
- Sleep duration (Total Sleep Time, TST, hours) was self- or caregiver-reported, values 
≤2h or ≥20h were excluded (N=81). 
- Sleep efficiency (SE, %) was calculated as (TST/TIB)*100. Note that TST and bedtimes 
and wake times were assessed separately, which may result in implausible values, 
e.g. TST of 7.5, and TIB between 11pm and 7am results in implausible SE, but likely 
represents high SE. To balance bias in estimates with loss of precision: values be-
tween 100% and 110% were recoded to 100% (mainly errors in reporting times, 
n=7,630, 8.8%), values above 110% were excluded (n=2,597, 2.9%, most from the 
largest cohort, Lifelines Study).
- Daytime napping was defined as reporting ‘regularly’ or ‘frequently’ sleeping ≥30min 
during the day (yes/no). 
- Insomnia symptoms (yes/no) included difficulty initiating sleep (DIS), defined as 
trouble falling asleep (≥30 minutes); difficulty maintaining sleep (DMS), defined as 
trouble falling asleep again after nocturnal awakening; and early morning awaken-
ing (EMA), defined as waking up earlier than desired and not being able to fall asleep 
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anymore. Insomnia symptoms were present if symptoms were reported to occur 
often, frequently, or ≥3 times per week.23 
- Sleep medication was defined as the reported use of any medication to aid sleep at 
least once a week (yes/no). 
- Non-restorative sleep was defined as not feeling rested when waking up in the morn-
ing, reported at least ‘often’ or ≥3 times per week (yes/no). 
- Sleepiness was defined as ‘feeling sleepy’ during the day, reported at least ‘often’ or ≥3 
times per week (yes/no).
- Snoring was present if snoring was reported at least once a week (yes/no).
- Poor sleep quality was present if any questions on how individuals perceived or 
judged their habitual sleep were answered with “bad”, “unsatisfactory”, “insufficient”, 
or similar qualifications (yes/no).
Socio-demographic variables
Ethnic origin was based on self-report on the country of birth of the participant and his/
her parent24 and categorized into European origin - Dutch, European origin – other, and 
non-European origin.22 Educational level was based on self-reported highest education 
and categorized into low (lower vocational training, or ≤3 years at general secondary), 
medium (>3 years general secondary school, intermediate vocational training or first 
year of higher vocational training), or high (university degree, higher vocational train-
ing).21 Having paid employment and having a partner (including non-cohabiting) were 
self-reported and classified as yes/no. 
Health risk indicators and lifestyle variables
Smoking was self-reported and categorized into: never, former, or current smoker. BMI 
(kg/m2) was calculated based on self-reported or measured weight and height. BMI from 
18.5 kg/m2 to 25 kg/m2 was defined as normal weight. Underweight was defined as BMI 
below 18.5kg/m2, overweight as BMI above 25 kg/m2 and obese above 30 kg/m2. These 
variables were only defined for adults.
Complementary objective sleep estimates
In two cohorts from the Netherlands, subjective sleep reports were collected simul-
taneously with sleep diaries and actigraphy. In the Generation R Study children aged 
10-15 years (n=1386) wore Geneactiv watches during 9 days.25 In the Rotterdam Study 
participants aged 45-98 years (n=1940) wore Actigraphy watches during 7 days.26 
Actigraphic sleep variables were estimated with validated algorithms. Actigraphy and 
diary sleep estimates were averaged across days. The actigraphic sleep variables were 




To evaluate consistency across countries, the IPD analyses were complemented by data 
from international cohorts. First, the UK Biobank (UKBB) (www.ukbiobank.ac.uk) is a large 
population-based cohort study aimed at improving prevention, diagnosis and treat-
ments of various illnesses. Between 2006 and 2010, approximately 9.2 million people 
aged 40-69 years were invited. Second, US data were obtained from the National Health 
Interview Survey (NHIS, https://www.cdc.gov/sleep), harmonized by Integrated Public 
Use Microdata Series (https://nhis.ipums.org/nhis/), a nationally representative survey 
of non-institutionalized American adults surveyed annually (2004-2017). We included 
adults aged 18-84 years with non-missing responses for the respective sleep measures.
In the UKBB, adults reported on TST by answering the question “About how many hours 
sleep do you get in every 24 hours? (please include naps)”. We excluded participants re-
porting usual daytime napping from the UKBB (n=26,561). NHIS participants answered 
the question “On average, how many hours of sleep do you get in a 24-hour period?”, with 
responses in hour increments. Symptoms of insomnia in the UKBB were assessed by the 
question: “Do you have trouble falling asleep at night or do you wake up in the middle of the 
night?”, which did not map on any of our individual insomnia constructs, thus was not 
further analyzed. NHIS participants reported DIS and DMS using two questions: “In the 
past week, how many times did you have trouble falling asleep?” and ”In the past week, how 
many times did you have trouble staying asleep?”, respectively. Participants that reported 
having these symptoms “usually” in the UKBB, and “≥3 times per week” in the NHIS were 
coded as “yes”. These estimates were compared to the pooled IPD meta-analysis sample. 
Statistical analyses
We explored whether the population in the meta-analysis was representative of the 
general population of the Netherlands by comparing the distributions of age, sex, and 
education with the last Dutch Census in 2011.28 For descriptive purposes, we pooled the 
data across studies, with different studies contributing data for different sleep variables, 
according to what data had been collected. 
First, age and sex specific means and prevalence of sleep variables were computed 
based on systematically coded variables to reduce between-study heterogeneity (see 
Coding Protocol in Supplementary Text). Age categories were aligned to those of NSF: 
toddlers (1-2 years), preschoolers (3-5 years), school-aged children (6-13 years), teenag-
ers (14-17 years), young adults (18-25 years), adults (26-40 years), middle-aged adults 
(41-64 years), and older adults (65+ years). 
Second, variations in TST, SE, and TIB were plotted using age-specific percentiles (10th, 
25th, 50th, 75th, and 90th). To facilitate comparison, TST was also plotted against the NSF 
sleep duration recommendations: 11-14h for toddlers, 10-13 hours for preschoolers, 
9-11 hours for school-aged children, 8-10 hours for teenagers, 7-9 hours for adults 26-64 
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years old, and 7-8 hours for older adults.3 To explore detailed age-related changes in TST, 
SE and TIB we also estimated percentile curves against continuous age between 1 and 
100 years using gamlss R package. 
Third, we examined associations of sleep duration, sleep efficiency and insomnia 
symptoms with socio-demographic and health indicators using one step approach. 
We used linear mixed models, with a random intercept for each study to account for 
between study heterogeneity. The random effects for study were significant in all mod-
els. In these analyses, we only included participants aged 18 years and older as sleep 
characteristics change rapidly during childhood and adolescence.9 Three models were 
constructed: a “demographic determinants model” where we studied the association of 
mutually adjusted age (continuous), sex, educational level and ethnic origin with sleep 
variables, a “social determinants model” where we studied the association of employ-
ment status and partnership on sleep variables adjusted for demographic determinants, 
and a “health indicators model” where we studied the association of smoking and BMI 
with sleep variables adjusted for demographic determinants. 
As more sophisticated imputation methods cannot account for within-study cluster-
ing, missing values on age (0.3%) were imputed with the study-specific mean, and a 
missing category was used to account for missing values in categorical variables (educa-
tion=0.6%, ethnic origin=26.6, employment=7.4%, partner=62.2%, smoking=15.0%, 
BMI=13.3%). Ethnicity was not assessed in 8 studies, whereas of the studies in adult 
populations five did not assess employment and three did not assess smoking. 
Missing or implausible values on sleep variables were not imputed. Data were ana-
lyzed using SPSS Statistics, version 21 (IBM Corp., Armonk, NY) and R version 3.4.1.
RESULTS
We included 34 studies, identified by systematic review, including 200,358 participants 
from the Netherlands between the age of 1 and 100 years. Additionally, 471,759 persons 
(40 to 69 years old, 55.5% female) from the UK, and 409,617 persons (≥18 years, 55.8% 
female) from the US were included. Population characteristics of the studies identified 
in the systematic review are presented in Supplementary Table 1. Compared to data of 
the 2011 Dutch Census,28 females in age groups between 10 to 80 years were slightly 
over-represented (ranging from a 1% to 9% difference). 
Persons in both the high (29.9% vs, 29.0%, p=0.013) and the middle (37.3% vs. 34.4%, 
p<0.001) educational level were slightly overrepresented in our sample, compared to 
the population described in the Dutch Census of 2011. Study specific sleep estimates are 
provided in Supplementary Table 2.
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Time in bed, sleep duration and sleep efficiency
Adults (≥18 years) reported a mean±SD TIB of 7.8±0.9 hours, a TST of 7.1±1.0 hours, 
and a SE of 89±9% (Table 1). Short sleep duration (TST<6 hours) was reported by 6.5% 
of this population, whereas 25.8% reported a TST of <7 hours. Population percentile 
curves of TST and SE across age categories defined by NSF recommendations are shown 
in Figure 1, and in Supplementary Figure 2 for age (continuous). Although 24.5% of the 
population sleeps less than the recommended sleep duration for age, only 5.6% fall 
outside of the “acceptable” ranges (see Supplementary Table 3). More than half (51.5%) 
of 14-to-17-year-olds reported sleeping less than recommended 8-10 hours per night; 
those in the 25th percentile sleep 54 minutes less, whereas those in the 10th percentile 
sleep 96 minutes less than recommended. In all other age groups, even the 5% and 95% 
percentile groups, sleep duration was in the “acceptable range” as defined by the NSF 
3. SE decreases from mean±SD= 97±5% in childhood to 91±8% in teenage years. This 
SE decline continues into adulthood, however 25% of >65-year-olds reported sleeping 
over 95% of their TIB.
Sex difference were observed from adulthood onwards (Table 1). Adult women re-
ported a longer TST (B=0.14 hours, 95%CI: 0.18;0.21, p<0.001), but a marginally lower SE 
(B=-0.02%, 95%CI: -0.03;-0.02, p<0.001) than men (Supplementary Table 4). For example, 
women between 41 and 65 years of age sleep on average 7.1±1.1 hours, whereas at the 
same age men sleep on average 6.9±1.0 hours per night. However, the women sleep 
89±10% of the TIB, whereas men sleep 92±9% of the TIB. From about 14 years onwards, 
the between-person variation in TIB increases substantially, more so for men than for 
women (Figure 2). Sex-specific TIB percentiles using age (continuous) are shown in 
Supplementary Figure 3. From 14 years onwards bedtime is gradually delayed, whereas 
wake time remains stable around 7:00h across the lifespan (Figure 3). Poor sleep quality 
is most prevalent in persons (≥18 years) spending <6 hours in bed, whereas difficulty 
initiating sleep is most commonly reported by those spending ≥9 hours in bed (Figure 
4). 
We found that TIB is longer on weekend days than on weekdays only for age groups 
that go to school or work. In young children and older adults, the TIB on week- and 
weekend days is roughly equal. The weekday-weekend difference increases as children 
start going to school (median difference of 30 minutes), peaks in teenagers (median 
difference of 75 minutes), and is around 60 minutes in working adults. 
Daytime Napping
As expected, most children nap in the first 3 years (80% of 1-2 year-olds, 65% of 3 years-
old). Napping is less common during school age (12.7% of 6-13 year-olds nap) and 
adulthood (13.7% of people between 26 and 64 years nap regularly), than in persons 
aged >65 years (27%).
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Table 1. Time in bed, total sleep time and sleep efficiency, stratified by age and sex
Strata by age and 
sex
Time in bed, hours Total sleep time, hours Sleep efficiency, %
20 studies (198-2013) 15 Studies 1993 to 2015 15 Studies 2002 to 2013
N Mean ± SD N Mean ± SD N Mean ± SD
1-2 years
Total 3,240 11.7 ± 0.72 - - - -
Male 1,594 11.6 ± 0.73 - - - -
Female 1,646 11.7 ± 0.70 - - - -
3-5 years
Total 6,421 11.5 ± 0.6 1,266 11.6 ±0.6 1,183 99 ± 2
Male 3,241 11.4 ± 0.6 653 11.5 ± 0.6 604 99 ± 2
Female 3,180 11.5 ± 0.6 613 11.6 ± 0.6 579 99 ± 3
6-13 years
Total 18,905 10.8 ± 0.9 8,377 10.6 ± 1.0 6,931 97 ± 5
Male 9,477 10.7 ± 0.8 4,185 10.5 ± 0.9 3,461 97 ± 5
Female 9,420 10.8 ± 0.9 4,189 10.6 ± 1.1 3,468 97 ± 5
14-17 years
Total 3,747 8.8 ± 0.8 513 7.7 ± 1.1 509 91 ± 8
Male 1,745 8.7 ± 0.8 189 7.9 ± 1.0 186 92 ± 7
Female 2,000 8.8 ± 0.8 324 7.6 ± 1.1 323 91 ± 8
18-25 years
Total 1,174 8.3 ± 1.2 5,192 7.5 ± 1.1 - -
Male 588 8.0 ± 1.2 2,049 7.4 ± 1.1 - -
Female 606 8.5 ± 1.1 3,143 7.6 ± 1.0 - -
26-40 years
Total 23,896 8.0 ± 0.9 38,635 7.2 ± 0.9 21,204 89 ± 9
Male 9,938 7.7 ± 0.9 16,182 7.1 ± 0.9 8,678 90±8
Female 13,931 8.1 ± 0.8 22,453 7.3 ± 1.0 12,526 89±10
41-65 years
Total 51,086 7.8 ± 0.9 93,837 7.0 ± 1.1 49,513 90 ± 10
Male 21,235 7.5 ± 0.9 40,603 6.9 ± 1.0 20,570 92 ± 9
Female 29,851 7.9 ± 0.9 53,234 7.1 ± 1.1 28,943 89 ± 10
65+ years
Total 5,480 7.9 ± 1.1 8,195 7.0 ± 1.3 4,922 88 ± 13
Male 2,288 7.9 ± 1.1 3,504 7.2 ± 1.2 2,021 90 ± 11































































































































































































































































































Symptoms of insomnia increase from childhood (3 to 5 year-olds: 4% DIS, 6% DMS) into 
adolescence (6-13 year-olds: 13% DIS, 9% DMS). In adulthood, insomnia symptoms are 
least frequent in 26 to 40-year-olds and most frequent in >65-year-olds. DIS is most 
prevalent in 18 to 25-year-olds (22.6%), whereas DMS (23.2%) and EMA (23.5%) are most 
prevalent in the >65-year-olds. Sex difference in insomnia symptoms become evident 
only in puberty (i.e. for 14 to 17 year olds, Males vs. Females: 12% vs. 19% DIS, 16% vs. 
28% DMS). In adults, women are at increased odds for DIS (OR=2.26, 95% CI 2.16;2.36), 
DMS (OR=2.05, 95% CI 1.91;2.19), or EMA (OR=1.49, 95% CI 1.37;1.62; Supplementary 
Table 5) compared to men after adjusting for demographic factors.
Figure 3. Nighttime sleep timing across the lifespan (N=106,282)
Figure 4. Prevalence of having difficulty initiating sleep (N=95,603) and ‘poor’ sleep quality (N=77,854), 
across different durations of time in bed
Note: Data on both difficulty maintaining sleep and early morning awakenings and time in bed were not 
available
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Table 2. Prevalence of insomnia symptoms, stratified by age and sex
Strata by age
and sex
Difficulty initiating sleep Difficulty maintaining sleep Early morning awakenings
22 studies (1997-2015) 15 studies (1998-2015) 9 studie (1997-2015)
N % N % N %
1-2 years
Total 1,336 4.5 - - - -
Male 655 4.9 - - - -
Female 681 4.1 - - - -
3-5 years
Total 5,484 4.0 1,678 6.1 ND ND
Male 2,778 4.2 834 6.6 ND ND
Female 2,704 3.8 844 5.7 ND ND
6-13 years
Total 13,227 13.2 7,210 9.1 ND ND
Male 6,697 12.3 3,601 7.9 ND ND
Female 6,570 14.0 3,602 10.2 ND ND
14-17 years
Total 1,631 16.5 1,175 23.2 - -
Male 719 12.9 501 16.8 - -
Female 910 19.3 672 28.1 - -
18-25 years
Total 2,227 22.6 1,961 9.4 2,023 10.3
Male 969 19.4 856 8.6 892 9.2
Female 1,252 25.1 1,105 10.0 1,131 11.2
26-40 years
Total 26,264 7.2 3,795 11.3 1,636 14.1
Male 10,850 5.5 1,550 7.4 722 12.0
Female 15,413 8.3 2,244 13.9 913 15.7
41-65 years
Total 73,648 9.3 19,056 15.7 8,417 21.0
Male 31,637 5.4 8,640 10.5 3,904 17.5
Female 41,975 12.3 10,416 20.1 4,513 24.0
65+ years
Total 8,869 14.9 3,255 20.2 3,376 23.5
Male 3,841 8.0 1,527 14.5 1,579 18.3
Female 5,028 20.2 1,728 25.3 1,797 28.0
Note: Prevalence rates were not calculated if <200 participants in a cell. Abbreviations: ND=Not defined if 




Sleepiness is most prevalent in teenagers (20.4%; Supplementary Table 6). Although 
there are no clear sex difference in sleepiness, non-restorative sleep is more prevalent in 
women than in men. Women also use sleep medication more often (8.6% vs. 5.2% in 26 
to 40-year-olds, to 17.5% vs. 6.3% in >65-year-olds). Snoring is more commonly reported 
in adult men than in women (40.2% vs. 23.2%), although this difference becomes less 
pronounced at older ages (Supplementary Table 6).
Associations of socio-demographics with sleep characteristics in adults
Adults with a low educational level did not differ in TST (B=-0.01 hours, 95%CI -0.02;0.00, 
p=0.191) compared to highly educated adults, but reported a slightly lower SE (B=-
0.01%, 95% CI -0.03;-0.00, p<0.001). In addition, persons with a non-European ethnic 
origin sleep shorter (B=-0.30 hours, 95%CI: -0.34;-0.30, p <0.001), and less efficiently 
(B=-0.03%, 95%CI: -0.03;-0.02, p<0.001) compared to persons with Dutch ethnic origin. 
Similarly, both low education and non-European ethnic origin were risk indicators for 
insomnia symptoms (Supplementary Table 5). Having paid employment and a partner 
were both associated with longer sleep duration and less insomnia symptoms, indepen-
dent of demographics (Supplementary Table 4 & 5). 
Association of health risk indicators with sleep characteristics in adults
In adults, we observed shorter TST for overweight (2.4 minutes, 95% CI: 3.6;1.8) and 
obese persons (6.6 minutes, 95% CI: 7.2; 5.4), compared to persons with normal weight. 
Obese, but not overweight persons, had a marginally lower SE (B=-0.004%, 95%CI: -0.01; 
-0.00) and experienced more DIS (OR=1.08, 95%CI: 1.02; 1.17; Supplementary Table 4). 
Both former and current smokers reported sleeping shorter relative to non-smokers, 
and current smokers also reported a lower SE. Current smokers experienced more DIS, 
but experienced less DMS (Supplementary Table 5). 
Complementing subjective with objective sleep data
TIB and TST were between 0.4-1.9 hours shorter when estimated with actigraphy as 
compared to sleep diary reports of the same nights (Supplementary Table 7). Similarly, 
actigraphic SE estimates were lower compared to diary estimates, averaging to 9.7±7% 
difference in the Generation R sample, and 9.6±9% difference in the Rotterdam Study 
sample. The sleep diary SE estimates were also lower than those computed from the 
pooled IPD, except for the group of teenagers where SE based on pooled IPD was esti-
mated to be 91±8%, as compared to 95.6±4% estimated by sleep diary. 
According to actigraphic TST estimates, more than 80% of the population, sleeps less 
than the US recommendations (Supplementary Table 8). The proportion of persons 
sleeping less than the “acceptable” TST ranged between 16.3%-38.7% in the pediatric 
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cohort, and between 9.4%-47.3% in the older adults, as measured with actigraphy. 
Actigraphic sleep parameters of the adults from the Netherlands were compared with 
respective values from adults in the UK (Supplementary Table 9). Both TIB and TST were 
≥1 hour longer in the UK cohort regardless of age and sex, however SE differences were 
small (1.6% to 2.1%). Women (41+ years) reported sleeping shorter and/or less efficiently 
than men both in sleep diaries and sleep questionnaires, whereas actigraphy estimates 
indicate the opposite: women sleep longer and slightly more efficiently than men of 
similar age (Supplementary Table 7). This was also found in the UKBB cohort.
International comparisons
Average self-reported TST as well as sex difference in TST were similar in the adult 
Dutch, UK and US populations (Supplement Table 10). The proportion adults reporting 
TST shorter than recommended for age was the highest in the US (30.3%), compared 
to 24.5% in the Netherlands, and 25.0% in the UK. The proportion of adults sleeping 
less than the “acceptable” values were below 10% in all three countries. The prevalence 
of insomnia symptoms (Supplementary Table 11) was 1.5 to 2.9 times higher in the US 
sample (for DIS and DMS, across adult ages with the exception of 18-25 year olds) than 
in the Netherlands. Sex and age differences in insomnia symptoms were similar across 
populations: DIS reduced and DMS increased with advanced age, whereas women 
reported insomnia symptoms more commonly irrespective of age. 
DISCUSSION
Our results suggest that: i) the population of the Netherlands reported sleeping within 
“acceptable” sleep duration range at all ages, but more than half of teenagers slept 
almost an hour less than recommendations; ii) actigraphic sleep duration and efficiency 
are consistently lower than self-reported estimates, which limits the applicability of 
current recommendations to objective sleep variables, iii) insomnia symptoms were 
least frequent in 26 to 40-year-olds and most frequent in persons aged >65 years, and 
those spending 9 or more hours in bed; iv) self-reported TST did not differ substantially 
between adults from the Netherlands and from the UK and US, but insomnia symptoms 
were 1.5 to 2.9 times more prevalent in the US than in the Netherlands, v) poor sleep 
quality and insomnia symptoms were more prevalent than short sleep duration; vi) 
women, persons of non-European origin, overweight persons and smokers were par-




Our study is the largest descriptive sleep study to date. However, several methodologi-
cal issues must be discussed. First, variables such as sleep timing and duration may be 
more objectively assessed with actigraphy or polysomnography.29,30 However, subjec-
tive complaints are clinically relevant, and highly related to daily functioning. Moreover, 
the implementation of measures such as polysomnography in large-scale population-
based studies is currently limited. In this study we were able to complement subjective 
data with objective sleep parameters in teenagers and older adults. These are the two 
age groups with the highest prevalence of insufficient sleep duration. Sleep duration 
estimates differ by method of assessment, but habitual sleep duration is reasonably 
stable within individuals.31,32 Thus, the inter-individual differences in sleep duration can 
reliably be compared when assessed with the same method only. Moreover, absolute 
numbers should be interpreted with caution because age or reporter could influence 
sleep estimates (e.g. parents may underreport their children’s sleep onset latency and 
wake time during the night, resulting in higher SE estimates). Second, heterogeneity 
between studies could have introduced misclassification bias (e.g. different definitions 
of bedtimes and wake times can influence TIB estimates). However, access to IPD im-
proves data quality through standardization of definitions. Third, we could not assess 
how our estimates, and differences between meta-analyzed studies, were influenced 
by underlying sleep disorders (e.g. sleep apnea), psychiatric disorders, chronic medical 
conditions, or environmental or occupational factors such as screen exposure, noise, 
and shift work. Fourth, although we studied a representative large population sample 
of the Netherlands, and compared sleep estimates to other populations from developed 
countries, findings may not be generalizable to populations with different sociodemo-
graphic or cultural characteristics. These international comparisons were possible for 
some sleep parameters only. However, all studies sampled participants from the general 
population, which reduces the chance of selection bias, and increases the interpretabil-
ity of the comparisons. Fifth, multivariable adjusted models indicated that the reported 
differences in sleep patterns across socio-demographic groups were small, thus their 
clinical implications may be limited.
Comparison with other studies
In our study, 25% of the adult population reported sleeping less than the recommended 
7-9 hours, whereas the Centers for Disease Control and Prevention has estimated up to 
44.1% of the US population aged ≥18 years slept less than 7-9 hours.33 We showed that 
the average self-reported sleep duration does not differ between the Netherlands, US 
and UK, but the prevalence of sleeping below the recommended TST was higher in the 
USA population (30%), than in the European populations (24-25%). We also showed that 
the recommendations are only applicable to subjective sleep reports. Specifically, 80% 
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of participants above 40 years, have an actigraphic TST less than the “recommended” 7 
hours TST. It is important to note that a portion of this population still falls within the 
“acceptable” range of 6 to 11 hours developed by the NSF expert panel.3,4 The pooled IPD 
data show that 6.8% of the adult population report sleeping less than the “acceptable” 6 
hours, but this increased to 25% at an older age. Using actigraphic TST estimates up to 
47% adults were estimated to sleep less than the “acceptable” values. 
Based on an online questionnaire, Kerkhof has reported a higher percentage (30.4%) 
of <6 hours of sleep in an adult population from the Netherlands.7 Studies included in 
our meta-analysis have shown that participants aged 18-65 years old sleeping both less 
than 6 hours34 and less than 7 hours35 per night have higher cardiovascular risk as com-
pared to those sleeping 7 to 8 hours per night. A Time Use Survey Panel in industrialized 
countries in Europe and North America36 has also shown that older adults sleeping <7 
hours have lower self-reported health, although the “acceptable” sleep duration for this 
age group can be as short as 5 hours per night. It thus remains unclear what the ap-
propriate amount of self-reported sleep duration is for preserving health, and reference 
values for objective sleep duration are merely unknown. 
Despite the premise that ‘optimal’ sleep duration likely differs per outcome, individual 
and circumstances, providing reference values for sleep length can be useful in clinical 
or prevention practice. This way it is possible to estimate the extent of the problem (i.e. 
the proportion that falls outside of recommended values) which could guide public 
health policies for improving sleep in the general population. Therefore, we estimated 
sleep duration percentile curves, which to date have been estimated only in children 
and adolescents.9,10,37 Healthcare professionals can easily assess sleep characteristics by 
interviews or questionnaires, but with increased use of accelerometers in research and 
daily settings, reference curves for actigraphic sleep variables should also be estimated. 
Several previous observational studies have estimated the prevalence of insomnia in 
European populations.7,11,14,15,38 Our study estimates (7 to 23% depending on insomnia 
symptom and age group) largely correspond with those reported in telephone inter-
views by 25,579 persons from seven European countries in the 90’s.14 The prevalence of 
DIS and DMS in the Netherlands, however, was substantially lower than in the US. Our 
study, adds age-specific information on the prevalence of insomnia symptoms across the 
lifespan, and shows which insomnia symptoms are most common in each age group. We 
also show that these age related changes in insomnia symptoms are similar in the USA. 
This information could be used to improve sleep on a population level, i.e. young adults 
would likely benefit from interventions tackling difficulty initiating sleep, whereas older 
adults might need help with sleep maintenance or early morning awakenings. We also 
show that spending 7 to 8 hours in bed is associated with better sleep quality and fewest 
insomnia symptoms, similar to a general-population study in Norwich, UK.11 
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In line with previous reports based on smaller samples, we found using pooled IPD 
data that women report longer sleep duration but lower sleep efficiency.7,11 For example, 
a 28-year-old woman reporting to spend 9 hours in bed is in the 90th percentile of the 
female population of similar age, whereas, a 28-year-old man with the same TIB, would 
be in the 95th percentile of the male population of similar age. When measured with 
actigraphy, however, women’s sleep was slightly longer and more efficient than that 
of men in the Netherlands and in the UK. Women experience more insomnia problems 
than men in all three countries. This commonly reported difference7,14,38,39 emerges 
during puberty, suggesting sex hormones, among other social factors such as stress or 
parenting, might play a role in the development of insomnia problems. Interestingly, 
women do not report daytime sleepiness more often, despite experiencing more insom-
nia problems and using more sleep medication than men. 
Relevance of the study
The estimated population reference charts for sleep timing, sleep duration and ef-
ficiency across the lifespan, will help guide personalized advice on sleep. However, 
current recommendations are applicable only to self-reported average sleep duration. 
Given that poor sleep (i.e. low sleep quality or insomnia symptoms) is more common 
than short sleep (i.e. TST below “acceptable” values) in Europe and in the US, recom-
mendations for improving sleep might need to focus on sleep quality. Importantly, 
we identified subgroups that are prone to short or inefficient sleep, such as teenagers, 
women, persons of non-European origin, obese and smokers. These population strata 
could be used as sampling schemes when developing interventions to improve sleep at 
a population level. We also show that the lowest prevalence of poor sleep in the general 
population occurs in those spending 7 to 8 hours in bed. This finding, taken together 
with the relatively high prevalence of poor sleep despite close to appropriate sleep du-
ration, warrants towards defining new targets for sleep hygiene advice. In other words, 
by recommending optimal sleep duration we are unlikely to accomplish better sleep at 
a population level.
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SUPPLEMENTARy MATERIAL 



























5,750 publications screened  
381 publications eligible 
for full-text assessment 
5,932 publications identified (August 9th 
2019): 
 Embase: 4,272 
 Medline Ovid: 3,254 
 Web of Science: 982 
2,758 duplicate 
publications 
5,369 publications excluded 
after screening title and 
abstract screening 
239 publications excluded: 
 Not conducted in the Netherlands (n=101) 
 No descriptive sleep data (n=46) 
 Exposed or disordered populations (n=30) 
 Conducted in students (n=4) 
 Selected healthy (n=1) 
 RCT (n=1) 
 Web-based (n=7) 
 Case-control studies (n=23) 
 Published before the year 2000 (n=8) 
 Conducted in clinical populations (n=7) 
 Occupational studies in companies (n=5) 
 Sample size <100 (n=4) 
 Conducted in children below 1 year old (n=2) 
142 publications eligible 73+26 publications excluded 
due to multiple publications 
from same study 
43 studies identified with 
systematic review 

























8 did not provide individual participant data: 
 2: data not property of the author 
 1: high costs for use of data 
 1: no response 
 4: difficult communication 
36 studies contribute to 
individual participant 
meta-analysis 
43 studies identified 
through systematic review 
4 studies identified through 
personal contacts 
44 studies for which IPD was sought 
3 eligible studies for which 
IPD was NOT sought 
Supplementary Figure 1b. Flowchart of individual participant data (IPD) attainment
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(sleep/de OR ‘sleep medicine’/de OR ‘night sleep’/de OR ‘nonREM sleep’/de OR ‘REM sleep’/de OR ‘sleep pattern’/
de OR ‘sleep quality’/de OR ‘sleep stage’/de OR ‘sleep time’/de OR ‘sleep waking cycle’/de OR ‘slow wave sleep’/
de OR ‘sleep induction’/de OR ‘circadian rhythm’/de OR wakefulness/de OR insomnia/de OR ‘sleep disorder’/
de OR ‘sleep parameters’/de OR ‘sleep deprivation’/de OR ‘polysomnography’/de OR ((sleep* NEAR/10 (night 
OR nonrem OR rem OR pattern* OR qualit* OR quantit* OR stage* OR time OR cycle* OR induc* OR registrat* 
OR measure* OR habit* OR distur* OR durat* OR architect* OR consolidate* OR parameter* OR disrupt* OR 
efficien* OR nocturn* OR medicat* OR drug* OR assess* OR lack OR problem* OR poor)) OR ((circadian* OR 
diurnal* OR ultradian* OR Nyctohemer*) NEAR/3 rhythm*) OR wakeful* OR insomnia* OR Dyssomnia* OR 
polysomnogra*):ab,ti) AND (Netherlands/de OR (Netherland* OR dutch*):ab,ti,ca,ta,cy,ad) AND (‘cohort analysis’/
de OR ‘longitudinal study’/de OR ‘population research’/de OR population/de OR ‘epidemiological data’/de OR 
‘prospective study’/de OR ‘retrospective study’/de OR prevalence/de OR questionnaire/de OR psychometry/de 
OR (cohort* OR longitudinal* OR prospectiv* OR retrospective* OR (population NEAR/3 (general* OR based* OR 
research* OR healthy)) OR (epidemiolog* NEAR/3 data) OR prevalen* OR questionnaire* OR psychometr*):ab,ti) 
NOT ([animals]/lim NOT [humans]/lim) NOT (hospital/exp OR ‘hospital care’/exp OR (hospital* OR ‘intensive 
care’ OR ward OR icu ):ab,ti) NOT ((‘disorders of higher cerebral function’/exp OR (patient* OR case*):ab,ti) NOT 
(‘controlled study’/exp OR (control* OR group*):ab,ti)) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/
lim OR [Editorial]/lim)
2. Medline ovid
(exp Sleep/ OR “Sleep Medicine Specialty”/ OR exp “Sleep Wake Disorders”/ OR “Circadian Rhythm”/ OR 
wakefulness/ OR Polysomnography/ OR ((sleep* ADJ10 (night OR nonrem OR rem OR pattern* OR qualit* 
OR quantit* OR stage* OR time OR cycle* OR induc* OR registrat* OR measure* OR habit* OR distur* OR 
durat* OR architect* OR consolidate* OR parameter* OR disrupt* OR efficien* OR nocturn* OR medicat* OR 
drug* OR assess* OR lack OR problem* OR poor)) OR ((circadian* OR diurnal* OR ultradian* OR Nyctohemer*) 
ADJ3 rhythm*) OR wakeful* OR insomnia* OR Dyssomnia* OR polysomnogra*).ab,ti.) AND (Netherlands/ OR 
(Netherland* OR dutch*).ab,ti,jn,cp,in.) AND (exp “Cohort Studies”/ OR population/ OR “Epidemiologic Studies”/ 
OR prevalence/ OR questionnaires/ OR Psychometrics/ OR (cohort* OR longitudinal* OR prospectiv* OR 
retrospective* OR (population ADJ3 (general* OR based* OR research* OR healthy)) OR (epidemiolog* ADJ3 data) 
OR prevalen* OR questionnaire* OR psychometr*).ab,ti.) NOT (exp animals/ NOT humans/) NOT (exp hospitals/ 
OR exp “Hospital Units”/ OR (hospital* OR “intensive care” OR ward OR icu ).ab,ti.) NOT ((exp “Mental Disorders”/ 
OR (patient* OR case*).ab,ti.) NOT (exp “Controlled Clinical Trial”/ OR (control* OR group*).ab,ti.)) NOT (letter OR 
news OR comment OR editorial OR congresses OR abstracts).pt.
3. Web of science
TS=((((sleep* NEAR/10 (night OR nonrem OR rem OR pattern* OR qualit* OR quantit* OR stage* OR time OR 
cycle* OR induc* OR registrat* OR measure* OR habit* OR distur* OR durat* OR architect* OR consolidate* OR 
parameter* OR disrupt* OR efficien* OR nocturn* OR medicat* OR drug* OR assess* OR lack OR problem* OR 
poor)) OR ((circadian* OR diurnal* OR ultradian* OR Nyctohemer*) NEAR/2 rhythm*) OR wakeful* OR insomnia* 
OR Dyssomnia* OR polysomnogra*)) AND ((cohort* OR longitudinal* OR prospectiv* OR retrospective* OR 
(population NEAR/2 (general* OR based* OR research* OR healthy)) OR (epidemiolog* NEAR/2 data) OR 
prevalen* OR questionnaire* OR psychometr*)) NOT ((animal* OR rat OR rats OR mouse OR mice OR murine) NOT 
(human*)) NOT ((hospital* OR “intensive care” OR ward OR icu )) NOT (((patient* OR case*)) NOT ((control* OR 
group*)))) AND DT=(article) AND (TS=((Netherland* OR dutch*)) OR AD=((Netherland* OR dutch*))
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Coding steps and protocol
First, the sleep constructs were defined based on expert knowledge and exploration of 
the datasets included in our study. Two raters (D.K. and T.S.L.) coded all datasets in two 
phases. We first trained using the coding protocol on datasets from three adult cohorts 
(Rotterdam Study, NEMESIS, LASA) and three pediatric cohorts (Generation R, ChecKid, 
PIAMA), for which interrater performance was monitored and calculated by a third 
rater (M.P.C.M.L.). Agreement on the selection of variables measuring a certain construct 
(sleep characteristic) over these 6 cohorts was excellent (kappa coefficient 0.83). Inter-
rater reliability of the coded values (e.g. recoding categories) per construct was good 
to excellent (for continuous/ordinal variable: median intraclass correlation coefficient 
1.00 [interquartile range=0.92-1.00]; for nominal variables: median kappa coefficient 
1.00 [interquartile range 0.52-1.00], median percentage of agreement 88% [interquartile 
range=75-98%]). Consensus for disagreements on which constructs to code, and how to 
code them, was achieved by discussion and final decision of a third rater. No changes to 
the coding protocol were made after training.
Interrater reliability of coding in the next phase was further assessed for 25 random 
cohorts. Agreement on which constructs to code in this stage was excellent (kappa 
coefficient= 0.98). Disagreement of how the agreed-upon constructs had to be coded 
(74 out of 475) were discussed between raters after coding all datasets. Consensus was 




original variables provided by the cohorts.
•	 Keep	the	original	question	in	the	variable	label.
•	 Try	to	code	each	construct	using	one,	best	fitting	variable	that	measures	this	symp-






	 ü Variable name sex_studyname
	 ü Variable labels 0=“male”, 1=”female”
2. Age: exact age in years
	 ü Variable name age_studyname
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3. Ethnic origin is based on country of birth indicator or self-report
  o Dutch
  o European origin – other (e.g. other European, USA, Canada, Australia)
  o  non-European origin (e.g. Dutch Antilles, Suriname, Turkey, Morocco, Indone-
sia, Ghana)
*Children’s ethnic origin can be based on parent’s country of birth:
	 	 	 Ø If one parent is Dutch, the child is Dutch.
	 	 	 Ø If two parents are of non-Dutch origin, the ethnicity of the mother is used.
	 ü Variable name ethnicity_studyname
	 ü Variable labels 0=“Dutch”, 1=”other Western”, 2=” nonWestern”
4. Education will be based on the highest educational level finished for persons (>18 
years old) or parents (persons <18 years old). The categorization is:
  o High: university degree, higher vocational training
  o  Medium: more than 3 years general secondary school, intermediate voca-
tional training or first year of higher vocational training
  o  Low: no education, primary school, lower vocational training, intermediate 
general school or 3 years or less at general secondary school
	 ü Variable name education_studyname
	 ü Variable labels 0=“high”, 1=”medium”, 2=”low”
5. Employment: does the participant have a paid job (yes/no).
	 ü Variable name employment_studyname
	 ü Variable labels 0=“no”, 1=”yes”
Sleep variables
1. TST: self- or caregiver-reported hours of sleep.
  o Minutes are coded as decimals.
  o  When reported in categories, we will code it as numerical values to the closest 
quarter-hour.
  o Values ≤2h or ≥20h are considered implausible and are excluded
	 ü Variable name: TST_studyname
2. Clock bedtime: scheduled/usual time to go to bed.
  o Code it as a numerical value where minutes are coded as decimals.
  o  When bedtime is reported in categories, we will code it as numerical values to 
the closest quarter-hour.
  o  Values <17:00h and >12:00h are considered implausible, and are excluded. 
Add 24 to values after midnight (e.g. 1AM=25h).
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  o When weekend and weekday data is available, reports for weekdays are used.
  o Code a separate variable for weekend times (BedtimeWE_studyname).
	 ü Variable name: Bedtime_studyname
	 ü Variable name: BedtimeWE_studyname
3. Wake up time: scheduled/usual wake up time
  o Code it as a numerical value where minutes are coded as decimals.
  o  When wake time is reported in categories, we will code it as numerical values 
to the closest quarter-hour.
  o  Values before 01:00 and after 17:00 are considered implausible, and are ex-
cluded.
  o When weekend and weekday data is available, reports for weekdays are used.
a. Code a separate variable for weekend times
	 ü Variable name: Waketime_studyname
	 ü Variable name: WaketimeWE_studyname
4. TIB: time between usual bedtime and wake up time
  o Numerical value in hours.
  o  When reported in categories, we will code it as numerical values to the closest 
quarter-hour.
  o When weekend and weekday data is available, reports for weekdays are used.
  o Code a separate variable for the weekend times.
	 ü Variable name: TIB_studyname
	 ü Variable name: TIBwe_studyname
5. Daytime napping: sleeping during the day
	 •	 Adults:
  - Does the participant usually nap (no/yes)?
  - Regular napping for ≥30min per day.
  - Frequent napping
   ü Variable name: Nap_studyname: 0=“no”, 1=”yes”
6. Sleep consolidation: nighttime awakenings (yes/no)
  - YES= “Frequently”/”Often”/” ≥3x per week” awakes at night
  - YES= ≥2x awakening/night (>2x/night for children below 6 years old)
   ü Variable name: AWAKE_studyname
   ü Variable label “AWAKE_studyname”: 0=“no”, 1=”yes”
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Insomnia
A) Presence of insomnia symptoms: These symptoms will be coded as yes/no. Frequen-
cy-coded answer categories will fall into yes if the symptom occurs often/frequently/≥3 
times per week.
 1. Difficulty initiating sleep: difficulty falling asleep
  ü Variable name: INS1_studyname,
  ü Variable label “INS1_studyname”: 0=“no”, 1=”yes”
 2.  Difficulty maintaining sleep: Participant wakes up at night and has trouble going 
back to sleep (e.g. “Last month problems waking up at night and not going back 
to sleep”, “Regulary waking up and cannot go back to sleep”)
  ü Variable name: INS2_studyname
  ü Variable label “INS2_studyname”: 0=“no”, 1=”yes”
 3. Early morning awakenings
  ü Variable name: INS3_studyname
  ü Variable label “INS3_studyname”: 0=“no”, 1=”yes”
Other sleep quality
1. “Poor quality”: Question, or answer categories, containing words like: “quality”, “satis-
faction”, “good”, “bad”, or an opinion on sleep otherwise.
	 	 ü Variable name: SQbad_studyname
	 	 ü Variable label: SQbad_studyname”: 0=“no”, 1=”yes”
2. Non-Restorative sleep, “yes” indicates “non-restorative” sleep, e.g.:
 o Get enough sleep to feel rested upon waking in the morning (code reversed)
 o Feel non-rested after a normal night
 o Needs long in the morning to wake up
 o Not rested when waking up
	 	 ü Variable name: rest_studyname
	 	 ü Variable label: rest_studyname”: 0=“no”, 1=”yes”
3. Feeling sleepy during the day
 o  How often during the past month did you have difficulty staying awake during 
car rides, eating or social activities?
 o Sleepy during watching television
 o Feel drowsy or sleepy during the day
	 	 ü Variable name: sleepy_studyname
	 	 ü Variable label: sleepy_studyname”: 0=“no”, 1=”yes”
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4. Habitual snoring: Snore=1 is considered if the participant snores at least once a week. 
Here we are more lenient on coding ‘yes’ if the frequency of snoring is described over 
a different time frame (e.g. sometimes=yes)
	 	 ü Variable name: Snore_studyname
	 	 ü Variable label: Snore_studyname”: 0=“no”, 1=”yes”
5. Sleep medication: A user (Med=1) is considered if the participant uses sleep medica-
tion at least once a week. Here we are more lenient on coding ‘yes’ if the frequency of 
medication use is described over a different time frame (e.g. sometimes=yes)
	 	 ü Variable name: MED_studyname
Variable label: MED_studyname”: 0=“no”, 1=”yes
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Supplementary Table 3. Sleep duration according to recommendations








1-2 yrs 9 11-14 hrs - - 9-16 hrs - -
3-5 yrs 1,266 10-13 hrs 1.0 0.1 8-14 hrs 0 0
6-13 yrs 8,377 9-11 hrs 5.4 24.3 7-12 hrs 0.6 1.3
14-17 yrs 513 8-10 hrs 51.5 0.4 7-11 hrs 17.9 0
18-25 yrs 5,192 7-9 hrs 14.3 3.1 6-11 hrs 2.8 0.3
26-40 yrs 38,635 7-9 hrs 20.1 0.7 6-10 hrs 3.7 0.1
41-64 yrs 93,837 7-9 hrs 27.8 0.8 6-10 hrs 7.1 0.1
>65 yrs 8,195 7-8 hrs 35.4 10.6 5-9 hrs 4.7 2.0
Total 156,025 - 24.5 2.6 - 5.6 0.2
Note: Recommended and acceptable durations were derived from the US National Sleep Foundation 
(Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation’s updated sleep duration recommen-
dations: final report. Sleep Health. 2015;1(4):233-243).
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Supplementary Table 4. Determinants of sleep duration and sleep efficiency in persons ≥18 years old
Self-reported sleep duration, hrs Sleep efficiency, %
N=145,858 from 11 studies N=75,752 from 5 studies
B 95% CI P B 95% CI P
Demographic determinants model
Age, years -0.01 -0.0008;-0.007 <0.001 0.0003 -0.0001;-0.0004 <0,001
Sex
Male reference reference
Female 0.14 0.18; 0.21 <0.001 -0.02 -0.03;-0.02 <0.001
Education
High reference reference
Middle -0.02 -0.04; -0,01 0.001 -0.001 -0.003;-0.001 0.207
Low -0.01 -0.02; 0.004 0.191 -0.01 -0.03;-0.003 <0.001
Ethnic origin
European origin - Dutch reference reference
European origin - other -0.07 -0.12;-0.03 0.001 -0.01 -0.01;0.001 0.022




No 0.24 0.23;0.25 <0.001 -0.02 -0.03;-0.02 <0,001
Has a partner
Yes reference reference
No -0.06 -0.08;-0.05 <0.001 -0.01 -0.03;-0.02 0.005
Health risk indicators model
BMI
Underweight 0.08 -0.02;0.14 0.010 -0.01 -0.02;-0.01 0.002
Normal weight reference reference
Overweight -0.04 -0.06;-0.03 0.002 -0.001 -0.003;-0.001 0.229
Obese -0.11 -0.12;-0.09 <0.001 -0.004 -0.01;-0.002 <0.001
Smoking
nonsmoker reference reference
former smoker -0.03 -0.04;-0.02 <0.001 -0.003 -0.01;-0.001 <0.001
current smoker -0.06 -0.07;-0.04 <0.001 -0.001 -0.004;0.0001 0.078
Note: All estimates are adjusted for age, sex, education and ethnic origin. Betas are estimated using a linear 
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N=108,447 from 15 
studies
N=28,051 from 11 studies N=15,436 from 8 studies
OR 95% CI P OR 95% CI P OR 95% CI P
Demographic determinants model
Age 1.01 1.01;1.01 <0.001 1.02 1.01;1.02 <0.001 1.02 1.01;1.02 <0.001
Sex
Male Reference Reference Reference
Female 2.26 2.16;2.36 <0.001 2.05 1.91;2.19 <0.001 1.49 1.37;1.62 <0.001
Education
High Reference Reference Reference
Middle 1.38 1.31;1.46 <0.001 1.07 0.99;1.17 0.077 1.10 0.99;1.23 0.069
Low 2.01 1.90;2.13 <0.001 1.32 1.21;1.44 <0.001 1.30 1.37;1.75 <0.001
Origin/ethnicity
European origin - Dutch Reference Reference Reference
European origin - other 1.37 1.21;2.56 <0.001 1.17 1.003;1.37 0.045 1.24 0.92;1.66 0.160
Non-European origin 1.75 1.53;2.02 <0.001 1.35 1.12;1.63 0.002 1.09 0.87;1.37 0.436
Social determinants model, additionally adjusted
Employment
Yes Reference Reference Reference
No 1.77 1.68;1.86 <0.001 1.22 1.13;1.33 <0.001 1.01 0.91;1.14 0.801
Partner
Yes Reference Reference Reference
No 1.37 1.24;1.51 <0.001 1.11 0.98;1.24 0.078 1.20 1.09;1.32 <0.001
Health risk indicators model
BMI
Underweight 1.47 1.14;1.90 0.003 1.53 0.86;2.70 0.144 1.14 0.72;1.81 0.587
Normal weight Reference Reference Reference
Overweight 0.97 0.92;1.02 0.281 0.97 0.85;1.09 0.598 1.02 0.93;1.13 0.610
Obese 1.09 1.02;1.17 0.008 1.01 0.86;1.17 0.981 1.13 0.99;1.29 0.056
Smoking
Non-smoker Reference Reference Reference
Former smoker 1.03 0.97;1.09 0.289 1.02 0.91;1.16 0.671 1.11 1.01;1.23 0.036
Smoker 1.32 1.25;1.41 <0.001 0.79 0.66;0.95 0.012 0.95 0.82;1.11 0.511
Note: Odds ratios are estimated using a linear mixed model adjusted for age, sex, education and ethnic 
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6-13 yrs 900 9-11 hrs 98.1 0 18.1 1.6 7-12 hrs 16.3 0 0.4 0.2
14-17 yrs 486 8-10 hrs 87.7 0.6 24.2 2.8 7-11 hrs 38.7 0.6 3.7 0.2
41-64 yrs 93,837 7-9 hrs 89.2 0.1 54.7 1.2 6-10 hrs 47.3 0 14.7 0.2
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Supplementary Table 10. International comparisons of total sleep time, stratified by age and sex
Strata by age 
and sex







N Mean ± SD N Mean ± SD N Mean ± SD
18-25 years
Total 5,192 7.5 ± 1.1 - - 47,123 7.3 ± 1.4
Male 2,049 7.4 ± 1.1 - - 22,034 7.3 ± 1.3
Female 3,143 7.6 ± 1.0 - - 25,089 7.3 ± 1.4
26-40 years
Total 38,635 7.2 ± 0.9 - - 108,332 7.0 ± 1.3
Male 16,182 7.1 ± 0.9 - - 48,561 6.9 ± 1.2
Female 22,453 7.3 ± 1.0 - - 59,771 7.1 ± 1.3
41-64 years
Total 93,837 7.0 ± 1.1 405,331 7.1 ± 1.1 164,834 6.9 ± 1.4
Male 40,603 6.9 ± 1.0 178,456 7.0 ± 1.0 75,666 6.9 ± 1.3
Female 53,234 7.1 ± 1.1 226,875 7.1 ± 1.1 89,168 7.0 ± 1.4
≥65 years
Total 8,195 7.0 ± 1.3 66,428 7.3 ± 1.1 89,328 7.5 ± 1.6
Male 3,504 7.2 ± 1.2 31,593 7.4 ± 1.1 36,109 7.6 ± 1.6
Female 4,691 6.8 ± 1.4 34,835 7.2 ± 1.2 53,219 7.4 ± 1.6
Note: Prevalence was not calculated if <200 participants in a cell. Abbreviations: N=sample size; SD=standard 
deviation, NHIS=National Health Interview Survey
*only persons that did not report to take naps ‘usually’ were selected
Supplementary Table 11. International comparisons of the prevalence of insomnia symptoms, stratified 
by age and sex











N % N % N % N %
18-25 years
Total 2,227 22.6 17,107 20.6 1,961 9.4 17,100 16.3
Male 969 19.4 8,238 16.6 856 8.6 8,235 11.4
Female 1,252 25.1 8,869 24.2 1,105 10.0 8,865 20.9
26-40 years
Total 26,264 7.2 39,605 21.1 3,795 11.3 39,595 22.9
Male 10,850 5.5 17,811 17.3 1,550 7.4 17,801 17.9
Female 15,413 8.3 21,794 24.2 2,244 13.9 21,794 27.1
41-64 years
Total 73,648 9.3 63,299 23.1 19,056 15.7 63,265 32.3
Male 31,637 5.4 29,368 18.4 8,640 10.5 29,353 27.8
Female 41,975 12.3 33,931 27.2 10,416 20.1 33,912 36.3
≥65 years
Total 8,869 14.9 39,679 18.1 3,255 20.2 39,640 29.9
Male 3,841 8.0 16,392 14.1 1,527 14.5 16,380 28.3
Female 5,028 20.2 23,287 21.0 1,728 25.3 23,260 31.1
Note: Prevalence rates were not calculated if <200 participants in a cell. Abbreviations: ND=not defined if 
















Circadian rhythms, including 24-hour activity rhythms, change with age. Disturbances 
in these 24-hour activity rhythm at older age have also been implied in various diseases. 
This review evaluates recent findings on 24-hour activity rhythms and disease in older 
adults.
Growing evidence supports that 24-hour activity rhythm disturbances at older age are 
related to the presence and/or progression of disease. Longitudinal and genetic work 
even suggests a potential causal contribution of disturbed 24-hour activity rhythms 
to disease development. Interventional studies targeting circadian and 24-hour activ-
ity rhythms demonstrate that 24-hour rhythmicity can be improved, but the effect of 
improving 24-hour rhythmicity on disease risk or progression remains to be shown.
Increasing evidence suggests 24-hour activity rhythms are involved in age-related 
diseases. Further studies are needed to assess causality, underlying mechanisms, and 
the effects of treating disturbed 24-hour activity rhythms on age-related disease.
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INTRODUCTION
The circadian rhythm is integral to physiological processes throughout the body.1 These 
approximately 24-hour rhythms are regulated by the master clock located in the brain’s 
suprachiasmatic nucleus (SCN),2 and are shaped using endogenous and exogenous cues. 
Together, this ensures that our physiological functioning can be optimized and adapted 
to changing environmental conditions and social demands.3 Circadian rhythms can be 
observed in a range of physiological and behavioral processes throughout the body, for 
example fluctuations in clock gene expression, hormone levels, body temperature, and 
cognitive processes.1 Although many of these fluctuations are valid and precise markers 
of the circadian rhythm, they are often less feasible to study when the circadian rhythm 
needs to be assessed over longer periods of time or in large populations. An accessible, 
affordable and unobtrusive alternative to measure 24-hour rhythmicity is actigraphy, 
also known as accelerometry. Actigraphy can measure activity continuously over mul-
tiple days, weeks or even months. Naturally, activity is under voluntary control and may 
therefore misrepresent some of the underlying endogenous rhythms. Yet, measuring 
24-hour activity rhythms with actigraphy has been demonstrated to be a valid method 
to estimate circadian rhythmicity, in both patients as well as healthy adults.1,4 With ever 
increasing recording quality, better storage capacities, longer recording lengths, and 
the availability of open source algorithms, actigraphy has become a mainstay for study-
ing circadian rhythms in research and clinical practice.5,6
Circadian rhythms, and associated 24-hour activity rhythms, are altered with increasing 
age.1,7 Older age is also accompanied by an increase in the prevalence of non-communi-
cable diseases.8 It has been hypothesized that changes in 24-hour activity rhythms might 
indicate poor health or even pose a risk factor for poor health, not the least because 
fragmented 24-hour activity rhythms have been associated with an increased risk of 
mortality.9 As modern 24/7 society puts a widespread strain on our rhythms, for example 
through artificial lighting and shift work, it is crucial to better understand the role of 
24-hour activity rhythm disturbance in the development of age-related disease. In this 
review, we will briefly discuss the measurement of 24-hour activity rhythms, give a short 
overview of age-related changes in 24-hour activity rhythms, and discuss recent findings 
around 24-hour activity rhythms and some of the most common diseases in older adults.
MEASURING THE 24-HOUR ACTIVITy RHyTHM
A range of scientific grade actigraphs, typically worn around the wrist, has become 
available over the past decades. Starting with relatively simple devices measuring activ-
ity on one axis, nowadays almost all actigraphs measure movement on three axes and 
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are equipped with additional sensors measuring temperature, light and/or heart rate. 
Typically, only the activity data has been used to estimate the 24-hour rhythm. Multiple 
commercial wearables that measure activity have also become available, their value in 
assessing 24-hour activity rhythms remains to be determined.10
Several methods have been developed to derive 24-hour rhythmicity estimates from 
actigraphy,4,11,12 the most used methods are based on adapted cosinor models4,11 and 
non-parametric models.12 From these models a range of 24-hour activity rhythms es-
timates is calculated, which are correlated to some extent.13 Both methods come with 
their own set of advantages and disadvantages. For example, non-parametric measures 
have been suggested to better reflect 24-hour rhythms in elderly persons, because 
rhythms are generally less cosine shaped in older adults.12 In contrast, cosinor measures 
seem to be associated more consistently with outcomes such as cognitive functioning.14 
A description of the most commonly used cosinor and non-parametric estimates can be 
found in Table 1.
24-HOUR ACTIVITy RHyTHMS AND AGING
Old age is accompanied by multiple changes in the 24-hour activity rhythm, including a 
well-described phase advance.13 In recent work a lower amplitude, lower mesor, earlier 
acrophase, and more fragmented rhythm have been described in older adults.6,9,15-17 
Daytime activity levels are also lower at old age,18 but nighttime activity levels do not 
necessarily change in old age.19 The stability of the 24-hour activity rhythm seems to 
remain similar across ages,16 and has even been suggested to be higher in old age.20 A 
recent study in 91,105 individuals suggested that age was not associated with relative 
Table 1. Commonly used cosinor and non-parametric 24-hour activity rhythm estimates.4,11,12
Variable Explanation
Cosinor
Acrophase Timing of maximum activity (clock time)
Amplitude Difference between maximum and minimum value of activity (score)
Mesor Average activity (counts/min)
Period Time interval over which cycles repeat (hours)
Pseudo-F Fit of activity data to the cosine function, indicating rhythm ‘robustness’ (score)
Non-parametric
Interdaily Variability Fragmentation of the rhythm relative to its 24-h amplitude (score)
Intradaily Stability Stability of activity profiles over days (score)
Relative Amplitude Normalized difference between most active 10 hours and least active 5 hours (score)
M10 onset Onset of most active 10-hour period (clock time)
L5 onset Onset of least active 5-hour period (clock time)
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amplitude,21 but this study only included persons aged 73 or younger. This fits previous 
suggestions that 24-hour activity rhythm disturbances are most pronounced in those 
aged 80 years or older.9,16
Older and more recent studies thus both demonstrate that middle-aged and elderly 
persons have ‘dampened’ and less robust 24-hour activity rhythms,6 similar to altera-
tions seen in endogenous measures of the circadian rhythm at older age.1 It is largely 
unknown to what extent these changes may be attributed to the aging process per se. 
They could also be caused by environmental changes that accompany older age, such 
as retirement, less physical activity, or the emergence of age-related diseases. Probably, 
a combination of endogenous and exogenous factors play a role in age-related changes 
in the 24-hour activity rhythm.1
24-HOUR ACTIVITy RHyTHMS AND NEURODEGENERATIVE DISEASE
Over the last 3 years neurodegenerative disease has been the most studied disease in 
relation to 24-hour activity rhythms. Indeed, circadian disturbances, including disrupted 
24-hour activity rhythms, are common in neurodegenerative disease.5,22,23 These distur-
bances are potentially attributable to neurodegenerative processes directly affecting 
circadian regulatory circuits,2,24 or indirectly through behavioral symptoms impairing 
daily functioning and inadequate exposure to exogenous cues. Vice versa, disturbed 
circadian rhythms have also been hypothesized to contribute to neurodegenerative 
processes.5 In the next paragraphs, we will focus on recent findings on the role of 24-
hour activity rhythm disturbances in Alzheimer’s disease and other dementias, and 
Parkinson’s disease.
Alzheimer’s disease and Dementia
Dementia, of which Alzheimer’s disease is the most common subtype, is characterized 
by progressive cognitive decline and impairment in activities of daily living.25 Disrup-
tions of 24-hour activity rhythms in these patients were first recorded over two decades 
ago,26 and have been reviewed recently.5,14,27 These disruptions predominantly include 
fragmentation and a reduced amplitude of the 24-hour activity rhythm, and behaviors 
such as ‘sun-downing’27 and frequent daytime napping.28 Recent cross-sectional studies 
report a lower amplitude,28-30 a lower stability,29-31 and more fragmentation29 in patients 
with dementia. More fragmented 24-hour activity rhythms were also found in persons 
with early-onset dementia.32 Together these disturbances substantially impair quality of 
life of patients and caregivers33,34 and are thought to be an important determinant for 
the institutionalization of patients.27
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Research increasingly focuses on the pre-diagnostic phase of dementia to investigate 
the potential etiological or predictive role that 24-hour activity rhythm disturbances 
may have in dementia. Two recent studies investigated persons with potential prodro-
mal symptoms of dementia, but no evidence was found for an association of phase with 
subjective cognitive complaints35 or of amplitude with mild cognitive impairment.30 
This was even though the latter was found to be disturbed in those with Alzheimer’s 
disease.30 In contrast, some earlier studies have reported a phase advance in persons 
with mild cognitive impairment compared to healthy controls36,37 and a higher fragmen-
tation and lower mesor in those with preclinical AD.16 Data from prospective cohorts 
provide some further insight into the temporality of the association of 24-hour activity 
rhythms with dementia. An advanced acrophase was associated with an increased risk 
of cognitive decline in elderly men,15 whereas in elderly women a phase delay and lower 
robustness of the rhythm were associated with an increased risk of dementia and mild 
cognitive impairment.38 A higher fragmentation was also related with a decline in cogni-
tion measured over the prior 12 years.39
Associations of 24-hour activity rhythms with biomarkers of neurodegeneration in 
non-demented individuals have been investigated to shed further light on the link 
between 24-hour activity rhythms and dementia. First, fragmentation was most strongly 
related to a cerebrospinal fluid biomarker profile indicative of Alzheimer’s disease, when 
compared to other disturbances.16 Additionally, fragmentation was related to temporal 
lobe atrophy in cognitively unimpaired persons29 and to loss of gray matter in parietal 
regions specific to early accumulation of Alzheimer’s pathology.39 Further research re-
mains needed to determine whether 24-hour activity rhythm estimates could also serve 
as a valid biomarker for dementia.
Parkinson’s disease
In Parkinson’s disease, which has a notable association with REM sleep behavior disor-
der,5 24-hour activity rhythms disturbances have been hypothesized to occur early in 
the disease process and to potentially contribute to various symptoms and pathological 
processes specific to Parkinson’s disease.40 Patients have a higher fragmentation, lower 
stability, lower amplitude, and lower mesor than healthy controls.40-42 A low stability is 
also associated with poorer cognitive performance in Parkinson’s disease.42 It is unclear 
to what extent the 24-hour activity rhythm estimates are affected by impaired motor 
functioning associated with the Parkinson’s disease diagnosis or dopaminergic treat-
ments for Parkinson’s disease.5
The longitudinal relation of 24-hour activity rhythms with incident Parkinson’s dis-
ease has received limited attention so far, but a recent study with 11 years of follow-up 
showed that daytime actigraphy-estimated inactivity, indicative of ‘napping’, was associ-
ated with increased risk of Parkinson’s disease.43 Longitudinal studies assessing 24-hour 
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activity rhythms in relation to Parkinson’s disease in particular, and neurodegenerative 
disease more broadly, are therefore highly needed.
24-HOUR ACTIVITy RHyTHMS AND LATE-LIFE PSyCHIATRIC DISEASE
Disturbances in 24-hour activity rhythms are related to a range of psychiatric disorders 
such as depression, anxiety, psychosis and schizophrenia,44,45 of which some are also 
common in old age. Depression is of specific interest in the context of this review as a 
second peak in the prevalence of depression starts around the age of 60 years. Depres-
sion, characterized by a depressed mood or a loss of pleasure as a key symptom, and ad-
ditionally symptoms such as weight change, changes in sleep, psychomotor agitation/ 
retardation, fatigue, worthlessness, cognitive complaints or suicidality,46 has a major 
impact on global health.47
Depression
Patients diagnosed with Major Depressive Disorder have a tendency to eveningness, 
delayed 24-hour activity rhythms, a dampened amplitude and a lower mesor.17,48-51 
Disturbed 24-hour activity rhythms are also related with the severity of depressive 
symptoms, even when symptoms are of a subclinical level, which is common in elderly 
persons. A cross-sectional population-based study of middle-aged and elderly persons 
found an association of a lower stability and higher fragmentation of the 24-hour ac-
tivity rhythm with more depressive symptoms.20,52 A preference for eveningness and a 
phase delay were also associated with severity of depressive symptoms.53,54 Potentially, 
the association of 24-hour activity rhythms and depressive symptoms differs between 
men and women; in one study associations of disturbed 24-hour activity rhythms with 
depressive symptoms were found in men but not in women.55
Increasing evidence supports that disturbances in the 24-hour activity rhythm are 
not only apparent during the depressive episode, but might also precede depressive 
episodes or may persist afterwards.49 A recent UK biobank study suggested a lower 
relative amplitude in those with a retrospectively determined lifetime incidence of 
major depressive disorder, bipolar disorder and mood instability.21 A longitudinal study 
in elderly men reported that both a late acrophase alone and the combination of an 
early acrophase with a dampened 24-hour activity rhythm amplitude were associated 
with a faster increase in depressive symptoms over time.56 Additionally, a Genome-Wide 
Association Study (GWAS) including 71,500 participants reported a possible association 
between genetic risk of a low relative amplitude and mood disorders.45
It remains unclear to what extent associations between disturbances of 24-hour activ-
ity rhythms and mental health are due to medication use.44,57 There is evidence that these 
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associations are independent of medication use,56 but we also know that some 24-hour 
activity rhythm disturbances are related to medication use. For example, eveningness 
and phase delay potentially hamper the efficacy of antidepressants,58,59 and ketamine 
might improve 24-hour activity rhythms, independent of its effect on mood.60
Other psychiatric disorders in late life
Bipolar disorders, in which the depressive episodes are accompanied by manic episodes, 
have also been related to disturbances in the 24-hour activity rhythm. Associations 
seem to be state-dependent, with depressive episodes being accompanied by a phase 
delay and manic episodes being accompanied by a phase advance.61,62 However, the 
disturbances in the 24-hour activity rhythms might not only be a state marker as the 
phase advance of 24-hour activity rhythms and lower mesor may persist after successful 
treatment of bipolar disorder.44
For anxiety, relatively common at older age, it was shown that more fragmented 24-
hour activity rhythms were associated with higher odds of having an anxiety disorder,52 
and that lower activity levels and a lower mesor were associated with current anxiety.48 
Additionally, disrupted 24-hour activity rhythms have also been linked to more suicidal 
behaviors,63,64 but the causality of this association remains to be determined. Although 
actigraphy has been used in patients witch schizophrenia, 24-hour rhythmicity has not 
often been assessed.65 Only one study assessed 24-hour activity rhythms and did not 
find an association of 24-hour rhythm estimates with positive or negative symptoms of 
schizophrenia.66
24-HOUR ACTIVITy RHyTHMS AND OTHER AGE-RELATED DISEASES
Aging is accompanied by an increase in other non-communicable diseases such as type 
2 diabetes, cardiovascular disease, lung disease, and cancer,8 which have also been sug-
gested to involve circadian and 24-hour activity rhythm disturbances.1,50
Cardio-metabolic disease
Cross-sectional studies reported prolonged napping,67 a lower amplitude,68 less sta-
ble,20,68,69 and more fragmented20 24-hour activity rhythms in middle-aged and elderly 
persons with a higher Body Mass Index, a well-known risk factor for cardio-metabolic 
disease. Additionally, less stable 24-hour activity rhythms were associated with increased 
odds of metabolic syndrome and hypertension in elderly women.69 Longitudinal work 
suggests that 24-hour activity rhythm disturbances might already be apparent early on. 
A longitudinal population-based study reported that a lower robustness of the rhythm 
and a lower amplitude were associated with an increased risk of overall cardiovascular 
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disease, and that a lower mesor was associated with an increased risk of coronary heart 
disease.70 It has also been repeatedly shown that shift work is a risk factor for cardio-
metabolic disease, such as type 2 diabetes, obesity and coronary artery disease,50,71,72 the 
24-hour activity rhythm has however not been assessed in these studies. Most of these 
findings have been based on observational studies, making it difficult to determine 
the underlying mechanisms. Experimental studies in humans do however suggest that 
short-term circadian misalignment already affects biomarkers for metabolic disease, 
such as systolic blood pressure and preclinical states of diabetes.73,74
Cancer
Disturbed 24-hour activity rhythms are also seen in those suffering from cancer. A study 
in palliative cancer care reported that 24-hour activity rhythms are more disrupted 
towards the end of life.75 Several recent studies also reported an association between 
24-hour activity rhythm disturbance and cancer-related mortality, most prominently in 
lung cancer patients, where early mortality risks were up to 4 times higher in patients 
with disrupted 24-hour activity rhythms compared to those with robust rhythms.76,77 
More disturbed 24-hour activity rhythms were also associated with a shorter survival 
time in patients suffering from head and neck cancers78 and patients receiving pallia-
tive cancer care.75 Cancer treatment also seems to affect the 24-hour activity rhythm, a 
recent longitudinal study showed that several 24-hour activity rhythm estimates, includ-
ing amplitude, worsen with each cycle of chemotherapy in women with breast cancer.79
RESEARCH AGENDA
Collectively, these studies suggest that with older age, 24-hour activity rhythms are 
dampened, more fragmented, and more advanced. Presence of 24-hour activity rhythm 
disturbances are associated with various age-related diseases. Most evidence is avail-
able for dementia and depression but these have also been the most studied diseases in 
relation to 24-hour activity rhythms. Associations between the 24-hour activity rhythm 
and disease also differ per 24-hour activity rhythm estimate, which creates a complex 
picture. Only a minority of studies has investigated the association of 24-hour activity 
rhythms and health longitudinally, which limits our knowledge on the temporality of 
associations between 24-hour rhythm disturbances and age-related disease. Although 
there is some evidence for a possible causal role of 24-hour activity rhythms in disease 
at old age, more definitive evidence needs to be generated with sophisticated analyses 
methods in prospective cohort studies and intervention studies.
Studies specifically intervening on circadian rhythms that take into account the 
24-hour activity rhythm remain scarce. A number of studies have reported reduced 
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circadian disruption after bright-light therapy in patients with dementia,80 Parkinson’s 
Disease,81 depression,82 cardiovascular disease,83 and cancer.84 However, it is largely 
unknown to what extent intervening on circadian factors and, subsequently 24-hour 
activity rhythms, improves relevant clinical outcomes such as disease progression or 
mortality. So far, we do know that interventions focusing on advancing circadian timing, 
such as early morning bright light therapy have a positive effect on mood. Bright light 
therapy decreases depression severity in depressed patients, and 8 weeks of dawn-dusk 
stimulation improved mood and reduced anxiety in elderly persons living in a care 
home.85 It remains to be determined if improvement in 24-hour activity rhythms is a 
mediating factor.
Together, we feel that three items are essential to add to the research agenda to 
improve our understanding of the role of 24-hour activity rhythms in health at older 
age. First, implementation of actigraphy in prospective cohort studies has not only been 
proven feasible, it is also needed to investigate temporality. It particularly creates a 
unique opportunity if the 24-hour activity rhythm disturbances can be studied before 
the diagnosis of the disease in population-based cohorts. These studies should ideally 
include repeated measurements of both disease-related constructs and actigraphy to 
gain more insight in potentially bi-directional associations. Second, studies have report-
ed successful improvement of circadian rhythms and mental health after interventions 
focused on the 24-hour rhythm, but effects on somatic conditions are largely unclear. 
Well-controlled intervention trials that integrate actigraphy and have longer follow-
up periods will be needed to assess whether treatment of disturbed 24-hour activity 
rhythms can reduce disease burden or even alter disease progression or incidence. This 
could also provide information for any potential preventive effects of targeting 24-hour 
activity rhythm disturbances. Lastly, as new studies become available with high speed, 
well-executed meta-analyses will be needed to direct the field. For this aim, a standard-
ized approach using the same estimates and methods between studies will be highly 
beneficial.
CONCLUSION
The 24-hour activity rhythm is disturbed in a broad range of age-related diseases. In 
neurodegenerative disease, psychiatric disease, cardio-metabolic disease and cancer, 
patients have more phase shifts, lower amplitudes, more fragmented and less stable 24-
hour activity rhythms. An increasing number of longitudinal studies suggest that these 
disturbed 24-hour activity rhythms may also precede disease, but causality remains to 
be determined. The need for longitudinal observational studies remains substantial, 
as well as the need for investigating promising interventions for those diseases where 
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circadian disruption could be involved in disease etiology, symptom maintenance or 
impaired quality of life.
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Subjective sleep quality is not associated with incident dementia: The Rotterdam Study. Journal 




Poor sleep is related to higher dementia risk, but this association is more equivocal for 
subjective sleep quality specifically. This study investigates the link between subjective 
sleep quality and dementia risk in the general population. We studied the role of subjec-
tive sleep quality in the risk of dementia in the general population.
In the prospective population-based Rotterdam Study, 4,835 persons (mean age 
72 years, 58% women) underwent a home interview (2002-2006) that included the 
validated Pittsburgh Sleep Quality Index (PSQI) to assess sleep quality. Participants were 
followed until 2015 for incident dementia, through in-person screening and continuous 
monitoring of medical records. We used Cox regression models to associate sleep qual-
ity with dementia risk, adjusting for age, sex, education, smoking, employment, coffee 
consumption, alcohol consumption, activities of daily living, cardiovascular risk factors, 
anxiety, depressive symptoms, cognition and snoring.
During 41,385 person-years (8.5 years mean), 420 participants developed dementia, of 
whom 320 Alzheimer’s disease (AD). Poorer subjective sleep quality was not associated 
with the risk of all-cause dementia (hazard ratio [HR] per SD increase in PSQI score: 0.91, 
95% CI 0.82-1.02) or AD (HR 0.92, 95% CI 0.81-1.05). Similarly, individual components 
of the PSQI were also not associated with dementia. Several sensitivity analyses, i.e. ex-
cluding last years of the follow-up time duration or restricting to those with best MMSE 
scores at baseline, did not reveal subgroups with increased risks.
In this study, we found no association of poor subjective sleep quality with higher risk 
of dementia.
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INTRODUCTION
Sleep problems are highly frequent in the elderly and sleep deprivation is known to 
acutely affect cognitive performance. Emerging evidence suggests that chronic sleep 
problems might increase the risk of cognitive decline,1 and possibly dementia.2-4 These 
associations are supported biologically as undisturbed sleep has been implicated in the 
clearance of amyloid-β, a pathological hallmark of Alzheimer’s disease (AD).5,6 Other im-
portant mechanisms through which sleep may affect dementia risk is through regulating 
synaptic homeostasis,7 affecting levels of neuro-inflammation in hippocampal areas,8 or 
hypoxia-related increased activity in inflammatory or oxidative pathways occurring in 
sleep-disordered breathing.1
Two recent meta-analyses substantiated this link of poor sleep and higher AD2 or 
dementia4 risk in the general population, for both quantitative and qualitative aspects 
of sleep. However, authors suggest distinct roles for different sleep aspects in risk for dif-
ferent dementia types,4 or even caution that short follow-up duration of studies, and use 
of heterogeneous, and thus incomparable, measures of sleep aspects hamper interpret-
ing results.2 Specifically for the general construct of subjective sleep quality, included 
studies used different measures, such as sleep disturbances or daytime problems, which 
only partly represent the construct. Also, sleep quality was measured with objective 
measures such as actigraphy, which, while important for accurate measurement of basic 
sleep parameters or insight in biological processes, might not fully capture the qualita-
tive experience of sleep, which inherently involves a subjective component.9-11
Studies using validated instruments that take the qualitative experience of sleep into 
account, such as the Pittsburgh Sleep Quality Index (PSQI), are more equivocal about the 
relation of subjective sleep quality with dementia. They have shown a link with imag-
ing12,13 or CSF14,15 markers of neurodegeneration, but results with cognitive decline have 
been inconclusive,1,16-19 and risk of dementia was hardly investigated. The few studies 
that did, interestingly, failed to find an association.20-22
It is important to study the relation of subjective sleep quality to dementia risk, as 
subjective sleep quality seems to be an independent aspect of sleep11 that has been 
ill-characterized in longitudinal studies in dementia risk so far. Also, in the context of 
identifying potentially modifiable risk factors for dementia, subjective measures are 
inexpensive and easily administered, and subjective sleep quality can be modified 
(e.g. through cognitive behavioral therapy, the recommended treatment approach for 
insomnia23). Studies investigating the relation of subjective sleep quality and dementia 
risk, with sufficient follow-up time to account for reverse causation, are needed. In this 
population-based cohort study we aim to investigate the association of subjective sleep 





The Rotterdam Study (RS) is an ongoing prospective population-based cohort study, 
starting in 1990, of inhabitants of the Ommoord district in Rotterdam aged 55 years or 
over, details of which have been described previously.24 The RS has been approved by 
the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare 
and Sport of the Netherlands, implementing the Population Studies Act: Rotterdam 
Study. All participants provided written consent to participate in the study and share 
information from their treating physicians.
In brief, inhabitants willing to participate underwent examination rounds, consisting 
of a home interview and two subsequent center visits, which were repeated every 4-5 
years. In between, incident disease is assessed through continuous linkage of the study 
database and medical records of general practitioners (GPs) which, in the Netherlands, 
also holds summaries of medical records from all specialist and inpatient care. Also, 
regular checks of nursing home medical records were performed. In 2000, the cohort 
was extended with new invitees from the same district and inclusion age. The current 
study includes all persons participating in the fourth wave of the original cohort (RS-I-4; 
2002-2004) and the second wave of the second cohort (RS-II-2; 2003-2006) when the 
PSQI was introduced. They were followed up from this baseline measurement until study 
ending at January 1st of 2014 (RS-I-4) or 2015 (RS-II-2).
Study population
Of 6052 individuals who were scheduled for a home interview, 145 did not complete the 
PSQI due to withdrawal of consent, calling in sick or logistic reasons. Another 140 par-
ticipants were excluded from the current analyses because they missed more than one 
of the seven component scores of the PSQI. We excluded an additional 119 participants 
with prevalent dementia at baseline, and 74 persons for not having any follow-up avail-
able for dementia, which left 5574 participants. Lastly, we included only participants 
with a Mini Mental State Examination (MMSE) score >25 at baseline to a final sample of 
4835 participants (82% of eligible).
Sleep quality
Sleep quality was measured with a Dutch version of the PSQI, which was filled out with 
the help of a research nurse. The PSQI assesses sleep quality and behavior in the past 
month using questions about bedtimes and multiple sleep problems.25 It was designed 
to distinguish ‘poor’ sleepers from ‘good’ sleepers in a clinical setting, and also has good 
test-retest reliability and validity when tested in a non-clinical sample of older adults.26 
Answer scores are combined in seven component scores (range: 0 – 3): quality, latency, 
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duration, efficiency, disturbances, medication and daytime dysfunction. These are 
summed to provide a global sleep quality score (range: 0 – 21). Higher scores indicate 
poorer sleep, with scores >5.0 indicating ‘poor’ versus ‘good’ sleepers. We calculated 
weighted component scores for participants that had one component score missing 
(330 out of 4835 participants [7%]) by multiplying six-component sum scores by 7/6. 
Mainly the components latency (n=148) and efficiency (n=138) were missing.
Dementia screening and surveillance
Participants were screened for dementia at baseline and subsequent center visits with 
the Mini-Mental State Examination27 and the Geriatric Mental Schedule organic level.28 
Those with a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score 
>0 underwent further investigation and informant interview, including the Cambridge 
Examination for Mental Disorders of the Elderly29. All participants also underwent routine 
cognitive assessment. In addition, the entire cohort was continuously under surveillance 
for dementia through electronic linkage of the study database with medical records from 
general practitioners and the regional institute for outpatient mental health care. Avail-
able information on cognitive testing and clinical neuroimaging was used when required 
for diagnosis of dementia subtype. A consensus panel led by a consultant neurologist 
established the final diagnosis according to standard criteria for dementia (DSM-III-R), 
Alzheimer’s disease (NINCDS–ADRDA) and vascular dementia (NINDS-AIREN).
Follow-up until end of the study was nearly complete (96.7% of potential person-
time). Participants were censored starting at date of dementia diagnosis, death, loss to 
follow-up, or study ending, whichever occurred first.
Covariates
Analyses were adjusted for potential confounders measured at baseline; selection was 
based on relevant publications.2,20-22,30-39 Smoking habits were assessed by interview and 
categorized as never, former or current smoking. Educational attainment was assessed 
by interview and categorized as primary, secondary/lower vocational, intermediate 
vocational and higher vocational/university. Having current paid employment was 
self-reported. Activities of Daily Living (ADL) were assessed by a Dutch version of the 
Stanford Health Assessment Questionnaire and measured in a ‘disability index’.40 Coffee 
consumption was categorized in 0-1, 2-3 or >3 cups/day. Habitual alcohol consumption 
was self-reported with a validated Dutch version of the Food Frequency Question-
naire,41 harmonized over use of different types of preparations and expressed in gr/
day intake. Body mass index (BMI) was calculated from measured weight and height 
(kg/m2). Hypertension was defined as elevated systolic (≥160) or diastolic (≥100 mm 
Hg) blood pressure (averaged from two right-arm measurements, sitting up, using a 
random-zero sphygmanometer), or self-reported use of antihypertensive medication. 
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Diabetes mellitus was defined as a fasting serum glucose level ≥7.0 mmol/L and/or 
self-reported use of anti-diabetic medication. Self-reported history of coronary heart 
disease (CHD) and cerebrovascular disease were confirmed via medical records. Total 
and high-density lipoprotein-cholesterol and glucose levels in serum were processed 
through an automated enzymatic procedure (Boehringer Mannheim System). Depres-
sive symptoms were assessed with the validated Dutch version of the Centre for Epide-
miological Studies Depression Scale.42 Cognitive status was assessed with the MMSE. 
Presence of one or more 12-month prevalent DSM-IV anxiety disorders was assessed by 
an adapted version of the Munich Composite International Diagnostic Interview. Loud 
snoring was reported by participants and/or bedpartners in categories of frequency per 
week. APOE-genotype was determined by either polymerase chain reaction on coded 
DNA samples in RS-I-4 or bi-allelic Taqman assays (rs7412 and rs429358) in RS-II-2, and 
classified by number of ε4-alleles.
Statistical analysis
We first explored the association of individual covariates with global PSQI score at 
baseline using age- and sex-adjusted linear regression. For our main analysis, we used 
Cox proportional hazard models to determine the association of global PSQI scores with 
incident dementia, with follow-up time as timescale. We constructed three incremental 
models. Model 1 was adjusted for age at baseline, sex, education, smoking, employ-
ment, coffee consumption, alcohol consumption and activities of daily living. Model 2 
was additionally adjusted for cardiovascular risk factors. Model 3 further incorporated 
MMSE-score, CES-D score, prevalent anxiety disorders, and snoring.
We performed several additional analyses. First, we studied the seven components 
of the PSQI separately as well as dichotomized global PSQI score in ‘poor’ vs. ‘good’ 
sleep quality. Second, we studied potential effect-modification by age, sex and clinically 
relevant depressive symptoms by stratification and formally testing for multiplicative 
interaction in the fully adjusted model.42 Third, to examine how the relation of sleep 
quality and dementia was modified by baseline cognitive status, beyond including only 
participants with an MMSE>25, we incrementally restricted our sample to participants 
with highest MMSE-scores, per point, as high as MMSE>28.Fourth, to aid comparison 
with other studies that use shorter follow-up times, we performed analyses after restrict-
ing follow-up duration by two incremental year intervals, i.e. end-date at 2, 4, 6, 8, and 10 
years after baseline. Fifth, we studied AD separately. Finally, we additionally adjusted the 
main analysis for number of APOE-ε4 alleles.
Missing data on covariates (≤13%) before including only participants with an MMSE 
>25 were imputed using 5 multiple imputation based on all variables used in our analy-
ses. We plotted Schoenfeld residuals of all variables against time, using the free and 
open ‘R’ software43 (package: ‘survival’): no violations of proportionality were identified. 
93
DEMENTIA – SUBJECTIVE SLEEP QUALITY
3
Statistical testing was performed two-sided at p<0.05. Data were analysed using SPSS 
Statistics, version 21 (IBM Corp., Armonk, NY).
RESULTS
Baseline characteristics are summarized in Table 1. The median PSQI score was 3 and 
30% of participants had poor sleep quality. At baseline, higher depressive symptoms, 
presence of anxiety disorders, female sex, higher age, less coffee consumption, worse 
scores on ADL, presence of hypertension or CHD, and less snoring were associated with 
Table 1. Baseline characteristics of the study population.
Characteristic (unit) N=4,835
Global PSQI score 3 (2-6)
Age in years 71.9 ± 7.4
Women 2791 (58%)
Medium or higher education 2264 (47%)
Never smoker 1483 (31%)
Currently employed 325 (7%)
Coffee consumption >3 cups/day 2489 (52%)
Alcohol consumption (gr/day) 7 (1-20)
Disability index 0.4 (0.1-0.7)
Body mass index (kg/m2) 27.6 ± 4.0
Hypertension 1732 (36%)
Total cholesterol (mmol/l) 5.6 ± 1.0
HDL-cholesterol (mmol/l) 1.5 ± 0.4
Diabetes mellitus 716 (15%)
History of CHD 291 (6%)
History of TIA or stroke 284 (7%)
CES-D 4 (2-8)
MMSE-score 28 (27-29)
Anxiety disorder 357 (8%)
Snoring ≥ 1/week 2009 (31.6%)
≥1 APOE-ε4 allele(s) 1211 (27%)
Missing 288 (6%)
Incident all-cause dementia 420 (9%)
Of which Alzheimer’s disease 320 (76%)
Values include imputed missing values and indicate frequency (%), or median (interquartile range) for categorical 
variables, and mean ± standard deviation for continuous variables, unless specified otherwise. Abbreviations: 
PSQI=Pittsburgh Sleep Quality Index; IQR= interquartile range; HDL= high-density lipoprotein; CES-D=Center for 
Epidemiologic Studies – Depression Scale; MMSE=Mini Mental State Examination; CHD=Coronary heart disease.
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worse sleep quality (Supplementary Table 1). During 13 years of follow-up (mean 8.5 
years), we observed 420 incident dementia cases, of which 320 had AD (76%).
We found no association of subjective sleep quality with the risk of dementia (hazard 
ratio [HR] per SD increase 0.91, 95% CI 0.81-1.02, Table 2). Additional adjustment did 
not substantially alter effect sizes. We found no association between worse scores on 
the separate PSQI-components and dementia risk with results consistent across com-
ponents (Table 3). After dichotomizing the global PSQI score, we found that poor sleep 
quality was not associated with a higher risk of dementia than good sleep quality (HR 
0.93, 95% CI 0.74-1.16).
Incrementally restricting analyses to participants with higher MMSE-scores at baseline 
resulted in hazard ratio estimates that were even closer to the null-value (Figure 1). We 
observed no significant interaction of PSQI with age, sex and CES-D, although a difference 
between men and women was suggested in the stratified analysis (Supplementary Table 
2). Results were similar when restricting the follow-up time to 2, 4, 6, 8 or 10 years (Figure 2). 
Finally, additionally adjusting for APOE-ε4 allele status (HR 0.91, 95% CI 0.79-1.30) or study-
ing AD separately (0.92, 95% CI 0.81-1.05) did not change results from the main analysis.
Table 2. Association of subjective sleep quality and dementia risk
Global PSQI score
(per SD increase)
Hazard ratio (95% CI)
Model 1 0.96 (0.86 - 1.06)
Model 2 0.95 (0.86 - 1.06)
Model 3 0.91 (0.81 - 1.02)
Estimates obtained from models with cases/N: 420/4835. Model 1: adjusted for age, sex, education, smoking, 
employment, coffee consumption, alcohol consumption, activities of daily living. Model 2: Model 1 + 
cardiovascular risk factors. Model 3: Model 2 + MMSE-score, depressive symptoms, anxiety and snoring. 
Abbreviations: CI=Confidence Interval; PSQI=Pittsburgh Sleep Quality Index; SD=Standard Deviation.
Table 3. Association of PSQI component scores and dementia risk
PSQI-components Cases/N HR (95% CI)
Quality 420/4806 0.88 (0.76-1.02)
Latency 407/4660 1.00 (0.89-1.10)
Duration 420/4808 0.96 (0.88-1.06)
Efficiency 411/4669 0.93 (0.83-1.03)
Disturbances 417/4780 0.85 (0.70-1.03)
Medication 420/4808 0.93 (0.83-1.04)
Daytime dysfunction 418/4795 0.96 (0.80-1.14)
Hazard ratios adjusted for age, sex, education, smoking, employment, coffee consumption, alcohol consumption, 
activities of daily living, cardiovascular risk factors, MMSE-score, depressive symptoms, anxiety and snoring, 
calculated per point increase for every component score. Abbreviations: CI=Confidence Interval; HR=hazard 
ratio; PSQI=Pittsburgh Sleep Quality Index.
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DISCUSSION
In this population-based cohort study with up to 13 years of follow-up, we did not find 
any association of subjective sleep quality, measured by PSQI, and the risk of all-cause 
dementia. All separate PSQI components were also not associated to incident dementia.
Figure 2. Association of subjective sleep quality and dementia risk, analyzed for cumulative 2-year follow-
up intervals from baseline.
Hazard ratios adjusted for age, sex, education, smoking, employment, coffee consumption, alcohol con-
sumption, activities of daily living, cardiovascular risk factors, MMSE-score, depressive symptoms, anxiety 
and snoring, calculated per standard deviation increase of global PSQI score. Estimates for each interval 
were obtained by censoring of all participants still at risk at year 2, 4, 6, 8 and 10 after baseline. Abbrevia-
tions: CI=Confidence Interval.
Figure 1. Association of subjective sleep quality and dementia risk, analyzed by incrementally restricting 
the sample to higher cognitive status.
Number of dementia cases per analyzed sample size is shown on the Y-axis. Hazard ratios adjusted for age, 
sex, education, smoking, employment, coffee consumption, alcohol consumption, activities of daily living, 
cardiovascular risk factors, MMSE-score, depressive symptoms, anxiety and snoring, calculated for samples 




Some methodological considerations deserve mention. We lacked non-selectively 
repeated measures of the PSQI to assess the association of time-varying subjective sleep 
quality exposure on dementia risk, which could have accounted for intra-individual 
variability of subjective sleep quality over time. Yet, PSQI scores have been shown to 
remain relatively stable in elderly persons over 3 years.44 Also, we could not assess the 
effect of time-varying covariates on our outcome. Next, baseline sleep quality in our 
study was relatively good compared to other population-based studies,17,18,26 which 
might have precluded us finding an effect as the contrast between participants was 
small. Also, we could not assess to what extent associations of common sleep disorder 
(i.e. insomnia and sleep apnea), or excessive daytime sleepiness with our exposure and 
outcome might have influenced our results, although this cannot easily explain the lack 
of an association. Lastly, ethnic and socioeconomic differences in sleep (behavior) limit 
generalizability of findings to persons of European descent with middle or high income.
We did not find an association of the subjective experience of sleep with dementia 
risk. Such null associations have been reported before in similarly designed studies that, 
besides their main analysis, also specifically included sleep quality measures. A Finnish 
study with a median follow-up duration of 22.5 years found no association between a 
single sleep quality question (“Do you usually sleep well?”) and AD.20 A large registry-
based study in Swedish twins21 used a validated sleep quality index of four questions 
and reported a similar risk estimate (HR 0.93, 95% CI 0.85-1.01) to our study over a 17 
year study period, just like the French Three City Study which studied the association of 
self-reported ‘poor’ sleep quality (rated ‘poor’, ‘average’ or ‘good’; compared to answering 
‘good’) with risk of dementia (OR 0.85, 95% CI 0.65-1.13) across 8 years.22 Noteworthy in 
our study is that individual PSQI-components were also not associated to dementia risk, 
which range from very subjective experience (e.g. the ‘quality’ component) to compo-
nents based on estimation of time. The components measure aspects of sleep quality 
that considerably overlap with sleep constructs that have been associated with demen-
tia risk in previous prospective population-based studies, for instance self-reported 
sleep duration,20,21,30-33 insomnia symptoms,34,35 or self-reported sleep disturbances.38,39
There are several possible explanations for these discrepancies across studies, includ-
ing ours. First, the predominantly positive associations in literature may indicate a role 
of sleep in dementia, but could equally well indicate publication bias. Indeed, in afore-
mentioned meta-analysis of sleep and dementia, the funnel plot showed significant 
asymmetry, which is indicative of publication bias.2 Another factor contributing to this 
predominance is the use of slightly differing sleep measures between studies that have 
been associated with dementia risk, caused by a lack of standardized measures of sleep 
feasible for use in large observational studies.2,26 Use of validated or well-known sleep 
instruments might increase the reproducibility of reported findings.
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Second, subjective reporting of sleep quality by persons that are at risk for dementia 
could introduce misclassification of sleep exposure that has to be taken into account 
in prospective studies. Intact cognition is a necessity for accurately recalling, reflecting 
on, and reporting past month’s sleep, judging its ‘quality’9 using questionnaires.45 As 
self-reported sleep is misclassified in the presence of cognitive impairment, even for 
measures as straightforward as sleep duration,46 we only included participants with 
MMSE>25 to minimize misclassification bias of sleep quality. Noteworthy, persons with 
mild cognitive impairment with a low-normal MMSE score may still be included in our 
sample, for which we incrementally restricted the sample on higher MMSE scores. If 
not accounted for, such bias causes some aspects of sleep that deteriorate simultane-
ously with cognitive status before dementia diagnosis, or subjective sleep measures in 
general, to be falsely related to dementia. Importantly, such a restriction of the study 
population based on baseline cognition is not likely to have prevented us finding an in-
creased dementia risk, as further incremental restrictions to higher MMSE-scores drove 
the hazard ratio estimate upwards: including participants with cognitive impairment 
might have further decreased the effect estimate towards an association of worse sleep 
quality and lower dementia risk, not higher dementia risk. This is supported by observa-
tions of better subjective sleep quality in early-stage AD-patients compared to controls, 
while actigraphic measures revealed their sleep to be worse than controls.47
Third, choice of follow-up duration influences the reported hazard ratios obtained 
from a Cox regression model, as it averages hazards over time into a single metric.48 
We accounted for this by analysing risks in shorter follow-up durations from baseline 
and found no association of poor sleep and higher dementia risk. We cannot exclude 
that poor sleep quality relates to increased dementia risk after 13 years, which might be 
biologically plausible considering that preclinical AD pathology is presumably present 
more than a decade49 before diagnosis. However, this might be unlikely as absence of 
associations on the short term show that reverse causation, or the effect of preclinical 
neurodegenerative pathology on sleep quality, did not materially influence our results. 
Additionally, significant differences in strength of associations between studies with 
short and long follow-up duration were not found in a recent meta-analysis.2
Fourth, methodological concerns were identified in previous studies on subjective 
sleep measures and dementia risk2: the relative dearth of studies of sufficient quality, 
need for long-term follow-up to better study temporality and controlling for comorbid 
disorders. These concerns were well addressed by using data from the Rotterdam Study, 
which has sensitive case-finding which will in general increase the effect size of any 
association found between exposure and outcome, minimal loss to follow-up, adequate 
follow-up duration, and elaborate work-up to extensively control for confounding.
Currently, qualitative assessments of sleep are less preferred in dementia research in 
comparison to more quantitative or objective measures of sleep, as they may provide 
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more unbiased measures.45 However, despite current efforts10 to capture for instance 
sleep quality objectively, measures obtained with polysomnography, the gold stan-
dard sleep measurement, cannot sufficiently explain differences in perceived quality 
of sleep.11 Therefore, a more quantitative assessment is not the same as a ‘less biased 
qualitative assessment’, as they seem to measure different constructs. Moreover, subjec-
tive assessments are important as perception of sleep will likely guide the diagnostic 
work-up in clinical practice. This underwrites the potential importance of studying sleep 
in dementia research with subjective assessments, also as great value is attributed to a 
person’s appraisal of their own health status, such as in patient-reported outcomes, in 
medicine at large.26
This study indicates that the value of subjective sleep quality as a potentially modifi-
able risk factor, or marker, of dementia is limited. Compared to the recent meta-analyses, 
our study shows that the relation between sleep and dementia risk differs depending on 
the aspect of sleep studied. Also, it emphasizes that negative results should be published 
to not artificially inflate conclusions on the role of sleep in dementia risk.
Future studies may want to confirm that subjective sleep quality is not related to 
dementia risk, or investigate related topics, such as the association of subjective sleep 
quality with cognitive decline, or the role of sleep quality as a marker or risk factor for 
incident dementia or cognitive decline in vulnerable subgroups such as persons with 
subjective memory complaints, or APOE-ε4 allele carriers.
Lastly, we reported determinants of sleep quality at baseline, most of which were 
related to sleep quality in the expected direction. Surprisingly, less coffee consump-
tion and less snoring were related to worse sleep quality. An association of less coffee 
consumption and worse sleep quality may be explained by individuals cutting back on 
coffee after experiencing worse sleep quality50 or may indicate a ‘healthy coffee drinker’-
effect.51 The association with less snoring is not readily explained, and may be due to 
unreliability in self-reporting.
In conclusion, in this study we found that subjective sleep quality measured by the 
PSQI is not associated with risk of dementia, nor are the separate PSQI components.
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SUPPLEMENTARy TABLES
Supplementary Table 1. Cross-sectional ssociations of baseline characteristics with subjective sleep qual-
ity
Characteristic (unit or category) Beta (95% CI)a P-value
Age (per SD increase) 0.43 (0.33; 0.53)* <0.001
Sex (women vs. men) 2.18 (1.98; 2.39)* <0.001
Education (per higher level) -0.05 (-0.17; 0.07) 0.430
Smoking status (ever vs. never) 0.02 (-0.14; 0.18) 0.819
Paid employment (present vs. absent) -0.15 (-0.56; 0.27) 0.490
Coffee consumption (per category increase) -0.21 (-0.38; -0.05)* 0.011
Alcohol consumption (per SD increase) -0.10 (-0.20; 0.01) 0.070
Disability index (per SD increase) 0.68 (0.57; 0.79)* <0.001
Body Mass Index (per SD increase) -0.06 (-0.16; 0.04) 0.262
Hypertension (present vs. absent) 0.37 (0.16; 0.58)* 0.001
Total cholesterol (per SD increase) -0.02 (-0.13; 0.08) 0.664
HDL-cholesterol (per SD increase) 0.04 (-0.06; 0.15) 0.438
Diabetes mellitus (present vs. absent) 0.02 (-0.26; 0.30) 0.895
History of coronary heart disease (present vs. absent) 0.67 (0.25; 1.09)* 0.002
History of TIA or stroke (present vs. absent) 0.26 (-0.17; 0.69) 0.235
CES-D (per SD increase) 1.46 (1.37; 1.55)* <0.001
MMSE-score (per point increase) -0.02 (-0.10; 0.06) 0.572
Anxiety disorder (present vs. absent) 1.74 (1.36; 2.12)* <0.001
Snoring ≥ 1/week (present vs. absent) -0.13 (-0.21; -0.04)* 0.003
APOE- ε4 alleles (per allele increase) -0.17 (-0.38; 0.04) 0.111
Estimates from linear regression model adjusted for age and sex, if applicable, calculated per unit increase 
of the determinant, with global PSQI score as dependent variable, and marked for significance at P<0.05. 
Analysis for APOE in n=4,521.
Abbreviations: CI=Confidence Interval; PSQI=Pittsburgh Sleep Quality Index; IQR= interquartile range; 




Supplementary Table 2. Association of subjective sleep quality and dementia risk, stratified by age, sex 
and depressive symptoms
Effect-modifier Cases/N HR (95% CI) P-value
interaction term
Age 0.780
≤ 71,0 years 97/2,550 0.95 (0.73-1.23)
> 71,0 years 323/2,254 0.90 (0.80-1.02)
Sex 0.342
Male 144/2,030 1.03 (0.82-1.30)
Female 276/2,773 0.87 (0.76-0.98)
Depressive symptoms 0.464
CES-D < 16 371/4,344 0.90 (0.79-1.02)
CES-D ≥ 16 49/463 0.92 (0.70-1.23)
Hazard ratios adjusted for age, sex, education, smoking, employment, coffee consumption, alcohol con-
sumption, activities of daily living, cardiovascular risk factors, MMSE-score, depressive symptoms, anxiety 
and snoring (excluding stratified variable), calculated per standard deviation increase of global PSQI score. 
Age is split at the median of the sample.





















We investigated and compared associations of objective estimates of sleep and 24-hour 
activity rhythms using actigraphy with risk of dementia.
We included 1,322 non-demented participants from the prospective, population-
based Rotterdam Study cohort with valid actigraphy data (mean age 66±8 years, 53% 
women), and followed them for up to 11.2 years to determine incident dementia.
During follow-up, 60 individuals developed dementia, of which 49 had Alzheimer’s 
disease. Poor sleep as indicated by longer sleep latency, wake after sleep onset, and time 
in bed and lower sleep efficiency, as well as an earlier ‘lights out’ time, were associated 
with increased risk of dementia, especially Alzheimer’s disease. We found no associa-
tions of 24-hour activity rhythms with dementia risk.
Poor sleep, but not 24-hour activity rhythm disturbance, is associated with increased 
risk of dementia. Actigraphy-estimated nighttime wakefulness may be further targeted 
in etiologic or risk prediction studies.
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INTRODUCTION
Sleep is essential to the brain as it supports learning and memory, regulates synaptic 
plasticity, and enhances waste clearance from the brain.1,2 Conversely, disturbed sleep 
may harm the brain through increased neuro-inflammation3 or atherosclerosis,4 or by ac-
cumulation of detrimental proteins involved in Alzheimer’s disease pathology.1,5 Against 
this background, sleep disturbances have been associated with incident dementia6,7 and 
as such may be regarded as a potential risk factor, a prodromal disease feature, or as 
signaling presence of preclinical brain pathology.
Sleep is closely related to the circadian timing system,8 functioning of which is reflected 
behaviorally in 24-hour rhythms of physical activity. Disturbed 24-hour activity rhythms 
have also been linked to dementia risk.9-11 Yet, it remains unknown how sleep and 24-
hour activity rhythms compare with respect to dementia risk, and to what extent these 
aspects contribute to risk independent from each other.12 Also, we need to consider 
relevant interactions, such as that of sleep disturbances with presence of the Apolipo-
protein E ε4 (APOE ε4) allele on risk of Alzheimer’s disease.13 Lastly, only a minority of 
population-based studies studied objectively measured sleep in relation to dementia 
risk, while most studies6,7,14 measured sleep using self-report measures as these are 
feasible to obtain in large study populations. Although important for evaluating sleep,15 
self-report measures may hamper attributing associations to sleep per se as they rely on 
cognitive and affective factors that determine the subjective appraisal of sleep.16
Sleep and 24-hour activity rhythms may be independently inferred from physical ac-
tivity measurements over multiple days using actigraphy. In this study, we investigated 
associations of actigraphy-derived sleep and 24-hour activity rhythm parameters with 
the risk of dementia, using over 11 years of follow-up data from the population-based 
Rotterdam Study cohort. We compared sleep and 24-hour activity rhythm parameters 
using mutually adjusted models, and investigated effect-modification by APOE ε4 status.
METHODS
Study setting and population
This study is embedded in the Rotterdam Study, a prospective population-based cohort 
in a Dutch suburban district starting in 1990.17 Examination rounds are repeated every 
4-5 years. Incident disease is assessed continuously with electronic linkage between 
the study database and medical records. The Rotterdam Study has been approved by 
the Medical Ethics Committee of the Erasmus MC. All participants provided written 




Between 2004 and 2007 (baseline of the current study), 2063 participants (78% of 
2632 invited) aged 62.4±9.4 years wore an actigraph for ≥4 days and also completed a 
daily sleep diary. We excluded participants with: i) Actigraph malfunctioning (n=197); ii) 
Less than 96 hours of consecutive recording (n=109); iii) Measurements during daylight 
savings (n=23); iv) Missing information on dementia status (n=54). Lastly, we excluded 
persons aged <55 years at baseline, as those were considered not at risk for dementia 
in a population-based setting (n=358).18 The 1,322 included individuals were on aver-
age 2.5 years younger, 8% less likely to be female, and had a 0.4 higher Mini-mental 
status examination score, but did not differ in questionnaire-assessed sleep or bedtimes 
compared to invited persons aged >55 who did not participate (n=768). Included 
participants were followed for 11,630 person-years (95% of possible total if no loss to 
follow-up19) until onset of dementia, loss to follow-up, death, or 1 January 2016.
Sleep and 24-hour activity rhythms
Participants wore an actigraph (ActiWatch model AW4, Cambridge Technology Ltd) 
for 138 ± 14 hours (median=144) and completed a sleep diary during the same time 
period.20 Participants pressed a marker button on the device to denote ‘lights out’ time 
and getting up time. Missing marker times (21% of all time values) were imputed from 
the sleep diary, or estimated by inspecting actigraphy recordings when sleep diaries 
were missing. Within the defined time in bed, total sleep time and wakefulness were es-
timated using a validated algorithm with a threshold of 20 activity counts.21 We defined 
‘sleep onset’ as the midpoint of the first immobile period lasting ≥10 minutes after ‘lights 
out’ with ≤one epoch of movement. Sleep onset latency was calculated as the time from 
‘lights out’ to sleep onset, and wake after sleep onset was calculated as the wakefulness 
after sleep onset. Sleep efficiency was calculated as total sleep time / time in bed * 100%.
We calculated the following indicators of the 24-hour activity rhythm22,23: Intradaily 
variability which quantifies the amount of alterations of activity-inactivity, interdaily 
stability which quantifies how activity profiles across days resemble each other, and the 
average time of day when the least active 5 consecutive hours started (L5 onset) indicat-
ing phase of most inactivity.
Correlations amongst sleep and 24-hour activity rhythm parameters at baseline in a 
similar study population have been reported previously.24
Dementia
Diagnosing dementia involved cognitive screening for all participants visiting the 
research center. We further assessed individuals scoring a Mini-mental state examina-
tion<26 or Geriatric Mental Schedule organic level>0 with the Cambridge Mental Disor-
ders of the Elderly Examination, including a spouse or informant interview. Simultane-
ously, for all participants we surveilled medical records of general practitioners and the 
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regional institute for outpatient mental health care for dementia.  A consensus panel 
adjudicated diagnoses according to standard criteria. In this study, we considered the 
outcomes of all-cause dementia (DSM-III-R; hereafter: dementia), and Alzheimer’s dis-
ease (NINCDS–ADRDA).
Covariates
Using the disjunctive cause criterion,25 we considered age, sex, education (categorized 
as primary, secondary/lower vocational, intermediate vocational and higher vocational/
university), paid employment, self-reported physical activity,26,27 habitual alcohol con-
sumption, body mass index, positive history of cardiovascular disease (TIA, stroke, heart 
disease), smoking status, presence of hypertension, and presence of diabetes mellitus as 
potential confounders or appropriate proxies for unmeasured confounders.25 Measure-
ments took place during home interviews or at research center visits and are described 
in detail elsewhere.28 For the sensitivity analyses we assessed depressive symptoms29 
(Centre for Epidemiological Studies - Depression Scale [CES-D]), possible sleep apnea 
(2 questions of the Pittsburgh Sleep Quality Index,30 napping (napping per day during 
daytime and evenings according to the sleep diary), and number of APOE ε4 alleles.28
Statistical analysis
We used Cox proportional hazards regression models to associate sleep and 24-hour 
activity rhythm parameters with incident dementia and Alzheimer’s disease, adjusted 
for age/sex and additionally for abovementioned confounders. We also investigated 
non-linearity in associations for total sleep time and time in bed by modeling a qua-
dratic term. We additionally adjusted all associations of sleep and bedtime parameters 
observed in the main analysis for the 24-hour activity rhythm variables, to evaluate 
their independence. In sensitivity analysis, we separately adjusted analyses for possible 
sleep apnea, napping, and number of APOE ε4 alleles, and restricted analyses to persons 
without clinically relevant depressive symptoms (CES-D ≤16).
Also, we presented stratified results for all parameters by APOE ε4 genotype (≥1 
ε4-allele versus no ε4-alleles), age (≤75 versus >75), and sex on risk of dementia, and 
formally tested multiplicative interaction by modeling a product term. We evaluated 
statistical significance of interaction terms at P<.0016, defined by applying a Bonferroni 
correction for testing 10 parameters across 3 stratifications (P=.05/30).
Lastly, we explored whether associations depended on follow-up time to provide 
some insight into possible reverse causation.31 We performed analyses in increasingly 
longer epochs of follow-up time from baseline (e.g. baseline to 2 years, baseline to 4 




Testing the proportional hazards assumption of the main analyses using Schoenfeld 
residuals indicated a violation for L5 onset. Please note that this non-proportionality was 
not removed, but made insightful with aforementioned analysis.31
Sleep variables were winsorized (i.e. values of outliers changed towards the mean) to 
3 SD and subsequently standardized to facilitate comparison. Missing values on covari-
ates (except APOE-genotype) were imputed using five multiple imputations, performed 
with IBM SPSS Statistics version 24 (IBM Corp, Armonk, NY). Statistical analyses were 
performed with R software (packages: survival, coxphf ).
RESULTS
We included 1,322 participants at baseline (Table 1) aged 66.1±7.6 years. During 11.2 
years of follow-up (median=9.5), 60 individuals developed dementia, including 47 with 
Alzheimer’s disease.
Longer sleep onset latency (hazard ratio [HR] per standard deviation [SD] increase 
1.44, 95% confidence interval [CI] 1.13-1.83) and longer time in bed (HR 1.40, 95% CI 
1.04-1.88) were associated with an increased risk of dementia. A higher sleep efficiency 
(HR 0.72, 95% CI 0.55-0.93) and later ‘lights out’ time were associated with decreased 
dementia risk (HR 0.56, 95% CI 0.41-0.76). For Alzheimer’s disease, aforementioned asso-
ciations were stronger, including an association for longer wake after sleep onset (Table 
2). In contrast, total sleep time was not associated with the risk of dementia (HR 0.97, 
95% CI 0.74-1.29) or Alzheimer’s disease (HR 0.92, 95% CI 0.68-1.26, Table 2). Estimates 
were not meaningfully different when only adjusted for age and sex (Table 2).
We found no statistically significant non-linearity after fitting quadratic terms for the 
associations of total sleep time (P value=.95) or time in bed (P value=.27) with dementia 
risk, nor with Alzheimer’s disease risk (P value=.44; P value=.30, respectively).
The 24-hour activity rhythms were not associated with dementia risk (Table 2). Afore-
mentioned associations of sleep parameters with dementia risk were also not affected 
by further adjustment for 24-hour activity rhythm parameters (Table 3).
Estimates remained similar after separate further adjustment for possible sleep apnea, 
number of naps, or number of APOE ε4 alleles (Supplementary Table 1). Also, restricting 
analyses to persons without clinically relevant depressive symptoms did not substan-
tially affect estimates (Supplementary Table 2).
Stratifying by APOE ε4 suggested that associations of sleep parameters with increased 
risk of dementia were present only in ε4-negative individuals (Table 4), but when for-
mally tested no sleep-by-APOE interaction term survived multiple testing.
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Table 1. Characteristics of study population at baseline
Characteristic (unit) Values (N=1,322)
Age at baseline (years) 66.1 ± 7.6
Female 699 (53%)
Educational level
Primary education 109 (8%)
Lower/intermediate or lower vocational 585 (44%)
Higher or intermediate vocational 390 (30%)
Higher vocational or university 238 (18%)
Paid employment 274 (21%)
Physical activity (MET-hours/week) 62 (19-96)





Body mass index (kg/m2) 28.0 ± 4.0
History of cardiovascular disease 1.1 (0.3 – 32.0)
Presence of hypertension 888 (67%)
Presence of diabetes mellitus 104 (8%)
Depressive symptoms (CES-D score) 3 (1-7)
Possible sleep apnea 369 (28%)
Napping (number of naps) 1 (0-3)
Presence of ≥1 APOE ε4 allele* 346 (26%)
Total sleep time (hours) 6.4 ± 0.9
Sleep efficiency (%) 79 (74-83)
Wake after sleep onset (hours) 1.1 (0.9-1.4)
Sleep latency (minutes) 13 (7-22)
Time in bed (hours) 8.2 ± 0.9
Bedtime (‘lights out’) (hh:mm) 23:50 ± 00:50
Time getting up (hh:mm) 08:05 ± 00:50
Intradaily variability (score) 0.40 (0.33-0.49)
Interdaily stability (score) 0.83 (0.76-0.88)
Onset least active consecutive 5 hours (hh:mm) 01:50 ± 01:08
Values are expressed as No. (%) for categorical variables and mean ± standard deviation or median (1st 
quartile – 3rd quartile) for continuous variables, unless specified otherwise. Includes imputed values for 
covariates.
*Missing 71 participants, including 3 persons with incident Alzheimer’s disease
Abbreviations: CES-D=Center for Epidemiological Studies – Depression Scale; MET=Metabolic equivalent 
of task; N=sample size.
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Dementia HR (95% CI) Alzheimer’s disease HR (95% CI)
Cases/N=60/1322 Cases/N=49/1322
Model 1 Model 2 Model 1 Model 2
Sleep
Total sleep time 0.99 (0.76-1.30) 0.97 (0.74-1.29) 0.95 (0.70-1.28) 0.92 (0.68-1.26)
Sleep onset latency 1.38 (1.10-1.74) 1.44 (1.13-1.83) 1.42 (1.11-1.83) 1.45 (1.11-1.89)
Wake after sleep onset 1.17 (0.92-1.51) 1.23 (0.95-1.59) 1.30 (1.00-1.70) 1.38 (1.05-1.81)
Time in bed 1.34 (1.00-1.80) 1.40 (1.04-1.88) 1.40 (1.01-1.95) 1.49 (1.06-2.10)
Sleep efficiency 0.78 (0.60-1.00) 0.72 (0.55-0.93) 0.72 (0.54-0.94) 0.66 (0.50-0.87)
Bedtimes
Time ‘lights out’ 0.57 (0.42-0.76) 0.56 (0.41-0.76) 0.55 (0.40-0.76) 0.53 (0.37-0.74)
Time getting up 0.79 (0.59-1.06) 0.79 (0.58-1.08) 0.81 (0.58-1.13) 0.79 (0.56-1.13)
24-hour activity rhythm
Intradaily variability 1.06 (0.82-1.38) 1.07 (0.82-1.40) 1.04 (0.78-1.40) 1.05 (0.78-1.41)
Interdaily stability 0.93 (0.71-1.22) 0.92 (0.70-1.20) 0.90 (0.67-1.21) 0.87 (0.65-1.17)
L5 onset 0.88 (0.69-1.13) 0.92 (0.72-1.17) 0.85 (0.65-1.12) 0.88 (0.67-1.16)
Hazard ratios were obtained with Cox regression models. Model 1 is adjusted for age and sex. Model 2 is ad-
ditionally adjusted for educational level, employment status, physical activity, alcohol consumption, body 
mass index, smoking status, history of cardiovascular disease, presence of hypertension, and presence of 
diabetes mellitus. Abbreviations: CI=Confidence interval; HR=Hazard ratio; L5=Least active consecutive 5 
hours of the day; N=sample size; SD=Standard deviation
Table 3. Associations of sleep parameters with incident dementia and Alzheimer’s disease, additionally 
adjusted for 24-hour activity rhythm parameters
Determinant
(per SD increase)
Dementia HR (95% CI) Alzheimer’s disease HR (95% CI)
Cases/N=60/1322 Cases/N=49/1322
Sleep
Total sleep time 1.00 (0.74-1.34) 0.93 (0.67-1.29)
Sleep onset latency 1.52 (1.17-1.97) 1.53 (1.14-2.05)
Wake after sleep onset 1.25 (0.95-1.64) 1.42 (1.07-1.90)
Time in bed 1.44 (1.06-1.95) 1.52 (1.07-2.15)
Sleep efficiency 0.70 (0.52-0.93) 0.63 (0.46-0.86)
Hazard ratios were obtained with Cox regression models, adjusted for main analysis confounder and addi-
tionally for intradaily variability, interdaily stability, and time of onset of the least active consecutive 5 hours 
of the day. Confounders included age, sex, educational level, employment status, physical activity, alcohol 
consumption, body mass index, smoking status, history of cardiovascular disease, presence of hyperten-
sion, and presence of diabetes mellitus. In all models, no 24-hour activity rhythm parameter was statistically 
significant at P value<0.05. We observed no multicollinearity: All variance inflation factors were lower than 
2. Abbreviations: CI=Confidence interval; HR=Hazard ratio; N=sample size; SD=Standard deviation
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Age-stratified analyses did not show a consistent pattern of differences in associations 
across age, and we found no statistically significant multiplicative interactions with age 
( Supplementary Table 3).
Sex-stratified analyses showed shorter total sleep time was associated with lower 
dementia risk in women, opposite to the direction of the point estimate in men. Vice 
versa, longer time in bed was associated with increased dementia risk only in men 
(Supplementary Table 3). Yet, we found no statistically significant interactions with sex.
For the sleep parameters, hazard ratio estimates remained mostly similar over increas-
ing follow-up time (Figure 1A). The strong association of later ‘lights out’ with lower 
dementia risk in the first 2 years of follow-up (HR 0.27, 95% CI 0.10-0.73) attenuated 
with increasing follow-up time (Figure 1B). Later L5 onset was associated with lower 
dementia risk in the first 2 years of follow-up only (HR 0.23, 95% CI 0.09-0.61) (Figure 1C). 
Incident cases in this period all had Alzheimer’s disease. Overall, findings were similar for 
Alzheimer’s disease.
Table 4. Effect-modification of associations of sleep, bedtime and 24-hour activity rhythm parameters with 
risk of dementia by APOE ε4
Determinant (per SD increase) Dementia HR (95% CI), APOE-stratified Interaction
ε4 carriers ε4 non-carriers
Cases/N*=21/346 Cases/N*=36/905 P value
Sleep
Total sleep time 1.04 (0.65-1.66) 0.96 (0.68-1.35) 0.89
Sleep onset latency 1.28 (0.82-2.01) 1.51 (1.10-2.06) 0.38
Wake after sleep onset 0.83 (0.49-1.39) 1.63 (1.19-2.25) 0.01
Time in bed 1.14 (0.72-1.82) 1.73 (1.16-2.57) 0.02
Sleep efficiency 0.95 (0.57-1.56) 0.61 (0.44-0.84) 0.04
Bedtimes
‘Lights out’ time 0.52 (0.31-0.87) 0.42 (0.27-0.65) 0.12
Getting up time 0.55 (0.31-0.98) 0.84 (0.56-1.26) 0.20
24-hour activity rhythm
Intradaily variability 0.75 (0.41-1.36) 1.16 (0.85-1.60) 0.03
Interdaily stability 1.36 (0.75-2.47) 0.85 (0.62-1.18) 0.07
L5 onset 0.70 (0.42-1.16) 0.94 (0.69-1.29) 0.48
Hazard ratios were obtained from Cox regression models, adjusted for age and sex (if applicable), and 
educational level, employment status, physical activity, alcohol consumption, body mass index, smoking 
status, history of cardiovascular disease, presence of hypertension, and presence of diabetes mellitus. We 
tested interaction through modeling a product term of the unstandardized determinant with the number 
of ε4-alleles. *Missing data on APOE ε4 genotype for 71 individuals in total, of whom 3 had incident Al-
zheimer’s disease. Abbreviations: APOE=Apolipoprotein E gene; CI=Confidence interval; L5=Least active 
consecutive 5 hours of the day; N=sample size
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Figure 1. Associations of sleep, bedtime and 24-hour activity rhythm parameters with incident dementia, 
over increasing epochs of follow-up time
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3DISCUSSION
In the general population, actigraphy-estimated longer sleep onset latency, longer wake 
after sleep onset, longer time in bed, and lower sleep efficiency, as well as earlier ‘lights 
out’ time, were associated with a higher risk of dementia. In contrast, 24-hour activity 
rhythm fragmentation or stability did not influence dementia risk.
Several methodological considerations should be mentioned. Actigraphy-derived 
behavioral rhythms do not necessarily equate to the endogenous circadian rhythm. 
Additionally, the gold standard for measuring sleep is polysomnography. Potential 
misclassification of sleep and circadian rhythms, and the low number of incident cases 
in this study, may have reduced our power to detect small effect sizes. Also, we could 
not assess the extent to which preclinical amyloid β (Aβ) or tau pathology, which may 
affect sleep-wake regulating brainstem regions33 years before dementia diagnosis,34,35 
confounded associations with dementia risk. Lastly, selection bias may have influenced 
our findings, although characteristics of included and non-included participants were 
largely similar.
Our study adds to previous actigraphy-based studies9,11,13,36-38 by showing that dis-
turbed sleep is more predictive of developing dementia than disrupted 24-hour activity 
rhythms. Instead of total sleep time, it was rather an increased amount of wakefulness 
when in bed, in line with previous findings,9,36 and an advanced ‘lights out’ time that 
determined dementia risk. We speculate that this indicates that a reduced capability 
to sleep when in bed drives dementia risk, rather than for example deliberate lifestyle 
choices to curtail sleep. Our findings suggest that individuals may have tried to adapt to 
such an ‘incapability’ to sleep by increasing time in bed, mainly by advancing ‘lights out’ 
time, to maintain a sufficient amount of sleep. Several mechanisms could underlie this 
incapability to sleep.
Associations of (A) sleep, (B) bedtimes and (C) 24-hour activity rhythm parameters with risk of dementia 
are shown for increasing epochs of follow-up time within the study timeframe. Hazard ratios for epochs 
in shorter follow-up time were obtained using multivariate Firth’s penalized Cox regression models. We 
obtained estimates after censoring all participants still at risk at 2 years (8 incident dementia cases), 4 years 
(15 cases), 6 years (28 cases), 8 years (47 cases), and after the total follow-up of 11.2 years after baseline 
(60 cases). Hazard ratios are adjusted for age, sex, educational level, employment status, physical activ-
ity, alcohol consumption, body mass index, smoking status, history of cardiovascular disease, presence of 
hypertension, and presence of diabetes mellitus, are expressed per standard deviation increase in the pa-
rameter, and plotted at a log2-scale. Please note that estimates obtained for sleep efficiency were inversed 
(transformed as 1/estimate depicting sleep ‘inefficiency’) for graphical comparison of effect sizes of sleep 
parameters.
Abbreviations: CI=Confidence interval; IS=Interdaily stability; IV=Intradaily variability; L5=Least active con-
secutive 5 hours of the day; SE=Sleep efficiency; SOL=Sleep onset latency; TIB=Time in bed; TST=Total sleep 
time; WASO=Wake after sleep onset
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First, associations may indicate presence of an underlying disease process that both 
increases dementia risk and impairs sleep, for which accumulation of Alzheimer’s 
disease pathology39 in the brain seems to be a likely40 substrate. Such confounding, 
however, is not in line with finding that associations for poor sleep seemed restricted to 
APOE ε4 non-carriers, and not ε4-carriers who are at increased risk of having more brain 
Aβ deposition at this age.40 Also, a previous study found that high intradaily variability 
was related strongest to an increased cerebrospinal fluid biomarker profile suggestive 
of preclinical Alzheimer’s disease.41 Yet, intradaily variability was unrelated to incident 
dementia or Alzheimer’s disease in our study. Also arguing against confounding by 
preclinical pathology are the time-stratified analyses, showing that poor sleep was not 
associated substantially stronger with dementia risk in short versus longer follow-up 
durations, in contrast to early ‘lights out’ and early L5 onset. Second, the slowly pro-
gressing dementia process may impair sleep not directly but through emergence of 
prodromal features such as behavioral or neuropsychiatric symptoms. This mechanism 
may be less likely as associations were also present in persons without depressive 
symptoms, and independent of napping. Third, sleep disorders, particularly the pres-
ence of sleep-disordered breathing, may underlie some of the associations of poor sleep 
with dementia risk.42 Sleep-disordered breathing may instigate neurodegenerative 
processes through intermittent hypoxia and oxidative stress, or through cardiovascular 
or proteostatic mechanisms.43 We could only account for such effects by adjusting for a 
self-reported proxy of sleep-disordered breathing, which might have been insufficient. 
Further research to disentangle the specific roles of actigraphy-estimated nighttime 
wakefulness and sleep-disordered breathing in neurodegenerative or Alzheimer’s dis-
ease pathologies remains needed.
Another remark regarding our APOE-stratified findings is that, interestingly, associa-
tions of sleep with dementia risk seemed restricted to APOE ε4 non-carriers, although we 
found no statistically significant interactions after correcting for multiple testing. Pos-
sibly, disturbed sleep and carrying APOE ε4 impact dementia risk similarly, e.g. through 
protein misfolding,39 synaptic44 or hematopoietic effects.4 The damage accumulated by 
carrying ε4 throughout life then marginalizes potential harmful effects disturbed sleep, 
or what underlies it, may have on dementia risk. The discrepancy of our findings with 
previous work,13 reporting that sleep fragmentation increases risk of Alzheimer’s disease 
only in APOE ε4-carriers, is not readily explained. Possibly, survival bias in this previous 
study13 through including old (mean age >80) ε4-carriers,45,46 or modeling poor sleep 
differently may have played a role.
We could not confirm the hypothesis that circadian disturbances, reflected by vari-
ability and stability of activity rhythms, are implicated47 in dementia etiology. Yet, the 
association of earlier L5 onset with increased dementia risk in the next 2 years sug-
gests a phase advance of nighttime inactivity as a prodromal feature of dementia and 
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Alzheimer’s disease. Heterogeneity of activity rhythm findings in dementia risk, includ-
ing ours, with regard to the direction of a prodromal phase shift10 and use of different 
modeling strategies11,48 should be further investigated.
In conclusion, actigraphy-estimated nighttime wakefulness indicating an incapability 
to sleep is associated with an increased risk of dementia, especially Alzheimer’s disease. 
At the same time, circadian disturbances as reflected in 24-hour activity rhythms played 
a limited role in dementia risk in this population of middle-aged and elderly persons.
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Supplementary Table 1. Associations of sleep, bedtime and 24-hour activity rhythm parameters with risk 
of dementia, additionally adjusted for sleep apnea, napping and APOE-ε4 genotype
Determinant
(per SD increase)
Dementia HR (95% CI), after additionally adjusting for:
Possible sleep apnea Napping No. of APOE-ε4 allele(s)
Cases/N=60/1,322 Cases/N=60/1,322 Cases/N=57/1,251
Sleep
Total sleep time 1.01 (0.76-1.35) 1.03 (0.77-1.37) 0.95 (0.72-1.27)
Sleep onset latency 1.44 (1.12-1.85) 1.44 (1.13-1.84) 1.45 (1.14-1.84)
Wake after sleep onset 1.23 (0.94-1.61) 1.23 (0.95-1.60) 1.24 (0.96-1.60)
Time in bed 1.43 (1.06-1.93) 1.50 (1.11-2.04) 1.39 (1.03-1.87)
Sleep efficiency 0.73 (0.55-0.96) 0.72 (0.55-0.94) 0.71 (0.55-0.92)
Bedtimes
‘Lights out’ time 0.56 (0.41-0.76) 0.54 (0.40-0.73) 0.56 (0.41-0.76)
Getting up time 0.79 (0.57-1.10) 0.82 (0.60-1.13) 0.79 (0.58-1.08)
24-hour activity rhythm
Intradaily variability 1.05 (0.79-1.40) 0.98 (0.73-1.33) 1.08 (0.82-1.41)
Interdaily stability 0.93 (0.70-1.23) 0.95 (0.72-1.25) 0.90 (0.68-1.19)
L5 onset 0.92 (0.72-1.19) 0.92 (0.72-1.19) 0.92 (0.72-1.18)
Hazard ratios were obtained from Cox regression models, adjusted for age, sex, educational level, employ-
ment status, physical activity, alcohol consumption, body mass index, smoking status, history of cardiovas-
cular disease, presence of hypertension, and presence of diabetes mellitus.
Abbreviations: APOE= Apolipoprotein E gene; CI=Confidence interval; HR=Hazard ratio; N=sample size.
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Supplementary Table 2. Associations of sleep, bedtime and 24-hour activity rhythm parameters with risk 
of dementia, in persons without clinically relevant depressive symptoms
Determinant (per SD increase) Dementia HR (95% CI)
Cases/N=56/1,209
Sleep
Total sleep time 0.95 (0.72-1.25)
Sleep onset latency 1.46 (1.14-1.88)
Wake after sleep onset 1.28 (0.99-1.64)
Time in bed 1.39 (1.03-1.88)
Sleep efficiency 0.70 (0.54-0.91)
Bedtimes
‘Lights out’ time 0.55 (0.40-0.74)
Getting up time 0.77 (0.56-1.06)
24-hour activity rhythm
Intradaily variability 1.00 (0.76-1.33)
Interdaily stability 0.95 (0.72-1.26)
L5 onset 0.82 (0.63-1.07)
Clinically relevant depressive symptoms were defined as a score ≥16 on the Center for Epidemiologic Stud-
ies – Depression Scale. Hazard ratios were obtained from Cox regression models, adjusted for age, sex, 
educational level, employment status, physical activity, alcohol consumption, body mass index, smoking 
status, history of cardiovascular disease, presence of hypertension, and presence of diabetes mellitus.
Abbreviations: CI=Confidence interval; N=sample size
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Supplementary Table 3. Effect-modification of associations of sleep, bedtime and 24-hour activity rhythm 
parameters with risk of dementia by age and sex
Determinant
(per SD increase)
Dementia HR (95% CI), age-
stratified
Dementia HR (95% CI), sex-
stratified











Total sleep time 1.18 (0.80-1.75) 0.74 (0.49-1.11) 0.14 1.39 (0.94-2.04) 0.66 (0.44-1.00) 0.02
Sleep onset latency 1.22 (0.83-1.78) 1.54 (1.11-2.16) 0.16 1.28 (0.85-1.92) 1.57 (1.16-2.14) 0.22
Wake after sleep 
onset 1.34 (0.97-1.84) 1.03 (0.66-1.62)
0.77
1.24 (0.87-1.75) 1.21 (0.82-1.79)
0.81
Time in bed 1.63 (1.09-2.44) 1.00 (0.62-1.63) 0.28 2.07 (1.33-3.22) 0.99 (0.65-1.50) 0.02
Sleep efficiency 0.75 (0.52-1.07) 0.68 (0.45-1.01) 0.40 0.83 (0.57-1.23) 0.64 (0.44-0.91) 0.29
Bedtimes
‘Lights out’ time 0.60 (0.40-0.89) 0.48 (0.28-0.83) 0.50 0.53 (0.36-0.79) 0.61 (0.38-0.98) 0.61
Getting up time 0.97 (0.63-1.49) 0.61 (0.37-0.99) 0.77 0.93 (0.59-1.45) 0.68 (0.43-1.06) 0.46
24-hour activity rhythm
Intradaily variability 1.46 (0.99-2.14) 0.93 (0.64-1.35) 0.12 0.79 (0.52-1.21) 1.35 (0.93-1.96) 0.08
Interdaily stability 0.88 (0.61-1.26) 0.94 (0.61-1.43) 0.27 1.13 (0.73-1.75) 0.82 (0.57-1.18) 0.42
L5 onset 0.89 (0.59-1.33) 0.87 (0.62-1.21) 0.34 0.69 (0.47-1.02) 1.10 (0.77-1.55) 0.06
Hazard ratios were obtained from Cox regression models, adjusted for age and sex (if applicable), and 
educational level, employment status, physical activity, alcohol consumption, body mass index, smoking 
status, history of cardiovascular disease, presence of hypertension, and presence of diabetes mellitus. The 
age cut-off of 75 years was chosen to balance dementia incidence between strata. We tested interaction 
through modeling a product term of the unstandardized determinant with age or sex.



















Sleep disturbances may signal presence of prodromal parkinsonism, including Parkin-
son’s disease. Whether general sleep quality or duration in otherwise healthy individuals 
is related to the risk of parkinsonism remains unclear. We hypothesized that both worse 
self-reported sleep quality and duration, as well as a longitudinal deterioration in these 
measures, are associated with the risk of parkinsonism, including Parkinson’s disease.
In the prospective population-based Rotterdam Study, we assessed sleep quality and 
duration with the Pittsburgh Sleep Quality Index in 7,726 persons (mean age 65 years, 
57% women) between 2002-2008, and again in 5,450 persons between 2009-2014. 
Participants were followed until 2015 for a diagnosis of parkinsonism and Parkinson’s 
disease. Outcomes were assessed using multiple modalities: interviews, physical exami-
nation, and continuous monitoring of pharmacy records and medical records of general 
practitioners. We used Cox regression to associate sleep, and changes in sleep over time, 
with incident parkinsonism and Parkinson’s disease, adjusting for age, sex, education 
and smoking status.
Over 64,855 person-years in 13 years of follow-up (mean: 8.4 years), 75 participants 
developed parkinsonism, of whom 47 developed Parkinson’s disease. We showed that 
within the first 2 years of follow-up, worse sleep quality (hazard ratio 2.38 per standard 
deviation increase (95% confidence interval 0.91-6.23)) and shorter sleep duration 
(hazard ratio 0.61 per standard deviation increase (0.31-1.21)) related to a higher risk of 
parkinsonism. Associations of worse sleep quality (hazard ratio 3.86 (1.19-12.47)) and 
shorter sleep duration (hazard ratio 0.48 (0.23-0.99)) with Parkinson’s disease were more 
pronounced, and statistically significant, compared to parkinsonism. This increased risk 
disappeared with longer follow-up duration. Worsening of sleep quality (hazard ratio 
1.76 per standard deviation increase (95% confidence interval 1.12-2.78)), as well as 
shortening of sleep duration (hazard ratio 1.72 per standard deviation decrease (1.08-
2.72)), were related to Parkinson’s disease risk in the subsequent 6 years. Therefore we 
argue that, in the general population, deterioration of sleep quality and duration are 





Parkinson’s disease is primarily characterized by motor disturbances,1 but also includes 
non-motor features. Sleep-wake disturbances are a common non-motor feature of Par-
kinson’s disease2-8 and related synucleinopathies.9-11 Sleep-wake disturbances are also 
reported to precede a diagnosis of parkinsonism in prodromal Parkinson’s disease.12 Ob-
jectively measured increases in sleep fragmentation have also been related to increased 
Parkinson’s disease pathology at brain autopsy in old individuals without Parkinson’s 
disease.13 Sleep-wake disturbances may be a risk factor for Parkinson’s disease, or indi-
cate presence of disease in a prodromal phase. 14,15
Several sleep disorders have been reported to precede Parkinson’s disease or related 
synucleinopathies,12 including rapid eye movement (REM) sleep behavior disorder1,16,17 
and obstructive sleep apnea.18-21 These seem to represent, however, only the ‘tip of 
the iceberg’ of various sleep-wake disturbances in prodromal Parkinson’s disease.22-27 
Subclinical impairments in sleep, such as poor sleep quality and short sleep duration, 
are more common in the general population and may well capture aforementioned 
sleep-wake disturbances. These impairments are particularly important as they are 
often investigated and easily determinable aspects of sleep in any healthcare setting. 
To date, however, only few studies investigated if sleep duration reflects prodromal 
Parkinson’s disease,27,28 and none studied sleep quality. Furthermore, it is unknown if 
long-term changes in sleep duration and quality relate to subsequent risk of parkinson-
ism, including Parkinson’s disease.
We studied the association of subjectively assessed sleep quality and duration with 
parkinsonism, including Parkinson’s disease. We hypothesized that i) worse sleep qual-
ity, and shorter sleep duration, are associated with the risk of parkinsonism, including 
Parkinson’s disease; and ii) deterioration in sleep quality and duration over time is 
associated with the subsequent risk of parkinsonism. We tested these hypotheses in 
a prospective, population-based study, using the Pittsburgh Sleep Quality Index to 
(repeatedly) measure sleep quality and duration, with up to 13 years of follow-up for 
incident parkinsonism.
METHODS
The study was embedded in the Rotterdam Study, a large, prospective, population-
based study in a suburban district in the city of Rotterdam, the Netherlands, details of 
which are described elsewhere.29 The study was set up to investigate the frequency, 
risk factors and natural history of common chronic diseases in the elderly, including 
neurodegenerative diseases such as Parkinson’s disease. The first cohort was initiated in 
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1990 and included 7,983 persons aged ≥55 years, and was expanded with 3,011 persons 
aged ≥55 years in 2000, and 3,932 persons aged ≥45 years in 2006. Examination rounds 
consisted of a home interview and visits to our dedicated research center, including 
a wide range of questionnaires and physical measurements. Visits are repeated every 
4-5 years. Measurements are kept similar across inclusion rounds and time. In between 
examination rounds, incident disease is assessed with continuous linkage of the study 
database and medical records of general practitioners, which also holds summaries 
from all specialist and inpatient care.
The Rotterdam Study has been approved by the Medical Ethics Committee of the Eras-
mus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, Welfare 
and Sport (Population Screening Act WBO, license number 1071272-159521-PG). The 
Rotterdam Study Personal Registration Data collection is filed with the Erasmus MC Data 
Protection Officer under registration number EMC1712001. This study is registered with 
the Netherlands National Trial Register and WHO International Clinical Trials Registry 
Platform under the shared catalogue number NTR6831. All participants provided writ-
ten informed consent to participate in the study and to have their information obtained 
from treating physicians.
Study population
We included participants from all three inclusion rounds when a sleep questionnaire, 
the Pittsburgh Sleep Quality Index (PSQI), was first introduced. At this baseline visit 
(between 2002-2008), we included 7,726 individuals who had valid data on sleep qual-
ity or sleep duration, did not have prevalent parkinsonism or Parkinson’s disease,30 and 
were not cognitively impaired based on a Mini-mental state examination (MMSE) score 
> 25. We followed the remaining participants until the first of: onset of parkinsonism or 
Parkinson’s disease, 1 January 2015, or death. Study follow-up for incident parkinsonism 
was nearly complete (64,855 person-years [98.1%]).31
For analyses of changes in sleep over time, we similarly included 5,450 individuals at 
the follow-up visit (between 2009-2014) and started follow-up time for parkinsonism 
and Parkinson’s disease after this visit. See Supplementary Fig. 1 for a detailed flowchart 
of included participants for analyses at baseline and the follow-up visit.
Assessment of sleep
Subjective aspects of sleep were measured with a Dutch version of the PSQI, which 
assesses past month’s average sleep quality. The PSQI32 has a good test-retest reliabil-
ity and validity in a non-clinical sample of older adults.33 Answers can be categorized, 
scored and combined into seven component scores ranging from 0 (not problematic) to 
3 (very problematic), labeled ‘quality’, ‘latency’, ‘duration’, ‘efficiency’, ‘disturbances’, ‘sleep 




PSQI score (range: 0 – 21) of subjectively assessed sleep quality (hereafter: ‘sleep qual-
ity’). Higher scores indicate poorer sleep, and scores > 5 indicate a ‘poor’ sleep quality.
For participants with more than one PSQI component missing, the global PSQI score 
was not calculated (n=156, 2%). To minimize loss of participants, we calculated weighted 
component scores for participants who missed one component score (n=1,099, 13%) by 
multiplying the six-component sum scores by 7/6. Most of these participants missed 
information on sleep disturbances (n=847) due to introducing a skip rule in PSQI items 
on disturbances (5a-5j32) in a subset of participants, to limit participant burden. If 
answers to items 5a-5b were both negative (‘not in the last month’), items 5c-5j were 
skipped. Weighting scores minimized any effect of the skip rule on global PSQI scores, 
as in persons who answered items 5a-5b negatively, weighted scores were not different 
between those who followed the skip rule versus those who did not (data not shown). 
Analogously, at follow-up we did not calculate the global PSQI score for 484 (8%) due 
to missing more than one PSQI component at the follow-up visit (and excluded partici-
pants who missed global PSQI score at the baseline visit so that changes could not be 
calculated [n=203]). We weighted scores for 252 participants (5%) who mostly missed 
data on efficiency (n=190; see flowchart in Supplementary Fig. 1).
Assessment of parkinsonism and Parkinson’s disease
A detailed description of parkinsonism and Parkinson’s disease assessment methods 
used in this study has previously been published.34 In short, we used four overlapping 
modalities to collect information on parkinsonism and Parkinson’s disease: in-person 
interviews, examinations, use of antiparkinsonian medication, and continuous monitor-
ing of medical records. Examinations included standardized screening assessments of 
parkinsonian signs (i.e. tremors, hypo- and bradykinesia, cogwheel rigidity, and postural 
reflex) by a trained research nurse during center visits. If one or more signs were present, 
individuals were subsequently invited for a structured physical examination by a trained 
research physician.
Parkinsonism was defined by presence of hypo- or bradykinesia in combination with 
≥1 cardinal sign (resting tremor, rigidity or postural imbalance) observed by any physi-
cian, or a clinical diagnosis of parkinsonism by a neurologist or geriatrician (if motor 
examination details were unavailable). Within those individuals, we diagnosed Parkin-
son’s disease in presence of a clinical Parkinson’s disease diagnosis by a neurologist or 
geriatrician, or a documented positive response to dopaminergic treatment in persons 
who did not have evidence for a secondary cause (e.g. preexistent dementia diagnosis, 
use of anti-dopaminergic drugs, cerebrovascular disease). We classified individuals with 
‘unspecified parkinsonism’ if they had multiple possible causes or lacked a clear underly-
ing cause of parkinsonism.
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Potential confounders and effect-modifiers
Analyses were adjusted for potential confounders measured at baseline, selected based 
on relevant publications1,22,35: age, sex, education and smoking history. Educational 
attainment was assessed by interview and categorized as primary, secondary/lower 
vocational, intermediate vocational, and higher vocational or university. Smoking habits 
were assessed by interview and categorized as never, former or current smoking. We 
also examined potential effect-modification by depressive symptoms and anxiety dis-
orders. Depressive symptoms were assessed with the validated Dutch version36 of the 
Centre for Epidemiological Studies Depression Scale.37 Presence of an anxiety disorder 
was assessed by an adapted version of the Munich Composite International Diagnostic 
Interview.38
Statistical analysis
A detailed explanation of our statistical methods is provided in the Supplementary Text. 
In short, we first used Cox proportional hazards regression models to associate both 
sleep quality and duration at baseline with both incident parkinsonism and Parkinson’s 
disease. As we found that the Cox model assumption of proportionality was violated 
in some analyses, we also examined how aforementioned associations changed over 
follow-up time by performing analyses in incremental epochs of follow-up time from 
baseline (extending follow-up time e.g. baseline to 2 years, baseline to 4 years, etc.)39, 
or using a stratified Cox model to obtain period-specific hazards (e.g. baseline to 2 
years, 2 to 4 years, etc.). We furthermore looked at the effect of other PSQI components 
separately. As sensitivity analyses, we restricted analyses to persons without comorbid 
depression and anxiety. We also investigated potential effect-modification by age, sex, 
and presence versus absence of any of four parkinsonian signs. Second, we related 
changes in sleep quality and duration between the baseline and the follow-up visit with 
incident parkinsonism and Parkinson’s disease after the follow-up visit.
Variables were standardized and, when right-skewed, log-transformed before stan-
dardization. Missing values on covariates were imputed using five multiple imputations.
RESULTS
Characteristics of the study sample at baseline are summarized in Table 1. Median global 
PSQI score was 3, and 2,115 participants (27%) scored over 5 indicating poor sleep qual-
ity. Global PSQI score and sleep duration were moderately correlated (Spearman’s r = 
-0.69; P<0.01)). During 13.0 years of follow-up (mean 8.4 years), we observed 75 incident 




Sleep quality was not associated with the risk of parkinsonism (hazard ratio [HR] per 
standard deviation [SD] increase in global PSQI score: 0.95 (95% confidence interval 
(CI) 0.76-1.20)) or Parkinson’s disease (HR per SD increase 0.87 (95% CI 0.65-1.16)). 
We observed similar estimates when analyzing categorized poor (versus good) sleep 
quality: HR 0.97 (95% CI 0.57-1.66) for parkinsonism, and HR 0.79 (95% CI 0.39-1.59) for 
Parkinson’s disease (Supplementary Table 2).
Longer sleep duration was not associated with the risk of parkinsonism (HR per SD 
increase 1.21, 95% CI 0.95-1.54) and PD (HR 1.24, 95% CI 0.92-1.69). After categorizing 
sleep duration, we did not observe a significant increase in risk with increasing catego-
ries of sleep duration (Supplementary Table 2).
In aforementioned analyses for Parkinson’s disease risk, but not for parkinsonism, 
the proportionality assumption for both sleep quality and duration was significantly 
violated.
Table 1. Characteristics of study population at baseline
Characteristic (unit) Total sample Incident PS No incident PS
N = 7,726 N = 75 N = 7,651
Age at baseline (years) 65.4 ± 10.3 71.6 ± 8.4 65.4 ± 10.3
Female 4,396 (57%) 33 (44%) 4,365 (57%)
Educational level
Primary education 708 (9%) 8 (11%) 700 (9%)
Lower/intermediate or lower vocational 3,088 (40%) 29 (39%) 3,060 (40%)
Higher or intermediate vocational 2,371 (31%) 24 (32%) 2,347 (31%)
Higher vocational or university 1,559 (20%) 14 (19%) 1,545 (20%)
Smoking status
Never 3,416 (44%) 34 (45%) 3,383 (44%)
Former 3,549 (46%) 33 (44%) 3,516 (46%)
Current 761 (10%) 8 (11%) 753 (10%)
Cognitive functioning (MMSE score) 28 (27-29) 28 (27-29) 28 (27-29)
Depressive symptoms (CES-D score) 3 (1-8) 4 (1-8) 3 (1-8)
Presence of any anxiety disorder 588 (8%) 8 (11%) 580 (8%)
Presence of any parkinsonian signs 807 (10%) 16 (21%) 792 (10%)
Sleep quality (global PSQI score) 3 (2-6) 3 (1-6) 3 (2-6)
Missing 46 (1%) 0 (0%) 46 (1%)
Sleep duration (hours) 6.8 ± 1.2 7.1 ± 1.3 6.8 ± 1.2
Characteristics of study population at baseline. Values are expressed as frequency (%) for categorical vari-
ables and mean ± standard deviation or median (interquartile range) for continuous variables, unless speci-
fied otherwise. Includes imputed values for covariates.
Abbreviations: CES-D=Center for Epidemiological Studies – Depression Scale; MMSE=Mini-mental state ex-
amination; N=sample size; PS=parkinsonism; PSQI=Pittsburgh Sleep Quality Index
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We found that worse sleep quality related to an increased risk of parkinsonism (HR 
2.38, 95% CI 0.91-6.23) in the first 2 years of follow-up, which disappeared when increas-
ing follow-up time from baseline (Fig. 1A). In these 2 years, associations were more pro-
nounced, and statistically significant, for Parkinson’s disease (HR 3.86, 95% CI 1.19-12.47) 
compared to parkinsonism. Results for sleep duration were analogous (Fig. 1B): short 
sleep duration was associated with an increased risk of parkinsonism (HR 0.61, 95% CI 
0.31-1.21) and Parkinson’s disease (HR 0.48, 95% CI 0.23-0.99). Additionally, analysis of 
period-specific hazard ratios using a stratified Cox model suggested that associations of 
worse sleep quality, and shorter sleep duration, with an increased risk of parkinsonism 
and Parkinson’s disease are confined to the first 2 years of follow-up (Supplementary 
Fig. 2).
Most PSQI components showed a similar pattern of associations with cumulative 
increasing follow-up duration, except for sleep medication (Fig. 2A-F). We observed 
noteworthy changes in effect sizes from short to long follow-up for sleep efficiency, 
and to a lesser extent for sleep quality, latency and daytime dysfunction (Fig. 2A-C; Fig. 
2F; Supplementary Table 3). Also, for daytime dysfunction, the direction of hazard ratio 
estimates changed over increasing epochs of follow-up (Supplementary Table 3).
We further restricted the sample to persons without clinically relevant depressive 
symptoms and without any anxiety disorder, leaving 6,605 individuals of which 61 cases 
of parkinsonism, including 39 cases with Parkinson’s disease. Associations over cumula-
tively increasing follow-up duration were similar to the total sample (Supplementary Fig. 
3). For the association of sleep duration with Parkinson’s disease, all hazard ratios shifted 
to higher values. As a result, longer sleep duration was now associated with increased 
Parkinson’s disease risk in the overall follow-up (HR 1.47, 95% CI 1.02-2.11), for which 
proportionality was not violated.
Analyses stratified at median age did not reach statistical significance. We observed 
hazard ratio estimates suggesting associations of worse sleep quality with a lower risk 
of parkinsonism and Parkinson’s disease in younger persons, while hazard ratios in older 
persons were close to the null. Similarly, estimates also suggested associations of longer 
sleep duration with a higher risk of both outcomes in younger persons. Case numbers in 
separate strata were small. Also, there were no significant interactions between age and 
sleep quality or duration on the risk of either outcome (Supplementary Table 4).
We observed a similar relation between sleep quality and duration and disease risk in 
persons without parkinsonian signs at baseline. Statistically testing these interactions 
on a multiplicative scale showed significant interactions of sleep quality with presence 
of parkinsonian signs on the risk of both parkinsonism and Parkinson’s disease (Supple-
mentary Table 4).
Characteristics of the study population at the follow-up visit are provided in Supple-




Figure 1. Associations of sleep quality and duration with risk of parkinsonism and Parkinson’s disease, per 
cumulatively increasing duration of follow-up
The associations of (A) sleep quality and (B) sleep duration with incident parkinsonism and Parkinson’s 
disease are shown for cumulatively increasing follow-up duration within the study timeframe. Hazard ratio 
estimates were obtained from multivariate Firth’s penalized Cox regression models by censoring all par-
ticipants still at risk at year 2, 4, 6, 8 and 10 after baseline, and after the total follow-up of 13 years. Hazard 
ratio estimates were adjusted for age at baseline, sex, educational level and smoking status, are expressed 
per standard deviation increase of (A) worse sleep quality, or (B) longer sleep duration, and are plotted at a 
(A) logarithmic (base 2) scale and (B) a linear scale. Abbreviations: CI=Confidence Interval; PD=Parkinson’s 
disease; PSQI=Pittsburgh Sleep Quality Index
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Figure 2. Associations of Pittsburgh Sleep Quality Index component scores with risk of parkinsonism and 
Parkinson’s disease, per cumulatively increasing duration of follow-up
The associations of the PSQI components (A) quality, (B) latency, (C) efficiency, (D) disturbances, (E) sleep 
medication, and (F) daytime dysfunction with incident parkinsonism and Parkinson’s disease are shown 
for cumulatively increasing follow-up duration within the study timeframe. Hazard ratio estimates were 
obtained from multivariate Firth’s penalized Cox regression models by censoring all participants still at risk 
at year 2, 4, 6, 8 and 10 after baseline, and after the total follow-up of 13 years. Estimates are adjusted for age 




measured over 10.9 years (on average 6.0 years) in all participants. In the subsequent 
6.0 years (average follow-up: 2.9) after the follow-up visit, we observed 25 incident 
parkinsonism cases, of which 17 with Parkinson’s disease.
Worsening of sleep quality was related to a subsequent increase in Parkinson’s disease 
risk (HR per SD increase 1.76, 95% CI 1.12-2.78), as was a shortening of sleep duration 
(HR per SD increase 1.72, 95% CI 1.08-2.72; Table 2). Results were independent of the 
absolute average level of sleep quality or duration (Table 2). Also, additional adjust-
ment for depressive symptoms at baseline did not attenuate results. Associations of 
sleep quality (HR 1.23, 95% CI 0.83-1.83) and sleep duration (HR 1.45, 95% CI 0.99-2.13) 
with incident parkinsonism were less pronounced. When examining hazard ratios over 
increasing epochs of follow-up time measured from the follow-up visit, we found that 
worsening of sleep quality, and shortening of sleep duration, were associated with 
parkinsonism on the short term, but not the longer term (Supplementary Fig. 4). For 
both sleep parameters, risk of Parkinson’s disease was also slightly higher on the short 
than on the long term.
score, and are plotted at different logarithmic (base 2) scales per component. For parkinsonism analyses, 
we included following numbers of participants: (A) 7716, (B) 7718, (C) 7473, (D) 6840, (E) 7725, (F) 7689 
(samples were 5 to 7 participants smaller for analyses on Parkinson’s disease). To ensure sufficient (>10%) 
observations in each category, we combined scores 2 and 3 for components quality, latency and efficiency, 
and scores 1, 2 and 3 for components disturbances, medication and daytime dysfunction.
Abbreviations: CI=Confidence interval; HR=Hazard ratio; N=Sample size; PD=Parkinson’s disease; 
PSQI=Pittsburgh Sleep Quality Index
Table 2. Association of changes in sleep quality and duration between the baseline and follow-up visit, and 
risk of parkinsonism and Parkinson’s disease
Determinant (unit) Parkinsonism Parkinson’s disease
Cases/N HR (95% CI) Cases/N HR (95% CI)
Change sleep quality (worse sleep) 25/5,206 1.23 (0.83-1.83) 17/5,244 1.76 (1.12-2.78)
Change sleep duration (shorter sleep) 25/5,244 1.45 (0.99-2.13) 17/5,238 1.72 (1.08-2.72)
Changes in sleep quality were modeled per standard deviation increase (‘worsening’) of global Pittsburgh 
Sleep Quality Index score, and changes for sleep duration were modeled as standard deviation decrease 
(‘shortening’) of sleep duration from the baseline visit to the follow-up visit. Hazard ratio estimates are ad-
justed for age at baseline, sex, educational level, smoking status and time interval between measurements. 
Additional adjustment for depressive symptoms at baseline minimally changed point and interval esti-
mates (data not shown). After additional adjustment for the average level of sleep quality or sleep duration 
of the two measurements, point and interval estimates for the relation with parkinsonism barely changed. 
Estimates for associations of change in sleep quality (HR 1.87, 95% CI 1.12-3.10) and change in sleep dura-
tion (HR 1.85, 95% CI 1.14-2.98) with risk of Parkinson’s disease increased. Bold estimates indicate statisti-




In the general population, baseline sleep quality and duration within the next 2 years 
relate to incident parkinsonism, and specifically to Parkinson’s disease. Similarly, dete-
rioration over 6 years in these parameters is associated with incident parkinsonism and 
Parkinson’s disease.
Several methodological considerations should be mentioned. First, our study focused 
on subjectively measured sleep, which does not necessarily reflect similar constructs 
as objective measurements. While the first incorporates the experience of sleep, objec-
tive measurements indicate physiological sleep. Therefore, subjective measures cannot 
provide similar insight in underlying biological processes as objective measures (e.g. 
polysomnography). Second, we did not include individuals with cognitive impairment 
to minimize information bias of sleep quality40,41 and duration40,42, but these individuals 
are at increased risk of having prodromal parkinsonism43 which could bias our associa-
tions. In addition, persons with cognitive impairment are also predisposed to develop 
REM sleep behavior disorder,44 which has been suggested to be associated to a longer 
sleep duration in the general population.45 This could lead to an underestimation of as-
sociations of sleep duration with parkinsonism and Parkinson’s disease. Third, although 
the PSQI is used in patients with Parkinson’s disease,46 it may miss Parkinson’s disease-
specific sleep disturbances.47,48 Patients with prodromal disease may thus underreport 
sleep problems, or overstate their sleep quality. If so, we have even underestimated 
especially short-term effect estimates of worse sleep quality with increased risk of 
parkinsonism and Parkinson’s disease risk. Fourth, the number of parkinsonism and 
Parkinson’s disease cases in our study is small, which may have unpowered us to detect 
small effects. Fifth, subjective assessment of sleep may be more prone to measurement 
error than objective methods. This lack of precision may have precluded us from detect-
ing small effect sizes. Sixth, we cannot exclude any residual confounding of medication 
use beyond those questioned in the PSQI in our estimates.
We found associations of poor sleep quality and short sleep duration with increased 
risk of parkinsonism, and especially Parkinson’s disease, in the first 2 years of follow-up, 
attenuating with incremental follow-up. Our study adds to the previous findings by 
showing that associations evidently change with incremental follow-up time. This is in 
line with findings of large registry-based studies in general practice that show increases 
in insomnia diagnoses 2 years,22,49 but not 5 and 10 years before diagnosis of Parkinson’s 
disease 22. Such results suggest that sleep disturbances occur as prodromal features 
rather than as causes of Parkinson’s disease and related synucleinopathies, as sleep 
is measured closer to the diagnosis of an incident case when follow-up is short. Our 




those severe enough to diagnose a sleep disorder, and therefore fit well with the variety 
of sleep disturbances preceding Parkinson’s disease.12
Mechanisms behind sleep disturbances marking prodromal Parkinson’s disease remain 
speculative. Sleep may be disturbed by early-stage dysfunction of serotonergic neurons 
in the dorsal raphe nuclei and sleep-promoting areas in the basal forebrain.50 Such 
dysfunction may also negatively impact switching between sleep and wake.51 Addition-
ally, early spread of pathology to the coeruleus/subcoeruleus complex may disturb REM 
sleep independent of REM sleep behavior disorder.15 Sleep may also be impaired via 
circadian dysfunction occurring around the time of diagnosis,2 via hypothalamic neuron 
loss,52,53 or via the loss of dopaminergic modulation.54
Of note, results do not exclude that sleep disturbances may cause Parkinson’s disease. 
An effect of sleep disturbance on neurodegenerative disease is plausible, as sleep de-
privation has been shown to increase levels of beta-amyloid, a pathological hallmark of 
Alzheimer’s disease. Mechanisms include decreased clearance,55 or activity-dependent 
increased production, of beta-amyloid. The sleep wake cycle has also been shown to 
regulate tau levels, and sleep deprivation can increase extracellular levels of tau and, 
interestingly, alpha-synuclein.56 A recent study importantly showed that increased ac-
tigraphy-derived sleep fragmentation in old individuals without Parkinson’s disease was 
associated with an increased burden of Parkinson’s disease pathology at brain autopsy.13 
This indicates that objective disturbances, besides subjectively impaired sleep, relates to 
Parkinson’s disease pathology. Unfortunately, the cross-sectional design does not allow 
inference on temporality of the association. Authors speculate that potential pathways 
between sleep fragmentation and disease risk may include increased oxidative stress, or 
reduced clearance of metabolic waste including extracellular α-synuclein.13
Analyses of changes in sleep quality and duration suggest that sleep in prodromal Par-
kinson’s disease already deteriorates over 2 years prior to diagnosis in the general popu-
lation, independent from baseline depressive symptoms, and the absolute levels over 
which the changes occurred. To our knowledge, the only study investigating changes 
in sleep has been performed in patients with REM sleep behavior disorder.57 This study, 
however, reported opposite findings: improving insomnia symptoms and increasing 
self-reported sleep duration increased the risk for conversion to Parkinson’s disease and 
dementia with Lewy bodies. Differences in findings could results from their selection of 
patients prone to develop a severe, cognitively more impaired subtype of prodromal 
Parkinson’s disease,58 but differences may additionally be explained by non-recognition 
of sleep problems due to including subjects with subclinical cognitive deficits.59-61 Their 
study not only had a high incidence (50%) of Lewy body dementia patients, but also 
showed underreporting (reporting increased sleep duration and quality discrepant 




If aforementioned changes in sleep were driven by a specific sleep disorder, REM 
sleep behavior disorder may not be a likely candidate: Persons with REM sleep behavior 
disorder in a population-based polysomnography study had a similar sleep quality, and 
even longer sleep duration, than others.45 REM sleep behavior disorder patients also did 
not perceive their sleep as worse, or shorter, than healthy controls.57
After excluding persons with comorbid depressive symptoms or anxiety disorders, re-
sults remained mostly similar. Noteworthy was that hazard ratio estimates of the relation 
of sleep duration with Parkinson’s disease risk were all slightly higher. This resulted in an 
association of longer sleep duration with increased Parkinson’s disease risk in the overall 
follow-up. Given the number of associations investigated in our sensitivity analyses, and 
the small number of cases when restricting the sample, this result may be a spurious 
finding and should be interpreted with caution.
A methodological explanation is that in these sensitivity analyses persons in a late 
prodromal phase of Parkinson’s disease may have been selectively excluded, as depres-
sion and anxiety are both part of the prodromal phase and considered predominantly 
late features.22,62,63 This could have resulted in selective exclusion of susceptible individu-
als39 resulting in a decreased long-term risk of Parkinson’s disease in those remaining 
individuals with short sleep duration. It is also possible that short sleep duration is 
merely symptomatic of (prodromal emergence of ) depression, which explains why 
exclusion of persons with depression resulted in an inverse association of sleep duration 
with Parkinson’s disease. Nevertheless, we re-emphasize the small number of cases in 
our analyses, which may have compromised the robustness of these findings.
Analogous to aforementioned sensitivity analysis, stratified analyses on the presence 
of parkinsonian signs might also select participants based on either a more advanced 
stage of an underlying neurodegenerative process, or its absence. A statistical interac-
tion with sleep quality could guide future investigations of identifying high risk groups 
for parkinsonism or Parkinson’s disease risk.
Patterns of associations between separate PSQI components and Parkinson’s disease 
risk over time indicate that, aside from sleep duration, efficiency may mark prodromal 
disease. This applies to sleep quality, latency and daytime dysfunction to a lesser extent. 
Although these aspects of sleep may correlate well to known markers of prodromal Par-
kinson’s disease such as pain or autonomic failure,22 or excessive daytime sleepiness,12,64 
results also warrant further investigation of these easily measured aspects of sleep in 
etiological or risk prediction efforts. Future studies on prodromal Parkinson’s disease 
are needed to investigate associations with objective measures of sleep, and to assess 
the predictive value of (perceived) shortening or worsening of sleep over known (sleep) 
markers of prodromal parkinsonism.
In conclusion, poor sleep quality and short sleep duration increased the risk of par-




tion change for the worse over 2 years prior to a diagnosis of parkinsonism, especially 
Parkinson’s disease. Both are congruent with presence of prodromal Parkinson’s disease 
progressively deteriorating sleep.
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2,091 persons not included in analyses, for 
the following reasons (excluded in this 
order):   
- 797 (8.1%) were not screened for 
parkinsonism 
- 23 had prevalent parkinsonism 
entering the Rotterdam Study 
- 1,137 (11.6%) scored ≤ 25 on the Mini-
mental state examination 
- 24 had prevalent parkinsonism at study 
baseline 
- 110 (1.1%) had missing data for both 
sleep quality and sleep duration  
 
9,817 (100%) participants were 
still alive at introduction of sleep 
questionnaire at baseline visit in 




7,726 (79%) filled out the PSQI with valid 
data on sleep quality OR sleep duration 
7,680 persons (78%) included 
in sleep quality analyses 
46 persons missed more than one 
component score and did not have 
global PSQI score calculated 
7,726 persons (79%) included 
in sleep duration analyses 
7,162 (100%) participants were still 
alive and participating in the follow-up 




5,450 (76%) filled out the PSQI with valid 
data on sleep quality OR sleep duration 
1,712 persons not included in analyses, for the 
following reasons (excluded in this order): 
- 427 (5.9%) were not screened for 
parkinsonism 
- 9 had prevalent parkinsonism entering the 
Rotterdam Study 
- 782 (10.9%) scored ≤ 25 on the Mini-mental 
state examination 
- 19 had prevalent parkinsonism at study 
baseline 
- 475 (6.6%) had missing data for both sleep 
quality and sleep duration  
 
5,239 persons (73%) 
included in analyses of 
change in sleep quality 
211 persons were missing global 
PSQI score at either the baseline or 
follow-up visit 
173 persons did not report 
sleep duration at the 
baseline visit 
5,277 persons (74%)  
included in analyses of 
change in sleep duration 





For our main analyses, we used Cox proportional hazard models to determine the as-
sociation of sleep quality, measured with the global PSQI score, and sleep duration at 
baseline with incident parkinsonism and Parkinson’s disease, using follow-up time as 
timescale. We repeated the main analysis after categorizing sleep quality and duration 
(sleep duration according to international recommendations for elderly individuals65).
When investigating the assumption of proportional hazards of the Cox model through 
visually examining and statistically testing the scaled Schoenfeld residuals, we found 
slight (0.01<p<0.05) violations of proportionality for both sleep determinants in the 
main analyses on Parkinson’s disease. This indicates that the hazard ratio, which provides 
an average of the relative risk over the included follow-up time, is a poor representation 
of the changes occurring over time within the study timeframe.39 To examine these 
changes over time, we repeated the main analyses for both outcomes after restricting 
follow-up to shorter study duration by censoring participants at 2, 4, 6, 8, and 10 years 
after baseline, using Firth’s penalized Cox regression analysis to account for low cumula-
tive incidences of outcomes after short follow-up.66,67 Such an approach shows how the 
choice of follow-up time from baseline affects the hazard ratio.39 Of note, proportionality 
was not violated for analyses of 6 years after baseline or shorter (for the association of 
sleep duration and Parkinson’s disease), or at 2 years after baseline (for the association 
of sleep quality and Parkinson’s disease). To further examine hazard ratio changes over 
time, we used a stratified Cox model by stratifying by follow-up time intervals of 0-2, 2-4, 
4-6, 6-8, 8-10, and 10-13 years. Hazard ratios were obtained by modeling the interaction 
of the determinant with a term of categorized follow-up time, and combining the coef-
ficients of point and interval estimation for the determinant and that stratum.
Next, to investigate if any associations found for global PSQI score were driven by 
specific components, we also investigated the relation between PSQI component scores 
(quality, latency, efficiency, disturbances, medication and daytime dysfunction) and 
incident parkinsonism or Parkinson’s disease, in overall and shorter follow-up durations 
similarly as described above. As sleep duration was already investigated separately, we 
did not additionally investigate the duration component of the PSQI (which categorizes 
reported sleep duration32). Also, we performed the main analyses in persons without 
any comorbid clinically relevant depressive symptoms (CES-D score ≥16) and without 
any anxiety disorders. Furthermore, we studied possible effect modification in the main 
analyses by median age, sex, and presence versus absence of any of four parkinsonian 
signs (scoring details published previously62), by performing stratified analyses and 
formally testing for multiplicative interaction. Proportionality was not violated in the 




We also examined how changes in sleep quality and duration between the baseline and 
follow-up visit were related to subsequent risk of parkinsonism and Parkinson’s disease. 
Follow-up time was calculated from the follow-up visit, and analyses were additionally 
adjusted for the time interval between the baseline and follow-up visit. A change in 
sleep quality was modeled by subtracting the baseline global PQSI score from the score 
at the follow-up visit, so that positive values indicated worsening of sleep quality over 
time. Change in sleep duration was modeled as shorter sleep duration, by subtracting 
self-reported sleep duration at the follow-up visit from that at baseline. We repeated 
analyses after i) additionally adjusting for averaged global PSQI score, or sleep duration, 
over baseline and follow-up visits to examine if effects were dependent on absolute 
levels (i.e. if decreases in e.g. sleep duration from 9 to 7 hours would be different from 
decreases from 7 to 5 hours); ii) adjusting for depressive symptoms at baseline to see 
if sleep changes were driven by depression. As we also observed non-proportionality 
of hazard ratios (0.01<p<0.05) in the analyses of changes in sleep quality and duration 
between the baseline and follow-up visit on the risk of parkinsonism, we also obtained 
period-specific hazard ratios for these relations.
To obtain normally distributed values and minimize the effect of outliers, we 
log-transformed (ln(variable + 1)) right-skewed variables (global PSQI score) and sub-
sequently winsorized (i.e. transformed towards the mean) outliers to three standard 
deviations from the mean (1.3% of observations for global PSQI score, 0.8% for sleep 
duration). Both variables were then standardized (subtracting the mean and dividing by 
the standard deviation) to facilitate comparison of effect sizes.
Missing data on covariates (missing values in covariates at baseline: median=1.6%, 
maximum=29.7% (smoking status)) were imputed using five multiple imputation based 
on all variables used in our analyses. Statistical testing was performed two-sided at 
p<0.05. Data were analysed using SPSS Statistics, version 21 (IBM Corp., Armonk, NY), 
and with the open R software (packages: ‘survival’, ‘coxphf’).
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Supplementary Table 1. Overview of incident parkinsonism diagnoses
Clinical diagnosis After the baseline visit
(N=7,726)
After the follow-up visit
(N=5,450)
Probable Parkinson’s disease 47 (63%) 17 (68%)
Vascular parkinsonism 3 (4%) 1 (4%)
Medication-induced parkinsonism 5 (7%) 1 (4%)
Progressive supra-nuclear palsy 1 (1%) 0
Multiple system atrophy 0 0
Corticobasal degeneration 1 (1%) 1 (4%)
Lewy body dementia 2 (3%) 0
Parkinsonism with dementia – not Lewy body type 2 (3%) 0
Unspecified parkinsonism* 14 (19%) 5 (20%)
All parkinsonism diagnoses 75 (100%) 25 (100%)
Number of diagnoses expressed as frequency (%), for the samples used in analyses at the baseline and 
follow-up visits.
*Denotes parkinsonism patients that did not have any of the above clinical diagnoses
Supplementary Table 2. Association between categories of sleep quality or duration and risk of incident 
parkinsonism or Parkinson’s disease
Determinant Categories Parkinsonism Parkinson’s disease
Cases/N HR (95% CI) Cases/N HR (95% CI)
Global
PSQI score
≤5 (‘good’ quality) 55/5,565 1.00 (reference) 36/5,562 1.00 (reference)
>5 (‘poor’ quality) 20/2,115 0.97 (0.57-1.66) 11/2,112 0.79 (0.39-1.59)
Sleep duration <7 hours 21/3,155 1.00 (reference) 13/3,150 1.00 (reference)
≥7 - ≤8 hours 45/4,033 1.61 (0.95-2.71) 28/4,031 1.65 (0.86-3.21)
>8 hours 9/538 2.19 (1.00-4.81) 6/537 2.54 (0.96-6.72)
Hazard ratios were obtained from Cox regression models, adjusted for age at baseline, sex, educational 
level, and smoking status, expressed in reference to the lowest global PSQI score, or sleep duration, cat-
egory. Categorization of sleep duration in three categories is based on the US National Sleep Foundation 
recommended sleep duration for elderly persons.65




Supplementary Figure 2. Associations of sleep quality and duration with risk of parkinsonism and Parkin-
son’s disease, over separate intervals of follow-up time
The associations of (A) sleep quality and (B) sleep duration with incident parkinsonism and Parkinson’s 
disease are shown for separate intervals of follow-up duration within the study timeframe, using a strati-
fied Cox model. Hazard ratio were estimated for the intervals 0-2 years, 2-4 years, 4-6 years, 6-8 years, 8-10 
years, and 10-13 years (end of follow-up) and obtained from modeling the interaction of the determinants 
with follow-up time strata. Hazard ratio estimates were adjusted for age at baseline, sex, educational level 
and smoking status, are expressed per standard deviation increase of (A) worse sleep quality, or (B) lon-
ger sleep duration, and are plotted at a logarithmic (base 2) scale. Abbreviations: CI=Confidence Interval; 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 3. Associations of sleep quality and duration with parkinsonism and Parkinson’s 
disease in persons without comorbid depression and anxiety, per cumulatively increasing duration of fol-
low-up
Associations of (A) sleep quality and (B) sleep duration with incident parkinsonism, and (C) sleep quality 
and (D) sleep duration with incident Parkinson’s disease, analyzed both in the total sample and in persons 
without clinically relevant depressive symptoms and anxiety disorders. Associations are depicted for cu-
mulatively increasing follow-up duration within the study timeframe. Hazard ratio estimates were obtained 
from multivariate Firth’s penalized Cox regression models by censoring all participants still at risk at year 
2, 4, 6, 8 and 10 after baseline, and after the total follow-up of 13 years. Estimates were adjusted for age at 
baseline, sex, educational level and smoking status, are expressed per standard deviation increase of PSQI 
score or sleep duration, and are plotted at a logarithmic (base 2) scale. Abbreviations: CI=Confidence Inter-
val; PSQI=Pittsburgh Sleep Quality Index
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Supplementary Table 4. Association of sleep quality or duration and risk of incident Parkinson’s disease or 




HR per SD increase
(95% CI)
Pint Cases/N Parkinson’s dis.




Age ≤67.5 y. 12/384 0.56 (0.31 – 1.00) 0.816 10/3837 0.62 (0.32 - 1.19) 0.683
>67.5 y. 63/3,840 1.07 (0.82 - 1.38) 37/3837 0.95 (0.69 - 1.32)
Sex Male 42/3,305 1.01 (0.74 - 1.38) 0.289 24/3300 0.81 (0.53 - 1.22) 0.479
Female 33/4,375 0.89 (0.63 - 1.25) 23/4374 0.93 (0.62 - 1.41)
Park. signs Present 16/804 1.96 (1.07 - 3.59) 0.004 12/802 1.53 (0.80 - 2.91) 0.048
Absent 59/6,876 0.80 (0.62 - 1.03) 35/6872 0.72 (0.52 – 1.00)
Sleep duration
Agea ≤67.5 y. 12/3,863 1.84 (0.97 - 3.50) 0.778 10/3859 1.68 (0.82 - 3.47) 0.406
>67.5 y. 63/3,863 1.11 (0.86 - 1.44) 37/3859 1.14 (0.82 - 1.60)
Sex Male 42/3,330 1.02 (0.73 - 1.43) 0.218 24/3323 1.26 (0.79 - 2.01) 0.870
Female 33/4,396 1.39 (0.98 - 1.97) 23/4395 1.21 (0.80 - 1.82)
Park. signs Present 16/807 1.00 (0.62 - 1.60) 0.270 12/805 1.09 (0.64 - 1.86) 0.460
Absent 59/6,919 1.29 (0.98 - 1.71) 35/6913 1.31 (0.91 - 1.89)
The associations of sleep quality and sleep duration with incident parkinsonism and Parkinson’s disease 
are shown stratified for several potential effect-modifiers. Hazard ratios were obtained from Cox regres-
sion models, adjusted for (if applicable) age at baseline, sex, educational level, and smoking status, and are 
expressed per standard deviation increase of global Pittsburgh Sleep Quality Index score or sleep duration. 
Multiplicative interaction was tested in a model including the main effects of the stratified variable, and 
a untransformed and non-standardized variable of sleep quality or sleep duration. Split at median age in 
sample. Bold indicates statistical significance at P<0.05. Abbreviations: CI=Confidence interval; dis=disease; 





Supplementary Figure 4. Associations of changes in sleep quality and duration between the baseline and 
follow-up visit with risk of parkinsonism and Parkinson’s disease, per cumulatively increasing duration of 
follow-up
The associations of changes in (A) sleep quality (‘worsening’) and (B) sleep duration (‘shortening’) between 
the baseline and follow-up visit with incident parkinsonism and Parkinson’s disease are shown for cumula-
tively increasing follow-up duration within the six-year study timeframe. Hazard ratio estimates were ob-
tained from multivariate Firth’s penalized Cox regression models by censoring all participants still at risk at 
year 2, 4, and after the total follow-up of 6 years. Hazard ratio estimates were adjusted for age at baseline, 
sex, educational level, smoking status, and time interval between measurements, are expressed per stan-
dard deviation increase of (A) worsening sleep quality, or (B) shorter sleep duration, and are plotted at a 




Supplementary Table 5. Characteristics of study population at follow-up visit
Characteristic (unit) N = 5,450
Age at baseline (years) 68.4 ± 8.9
Female 3,127 (57%)
Educational level
Primary education 398 (7%)
Lower/intermediate or lower vocational 2,161 (39%)
Higher or intermediate vocational 1,636 (30%)
Higher vocational or university 1,259 (23%)
Smoking status
Never smoker 1,748 (32%)
Former smoker 3,068 (56%)
Current smoker 637 (12%)
Cognitive functioning (MMSE score) 29 (27-29)
Presence of any parkinsonian signs 806 (15%)
Time interval between baseline and follow-up visits (years) 6.0 ± 0.6
Missing 49 (1%)
Sleep quality (global PSQI score) 3 (1-6)
Missing 9 (0%)
Change in sleep quality compared to baseline (global PSQI score increase) 0.0 ± 3.1
Missing 211 (4%)
Sleep duration (hours) 6.9 ± 1.3
Change in sleep duration compared to baseline (hours decrease) -0.1 ± 1.16
Missing 173 (3%)
Characteristics for eligible study population for analyses of sleep change at the follow-up visit. Values are 
expressed as frequency (%) for categorical variables and mean ± standard deviation or median (interquar-
tile range) for continuous variables, unless specified otherwise. Includes imputed values for covariates. Ab-
breviations: MMSE=Mini-mental state examination; PSQI=Pittsburgh Sleep Quality Index.

....want tussen droom en daad,
staan wetten in de weg,
en praktische bezwaren,
en ook weemoedigheid,
die niemand kan verklaren,
en die des avonds komt,
wanneer men slapen gaat.


























We aimed to investigate how disturbances in sleep and 24-hour activity rhythm are 
related to neurofilament light chain, an emerging plasma-based marker of neurodegen-
erative disease.
We included 4,712 persons from the Rotterdam Study who self-rated their sleep using 
the Pittsburgh Sleep Quality Index. A subset of 849 persons further underwent objective 
assessment of sleep and 24-hour activity rhythms using actigraphy. Simoa® assays were 
used to measure plasma levels of neurofilament light chain and additionally β-amyloid 
40, β-amyloid 42, and total-tau. Cross-sectional associations of sleep and 24-hour activ-
ity rhythms with biomarkers were assessed with multivariable linear regression models, 
adjusting for relevant confounders.
Associations of self-rated sleep, actigraphy-estimated sleep and 24-hour activity 
rhythms with neurofilament light chain were not statistically significant after multivari-
able adjustment and correction for multiple testing, except for a non-linear association 
of self-rated time in bed with neurofilament light chain (P=2.4*10-4). Similarly, we ob-
served no significant associations with β-amyloid 40, β-amyloid 42, and total-tau after 
multiple testing correction.
Sleep and 24-hour activity rhythms are not associated with neuronal damage, as 
indicated by plasma neurofilament light chain, in the general middle-aged and elderly 
population. Previously reported associations of sleep and 24-hour activity rhythm dis-
turbances with risk of neurodegenerative diseases such as all-cause dementia and 
Alzheimer’s disease are likely mediated, or driven, by other factors.
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INTRODUCTION
Sleep and 24-hour activity rhythm disturbances have been implicated in the etiology 
of neurodegenerative diseases such as dementia,1-4 but it remains largely unclear what 
pathophysiological processes explain these findings.4 Most studies have focused on 
beta-amyloid and tau pathology, both central hallmarks of Alzheimer’s disease.1,3,5 Yet, 
disturbed sleep and 24-hour activity rhythms may be linked to neurodegenerative 
disease risk through other pathophysiological processes as well.6-12
One key pathophysiological process in neurodegenerative diseases, including 
dementia, is neuronal damage.12 Neuronal damage can be captured in vivo by cerebro-
spinal fluid (CSF) levels of the cytoskeletal protein neurofilament light chain (NfL).13,14 
Importantly, NfL cannot only be determined in CSF but also less invasively in blood.15 
This broad biomarker might therefore be well suited to capture any impact of sleep and 
24-hour activity rhythms on neurodegenerative disease.
Studies that implemented blood-based NfL measurements have investigated the 
potential impact of sleep, but not 24-hour activity rhythm disturbance, on neuronal 
damage.16-21 One study showed that chronic insomniacs have higher serum NfL than 
controls, which may decrease after treatment.16 Others found no relation of disordered, 
subjectively impaired or experimentally deprived sleep with NfL in CSF or plasma.17-21 
To date, no large-scale population-based study investigated the relation of sleep and 
24-hour activity rhythm disturbances with neuronal damage indicated by NfL.
We studied the associations of sleep and 24-hour activity rhythms with plasma NfL 
in individuals from the population-based Rotterdam Study cohort, hypothesizing that 
both poor sleep and disturbed 24-hour activity rhythms were associated with higher 
plasma NfL. For comparison, we also studied associations of sleep and 24-hour activity 
rhythms with other plasma biomarkers of neurodegenerative disease (β-amyloid 40 
[Aβ40], Aβ42, and total tau [t-tau]).
METHODS
Study setting
This study is embedded in the population-based, prospective Rotterdam Study cohort, 
which includes individuals from a suburban district in Rotterdam, the Netherlands.22 
The cohort was initiated in 1990, including 7,983 participants aged ≥55 years, and was 
expanded first in 2000 with 3,011 participants aged ≥55 years, and again in 2006 with 
persons aged ≥45 years, totaling 14,926 participants. Examination rounds are repeated 
every 4 to 5 years.
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The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-
PG). The Rotterdam Study has been entered into the Netherlands National Trial Register 
(NTR; www.trialregister.nl) and into the WHO International Clinical Trials Registry Plat-
form (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number 
NTR6831. All participants provided written informed consent to participate in the study 
and to have their information obtained from treating physicians.
Study population
Between 2002 and 2005, 6,044 participants from the initiation cohort and first expansion 
round underwent venipuncture at the dedicated research center. Of those, 5,069 had 
sufficient plasma stores available for analyzing biomarkers. We excluded 232 persons for 
whom valid data on plasma NfL could not be obtained, and 20 persons with all-cause 
dementia at baseline to focus on at-risk individuals only. From the remaining 4,817 
participants, 4,712 provided valid data on one or more questionnaire-derived sleep 
parameters, of which 4,354 persons provided data on all parameters.
Also, of 4,817 participants, 1,346 individuals were invited to participate in an actigra-
phy study23; 970 agreed. Of these, 849 persons (88%) provided valid data for a minimum 
of 4 consecutive 24-hour periods.23
Self-rated sleep
Participants rated sleep using a Dutch version of the Pittsburgh Sleep Quality Index 
(PSQI24). The PSQI measures sleep over the past month and has a good test-retest reli-
ability and validity in a non-clinical sample of older adults.25 Items include bedtimes and 
total sleep time at night, from which we derived time in bed and sleep efficiency, and 
time to fall asleep (sleep latency). Additionally, all items were summed to obtain the 
global PSQI score, indicating subjective sleep quality. The PSQI score ranges from 0-21, 
and higher scores indicate a poorer subjective sleep quality.
We excluded persons missing ≥2 PSQI components (n=60), and calculated a weighted 
global PSQI score when only 1 component was missing (n=173) by multiplying the six-
component sum score by 7/6. The PSQI was completed a median of 18 days (interquartile 
range [IQR] =17-19) before venipuncture.
Objectively estimated sleep and 24-hour activity rhythms
Participants wore an actigraph (Actiwatch model AW4, Cambridge Technology Ltd.) 
which measures acceleration summed as counts per 30-second epochs. We instructed 
participants to wear the actigraph for 7 days and nights around the non-dominant wrist, 
and to remove it only while bathing. Participants had to press a marker button on the 
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device when attempting to fall asleep (hereafter: ‘lights out’) and getting out of bed the 
next morning (hereafter: ‘lights on’). They also kept a daily sleep diary.23 Missing marker 
times were imputed from the diary, or estimated by inspecting recordings if diary times 
were missing. We removed 24-hour periods in which >3 continuous hours of no activity 
were recorded to minimize a ‘time of day’ effect. Actigraphy recordings averaged 137.9 
± 13.6 hours, and were initiated a median of 28 days (IQR=9-287) after venipuncture. 
Within the marker-defined time in bed, we estimated sleep (i.e. total sleep time) and 
wakefulness using a validated algorithm with a threshold of 20 counts.23 We defined 
‘sleep start’ as the midpoint of the first immobile ≥10 minute period after ‘lights out’ with 
≤1 movement epoch.23 Sleep onset latency was calculated as the time from ‘lights out’ 
to ‘sleep start’, and wake after sleep onset as wakefulness after ‘sleep start’. We calculated 
sleep efficiency as total sleep time divided by time in bed * 100%.
We also used counts to calculate non-parametric indices of the 24-hour activity 
rhythm26: Intradaily variability (IV) which indicates the amount of alterations of activity-
inactivity, interdaily stability (IS) which indicates how daily profiles in the recording 
resemble each other, and onset time of the least active 5 consecutive hours (L5 onset) 
which indicates the phase of lowest activity. A disturbed 24-hour activity rhythm is 
reflected by a high IV and a low IS.
Measurement of plasma concentrations of NfL, Aβ40, Aβ42, and t-tau
Participants came to the dedicated research center where a venipuncture was performed 
between 8:00-10:30 AM after an overnight fast. Blood was sampled in ethylenediamine 
tetra-acetic acid-treated containers and centrifuged. The plasma was aliquoted and 
frozen at -80⁰C according to standard procedures. Measurements were performed in two 
batches. All measurements were performed at Quanterix (Lexington, MA, USA) on a single 
molecule array (Simoa®) HD-1 analyzer platform27 and samples were tested in duplicate. 
Two quality control samples were run on each plate for each analyte. Neurofilament light 
chain was measured by using the NF-light advantage kit.28 The Simoa Human Neurology 
3-Plex A assay was used for measuring the concentration of Aβ40, Aβ42, and t-tau. Data 
was excluded if duplicates or single measurements were missing, if the concentration 
coefficient of variation exceeded 20%, or control samples were out of range.
Covariates
We considered age, sex, education (categorized as primary, secondary/lower vocational, 
intermediate vocational and higher vocational/university), batch number of biomarker 
analysis, time interval between measurements of sleep and biomarker, habitual alco-
hol consumption, presence of self-reported paid employment, smoking status (never, 
former, current), body mass index (BMI), presence of hypertension (resting blood 
pressure >140/90 mmHg, or use of blood pressure-lowering medication), presence of 
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diabetes mellitus (fasting serum glucose level ≥7.0 mmol/l, or use of glucose-lowering 
medication), total cholesterol level in serum in mmol/l, a positive history of heart disease 
(myocardial infarction, heart failure, or coronary revascularization procedure), and pos-
sible sleep apnea defined using PSQI items on loud snoring and respiratory pauses29 as 
potential confounders, or as proxies for unmeasured confounders. Measurements were 
performed during the home interview or center visits, as detailed previously.30
Additionally, we assessed clinically relevant depressive symptoms defined as a score 
<16 on the validated Dutch version31 of the Centre for Epidemiological Studies - Depres-
sion scale (CES-D), cognitive impairment defined by an Mini Mental State Examination 
(MMSE) score ≤25, and a history of stroke ascertained during examination rounds and 
by continuous monitoring as detailed previously.30
All sleep parameters were winsorized at 3 SD from the mean, and subsequently 
standardized. Biomarker values were log-transformed (base=2) to approach a normal 
distribution, winsorized to 3 SD and standardized to facilitate comparison across differ-
ent biomarkers.
We used linear regressions to analyze the association of sleep and 24-hour activity 
rhythm parameters with plasma NfL. We investigated self-rated sleep (PSQI score, total 
sleep time, sleep onset latency, time in bed, and sleep efficiency), actigraphy-estimated 
sleep (total sleep time, sleep onset latency, wake after sleep onset, time in bed, sleep ef-
ficiency), 24-hour activity rhythms (intradaily variability, interdaily stability and L5 onset) 
and times of ‘lights out’ and ‘lights on’. Analyses were adjusted for age, sex, educational 
level, batch, and time interval between measurements of sleep and biomarkers (model 
1), and additionally for alcohol consumption, employment status, smoking status, BMI, 
hypertension, diabetes mellitus, total cholesterol, history of heart disease, and possible 
sleep apnea (model 2). Furthermore, as total sleep time and time in bed are known to 
show U-shaped relations with various poor health outcomes, we assessed non-linear as-
sociations of these parameters (self-rated and actigraphy-estimated) with NfL by adding 
quadratic terms of the determinant.
We additionally restricted analyses to persons without clinically relevant depressive 
symptoms, without cognitive impairment, and without prevalent stroke.
Besides NfL, other biomarkers may also be potentially important. Therefore, we also 
examined associations of sleep and 24-hour activity rhythms with other plasma bio-
markers of neurodegenerative disease: Aβ40, Aβ42, and t-tau.
We performed statistical testing and considered associations below the threshold 
of P<0.0046 as statistically significant, which corrected for testing 15 self-rated and 
actigraphy-estimated parameters in this study. This threshold was defined by computing 
the number of effective tests (Meff=11.14) based on correlations between all parameters, 
and applying a Sidak correction. We considered associations as nominally significant at 
P<0.05.
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Table 1. Characteristics of study population
Characteristic (unit) Total sample Actigraphy subsample
N=4,712 N=849
Age at sleep measurement (years) 71.1 (66.1 – 77.2) 66.7 (63.7 – 73.1)
Female 2,700 (57%) 433 (51%)
Medium or higher education 2,088 (45%) 428 (51%)
Alcohol consumption (gr/day) 7 (1-20) 9 (1-20)
Paid employment 303 (6%) 74 (9%)
Never smoker 1,480 (31%) 264 (31%)
Body mass index (kg/m2) 27.6 ± 4.1 27.9 ± 4.0
Hypertension 2,569 (54%) 414 (49%)
Diabetes mellitus 472 (10%) 84 (10%)
Total cholesterol in serum (mmol/l) 5.6 ± 1.0 5.7 ± 1.0
History of heart disease 704 (15%) 89 (10%)
Possible sleep apnea 580 (12%) 113 (13%)
Self-rated sleep
Global PSQI score 3 (2-6) 3 (1-6)
Duration (hours) 6.8 ± 1.3 6.9 ± 1.2
Latency (minutes) 10 (5 - 30) 10 (5 - 30)
Time in bed (hours) 7.7 ± 1.1 7.7 ± 1.0
Efficiency (%) 93 (83 – 99) 93 (86 – 100)
Actigraphic sleep and 24h activity rhythms
Total sleep time (hours) - 6.5 ± 0.8
Latency (minutes) - 18 (12 – 26)
Wake after sleep onset (hours) - 1.1 (0.9 – 1.4)
Time in bed (hours) - 8.3 ± 0.8
Efficiency (%) - 79 (74 – 83)
Intradaily variability (score) - 0.41 (0.34 – 0.52)
Interdaily stability (score) - 0.83 (0.76 – 0.88)
L5 onset (hh:mm) - 01:53 ± 01:10
‘Lights out’ time (hh:mm) - 23:51 ± 00:48
‘Lights on’ time (hh:mm) - 08:10 ± 00:45
Neurofilament light chain (pg/ml) 13 (10-18) 11 (9-15)
Range 3 – 390 4 – 214
Values are expressed as frequency (%) for categorical variables and mean ± standard deviation or median 
(1st quartile – 3rd quartile) for continuous variables. Includes imputed values for covariates. Missing values 
for self-rated sleep parameters were 60 for PSQI score, 58 for sleep duration, 198 for sleep latency, 159 for 
time in bed, and 212 for sleep efficiency. Actigraphic time in bed was not automatically calculated but 
based on ‘lights out’ and ’lights on’ times specified daily by participants using the actigraph marker buttons 




Missing values on covariates were imputed using five multiple imputations with IBM 
SPSS Statistics version 24 (IBM Corp, Armonk, NY). Analyses were performed with R 
software.
RESULTS
For self-rated sleep parameters, we found no significant linear associations with plasma 
NfL in model 2 (Table 2). The association of self-rated longer time in bed with higher NfL 
in model 1 (beta per standard deviation [SD] increase of 0.038 SD increase in log(NfL), 
95% confidence interval [CI] 0.015; 0.060, P=0.0013) was attenuated after additional 
multivariable adjustment (Table 2). The quadratic term of self-rated time in bed was 
significantly associated with NfL in model 2 (P=2.4*10-4): Compared to a self-rated nor-
Table 2. Associations of self-rated and actigraphy-estimated sleep parameters with neurofilament light 
chain levels in plasma
Determinants Model 1 Model 2
Mean diff. (95% CI) P Mean diff. (95% CI) P
Self-rated
PSQI score 0.023 (-0.001; 0.046) 0.06 0.014 (-0.009; 0.037) 0.23
Sleep duration 0.005 (-0.018; 0.027) 0.68 0.006 (-0.015; 0.028) 0.57
Sleep latency 0.017 (-0.010; 0.044) 0.23 0.006 (-0.021; 0.032) 0.66
Time in bed 0.038 (0.015; 0.060) 0.001 0.032 (0.009; 0.054) 0.01
Sleep -0.032 (-0.056; -0.008) 0.01 -0.024 (-0.048; -0.001) 0.04
Actigraphy
Total sleep time -0.006 (-0.058; 0.047) 0.83 -0.030 (-0.082; 0.022) 0.26
Sleep latency -0.008 (-0.062; 0.045) 0.76 -0.004 (-0.057; 0.048) 0.88
WASO 0.023 (-0.028; 0.073) 0.37 0.021 (-0.028; 0.071) 0.40
Time in beda 0.001 (-0.051; 0.053) 0.97 -0.021 (-0.073; 0.030) 0.41
Sleep efficiency -0.004 (-0.055; 0.047) 0.87 -0.016 (-0.066; 0.034) 0.52
Estimates indicate standard deviations change in NfL with a standard deviation increase in the determinant. 
Estimates were obtained with linear regression, adjusted for age and sex, educational level, batch, time in-
terval between measurement of sleep and biomarkers (model 1), and additionally for alcohol consumption, 
employment status, smoking status, body mass index, presence of hypertension, presence of diabetes mel-
litus, total serum cholesterol level, history of cardiovascular disease, and possible sleep apnea (model 2). 
Analyses were performed in 4,652 persons for PSQI score, in n=4,654 for sleep duration, in n=4,514 for sleep 
latency, in n=4,553 for time in bed, and in n=4,500 for sleep efficiency. Actigraphy analyses were performed 
in 849 persons. Please note that actigraphy-derived time in bed was not automatically calculated but based 
on ‘lights out’ and ‘lights on’ times, specified daily by participants using actigraph marker buttons and a 
sleep diary. Abbreviations: CI=Confidence interval; diff.=difference; PSQI=Pittsburgh Sleep Quality Index; 
WASO=Wake after sleep onset.
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mal time in bed (7-9 hours), spending a long time in bed (>9 hours) was significantly 
associated with higher NfL (0.174, 95% CI 0.087; 0.261, P=8.6*10-5), but spending a short 
time in bed (<7 hours) was not (-0.007, 95% CI -0.056; 0.041, P=0.76).
Actigraphy-estimated sleep parameters were not related to NfL in plasma (Table 2). 
We found no non-linear associations for actigraphy-estimated total sleep time and time 
in bed.
We observed no significant associations of 24-hour activity rhythm parameters with 
NfL beyond the multiple testing corrected threshold (Table 3).
Restricting the abovementioned main analyses to individuals without clinically rele-
vant depressive symptoms, without cognitive impairment or stroke did not substantially 
change effect sizes (Table 4).
For comparison, we also investigated associations of sleep and 24-hour activity 
rhythm parameters with other biomarkers of neurodegenerative disease. Median (IQR) 
plasma levels in pg/mL for 4,712 persons were 259.5 (230.3 – 294.0) for Aβ40, 10.3 (8.8 
– 11.9) for Aβ42 and 2.4 (1.9 – 3.0) for t-tau. In comparison to associations with NfL, we 
observed slightly larger effect sizes and more associations exceeding P<0.05 including 
associations of poorer subjective sleep quality, longer self-rated time in bed and lower 
self-rated sleep efficiency with higher plasma concentrations of β-amyloid isoforms 
(Table 5). Yet, no association was statistically significant beyond the threshold corrected 
for multiple testing (Table 5).
Table 3. Associations of actigraphy-estimated 24-hour activity rhythm parameters and bedtimes with neu-
rofilament light chain in plasma
Determinants Model 1 Model 2
Mean difference (95% CI) P Mean difference (95% CI) P
Intradaily variability 0.022 (-0.033; 0.078) 0.43 0.036 (-0.019; 0.092) 0.19
Interdaily stability 0.000 (-0.051; 0.052) 0.99 -0.017 (-0.068; 0.033) 0.50
L5 onset -0.008 (-0.059; 0.043) 0.76 -0.005 (-0.054; 0.045) 0.85
‘Lights out’ time -0.050 (-0.103; 0.004) 0.07 -0.033 (-0.086; 0.020) 0.22
‘Lights on’ time -0.044 (-0.095; 0.008) 0.10 -0.049 (-0.100; 0.001) 0.06
Estimates indicate standard deviations change in NfL with a standard deviation increase in the determi-
nant Outcome values of neurofilament light chain (NfL) in nmol/l were natural log-transformed and then 
expressed per standard deviation of ln(NfL). Estimates were obtained with linear regression, adjusted for 
age and sex, educational level, batch, time interval between measurement of sleep and biomarkers (model 
1), and additionally for alcohol consumption, employment status, smoking status, body mass index, pres-
ence of hypertension, presence of diabetes mellitus, total serum cholesterol level, history of cardiovascular 
disease, and possible sleep apnea (model 2). Analyses were all performed in 849 persons. Please note that 
actigraphy-derived bedtimes were specified daily by participants using actigraph marker buttons and a 




Table 4. Associations of sleep with neurofilament light chain in plasma in persons without depressive 
symptoms, cognitive impairment or stroke
Determinants No depressive symptoms No cognitive impairment No stroke
Mean diff. (95% CI) Mean diff. (95% CI) Mean diff. (95% CI)
Self-rated
PSQI -0.001 (-0.026; 0.025) 0.008 (-0.017; 0.032) 0.010 (-0.013; 0.033)
TST 0.015 (-0.009; 0.038) 0.001 (-0.023; 0.025) 0.006 (-0.016; 0.028)
SOL 0.000 (-0.029; 0.030) -0.001 (-0.03; 0.028) 0.001 (-0.026; 0.028)
TIB 0.035 (0.012; 0.059)** 0.022 (-0.002; 0.046) 0.028 (0.006; 0.051)*
SE -0.016 (-0.042; 0.009) -0.022 (-0.047; 0.003) -0.022 (-0.045; 0.001)
Actigraphy
TST -0.024 (-0.077; 0.030) -0.027 (-0.085; 0.030) -0.029 (-0.082; 0.025)
SOL -0.013 (-0.069; 0.042) -0.003 (-0.061; 0.054) -0.003 (-0.055; 0.049)
WASO 0.011 (-0.040; 0.062) 0.016 (-0.037; 0.069) 0.021 (-0.029; 0.070)
TIB -0.032 (-0.086; 0.021) -0.029 (-0.085; 0.028) -0.016 (-0.069; 0.036)
SE -0.001 (-0.053; 0.051) -0.010 (-0.064; 0.044) -0.016 (-0.066; 0.034)
IV 0.018 (-0.039; 0.076) 0.046 (-0.015; 0.107) 0.042 (-0.012; 0.097)
IS -0.006 (-0.058; 0.047) -0.018 (-0.074; 0.038) -0.010 (-0.060; 0.041)
L5 onset -0.014 (-0.065; 0.037) -0.023 (-0.076; 0.031) 0.003 (-0.047; 0.053)
Lights out -0.035 (-0.089; 0.020) -0.029 (-0.086; 0.027) -0.039 (-0.091; 0.014)
Lights on -0.063 (-0.115; -0.010)* -0.055 (-0.111; 0.001) -0.050 (-0.101; 0.001)
Absence of depressive symptoms was defined as CES-D score ≥16; absence of cognitive impairment as 
defined as MMSE score >25. Estimates were obtained with linear regression, indicate standard deviations 
change in NfL with a standard deviation increase in the determinant), and were adjusted for age and sex, 
educational level, batch, time interval between measurement of sleep and biomarkers, alcohol consump-
tion, employment status, smoking status, body mass index, presence of hypertension, presence of diabe-
tes mellitus, total serum cholesterol level, history of cardiovascular disease, and possible sleep apnea. For 
self-rated determinant analyses, cases per analysis ranged from 4,063-4,181 restricted to persons without 
depressive symptoms, from 3,909-4,042 in persons without cognitive impairment, and from 4,289-4,431 in 
persons without prevalent stroke. For actigraphy-derived determinants, cases in analyses were n=785 (de-
pressive symptoms), n=756 (cognitive impairment) and n=817 (stroke). Please note that actigraphic time in 
bed was not automatically calculated but determined by ‘lights out’ and ’lights on’ times specified through 
pressing actigraph marker buttons and the sleep diary. ** P=0.0035; *Nominal statistical significance at 
P<0.05. Abbreviations: CES-D= Center for Epidemiological Studies – Depression scale; CI=Confidence inter-
val; diff.=difference; IS=Interdaily stability; IV=Intradaily variability; L5=average least active 5 hours of the 
day; MMSE=Mini-mental state examination; PSQI=Pittsburgh Sleep Quality Index; SD=Standard deviation; 
SE=Sleep efficiency; SOL=sleep onset latency; TIB=Time in bed; TST=Total sleep time; WASO=Wake after 
sleep onset
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Table 5. Associations of sleep and 24-hour activity rhythms with biomarkers of neurodegenerative disease 
in plasma
Determinants β-amyloid 40 β-amyloid 42 Total tau
Mean diff. (95% CI) Mean diff. (95% CI) Mean diff. (95% CI)
Self-rated
PSQI score 0.020 (-0.008; 0.047) 0.030 (0.002; 0.057)* -0.016 (-0.045; 0.013)
TST 0.005 (-0.021; 0.032) -0.007 (-0.034; 0.020) 0.018 (-0.009; 0.046)
SOL 0.008 (-0.025; 0.040) 0.009 (-0.023; 0.041) -0.003 (-0.036; 0.031)
TIB 0.033 (0.006; 0.060)* 0.032 (0.005; 0.059)* 0.019 (-0.009; 0.047)
SE -0.020 (-0.048; 0.008) -0.038 (-0.066; -0.010)* 0.009 (-0.020; 0.038)
Actigraphy
TST -0.051 (-0.116; 0.013) -0.025 (-0.086; 0.036) 0.034 (-0.032; 0.100)
SOL -0.001 (-0.066; 0.064) 0.019 (-0.042; 0.080) 0.007 (-0.060; 0.074)
WASO 0.049 (-0.012; 0.110) 0.051 (-0.006; 0.109) 0.045 (-0.018; 0.108)
TIBb -0.036 (-0.099; 0.028) 0.005 (-0.055; 0.065) 0.061 (-0.004; 0.127)
SE -0.047 (-0.109; 0.015) -0.050 (-0.108; 0.008) -0.028 (-0.092; 0.036)
IV 0.066 (-0.002; 0.134) -0.002 (-0.067; 0.062) -0.007 (-0.077; 0.063)
IS -0.022 (-0.085; 0.041) 0.018 (-0.041; 0.077) -0.025 (-0.089; 0.040)
L5 onset 0.019 (-0.042; 0.080) 0.027 (-0.031; 0.085) 0.020 (-0.043; 0.083)
Lights out 0.007 (-0.058; 0.072) -0.017 (-0.079; 0.044) 0.019 (-0.048; 0.085)
Lights on -0.027 (-0.089; 0.036) -0.017 (-0.076; 0.042) 0.074 (0.010; 0.139)*
Estimates were obtained with linear regression, indicate standard deviations change in biomarker with a 
standard deviation increase in the determinant, and are adjusted for age and sex, educational level, batch, 
time interval between measurement of sleep and biomarkers, alcohol consumption, employment status, 
smoking status, body mass index, presence of hypertension, presence of diabetes mellitus, total serum 
cholesterol level, history of cardiovascular disease, and possible sleep apnea. Numbers of cases per analysis 
differed as both determinants and outcomes had different numbers of missing values. For self-rated deter-
minants, numbers varied from 4,486 (association total sleep time with total tau) to 4,146 (sleep efficiency 
with β-amyloid 42). For actigraphy-derived determinants (all n=849), numbers varied from 824 (total tau) 
to 806 (β-amyloid 42). Please note that actigraphic time in bed was not automatically calculated but based 
on ‘lights out’ and ’lights on’ times specified by participants. *Nominal statistical significance at P<0.05. 
Abbreviations: CI=Confidence interval; diff.=difference; IS=Interdaily stability; IV=Intradaily variability; 
L5=average least active 5 hours of the day; PSQI=Pittsburgh Sleep Quality Index; SD=Standard deviation; 





In this population-based study in middle-aged and elderly persons, sleep and 24-hour 
activity rhythms were not associated with plasma NfL, except for a non-linear associa-
tion of self-rated time in bed with NfL.
We speculate that the association of self-rated long time in bed with higher plasma 
NfL might not reflect sleep per se, but instead overall poor health or underlying subclini-
cal disease.32,33 Sensitivity analyses suggested that cognitive impairment or stroke, but 
not depressive symptoms, could be examples of underlying impaired health explaining 
the association of self-rated longer time in bed and higher plasma NfL. Further research 
is needed to investigate to what extent self-rated time in bed is a more valid marker of 
overall health than sleep per se.
Recently, we demonstrated that actigraphy-estimated poor sleep was associated with 
the risk of all-cause dementia and Alzheimer’s disease in the Rotterdam Study. (Lysen et 
al., submitted) Yet, sleep and 24-hour activity rhythm disturbances are not clearly associ-
ated with NfL in the current study which is embedded in the same cohort, suggesting 
that pathophysiological processes indicated by NfL do not play a role in the association 
of poor sleep with dementia. These findings could be explained in several ways.
First, the potentially harmful effects of poor habitual sleep or 24-hour activity rhythm 
disturbances on neuronal health may not lead to NfL release. At a cellular level, release 
of NfL, most abundantly present in the axon, occurs after apoptosis or axon-specific neu-
ronal insults.34,35 Sleep or 24-hour activity rhythm disturbances may involve neuronal 
insults that invoke various stress responses that potentially impair neuronal function, 
but not lead to apoptosis. Other pathophysiological processes are therefore likely to un-
derlie the link between sleep, 24-hour activity rhythms and neurodegenerative disease.
Second, we measured sleep with questionnaires and actigraphy. These measures 
cannot diagnose sleep disorders such as insomnia or sleep-disordered breathing,36 
or important physiological aspects of sleep such as slow-wave activity. This could 
explain why a previous study showed higher serum NfL in chronic insomniacs versus 
controls, while we found no population-based association of subjective sleep quality, an 
insomnia-related construct, with NfL.16
Third, the sleep and 24-hour activity rhythm disturbances studied here may not have 
been severe enough to elevate NfL in plasma. Our hypothesis was based on mechanistic, 
animal-based studies6-8,37-39 using mostly experimental sleep deprivation. However, we 
studied observational differences in habitual sleep, and these more chronic distur-
bances might pose less harm to neuronal health than experimentally induced reduc-
tions in sleep. Indeed, a previous study also did not find an association of observational 
differences in subjective sleep quality with NfL, using CSF measurements.18 Additionally, 
experimental studies that used partially deprived sleep to only four hours for five nights 
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also found no effects on NfL in CSF,17 or serum.20 This suggest that the relation of sleep 
with NfL seems limited.
Compared to NfL, the associations of sleep and 24-hour activity rhythms with Aβ40, 
Aβ42 and t-tau in plasma were slightly more pronounced in effect size, yet no associa-
tions survived multiple testing correction. This is surprising as sleep is known to regulate 
brain β-amyloid levels,6 and habitual sleep is related to CSF β-amyloid, and parenchymal 
β-amyloid deposition.5 We measured Aβ42 in plasma which may be subject to more 
disturbing factors and may differ from measurement in CSF.40 This could have obscured 
detecting an association and should be studied further.
Several methodological considerations need to be mentioned. First, our largely nega-
tive findings could indicate invalidity of our measurement in plasma instead of CSF. Yet, 
high NfL and reduced Aβ42 were associated with an increased risk of all-cause dementia 
and Alzheimer’s disease in our cohort (De Wolf et al., in press). Second, correlations of 
NfL between CSF and plasma are lower in healthy versus diseased persons,41 lowering 
our sensitivity to detect relevant plasma NfL increases, especially in the actigraphy 
subgroup. Third, associations with plasma NfL may not reflect increased damage but dif-
ferential equilibration across fluid compartments, as poor sleep may disturb blood-brain 
barrier function.42,43 Fourth, cross-sectional associations may not be detected as plasma 
NfL levels may lag behind neuronal injury by months.44 Yet, our single sleep measures 
are relatively stable over time,45 and we adjusted analyses for the time interval between 
sleep and NfL measurement. Fifth, actigraphy estimates may misclassify sleep and only 
indirectly reflect circadian functioning. Study strengths include using a large sample an-
chored in the general population, measuring sleep with two modalities, simultaneously 
investigating multiple relevant biomarkers, and correcting for various confounders.
In conclusion, sleep and 24-hour activity rhythm disturbances in the general middle-
aged and elderly population are not consistently associated with plasma NfL, even 
though sleep disturbances and NfL have separately been associated with incident 
all-cause dementia and Alzheimer’s disease. Therefore, associations linking sleep and 
24-hour activity rhythms with these incident neurodegenerative disease are unlikely to 
be mediated, or driven, by neuronal damage as indicated by plasma NfL.
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Sleep has been hypothesized to facilitate waste clearance from the brain. Reduced 
waste clearance may be indicated by an enlargement of perivascular spaces on brain 
magnetic resonance imaging (MRI). Therefore, we investigated the association of sleep 
with perivascular space counts.
In 561 participants (mean age 62 ± 6, 52% women) from the population-based Rot-
terdam Study cohort, we measured total sleep time, sleep onset latency, wake after 
sleep onset and sleep efficiency with actigraphy and polysomnography. The number of 
perivascular spaces was determined in four regions (centrum semiovale, basal ganglia, 
hippocampus and midbrain) via a machine learning algorithm using T2-contrast MR 
images. Associations were analysed with zero-inflated negative binomial regression 
models adjusted for potential confounders, taking into account multiple testing.
Higher actigraphy-estimated sleep efficiency was associated with a higher perivas-
cular space count in the centrum semiovale (odds ratio 1.10, 95% confidence interval 
1.04-1.16, P=0.0009). No polysomnographic sleep parameters were associated with 
perivascular space count in any region. Results were largely similar after additionally 
accounting for sleep-disordered breathing parameters, brain volumes, cerebral small 
vessel disease markers, or the time between measurements of sleep and MRI in our 
analyses.
The association of sleep with perivascular space counts in the middle-aged and el-
derly population remains limited to an association of higher actigraphy-estimated sleep 
efficiency with higher perivascular space load in the centrum semiovale. Further work is 





Sleep has been hypothesized to be a key driver of waste clearance from the brain.1 Brain 
waste clearance involves a glia-dependent, lymphatic-like system named the ‘glymphat-
ic’ system.2,3 Glymphatic clearance involves exchange of interstitial and cerebrospinal 
fluid across the perivascular space,2 which surrounds small blood vessels throughout 
the brain.2 Sleep has been shown to substantially enhance such clearance.1 Although 
glymphatic clearance and its determinants have been primarily studied in animals,4,5 
emerging evidence also supports a role of sleep in waste clearance from the brain in 
humans.6-8
It has been suggested that glymphatic clearance in humans can be studied through 
visualizing perivascular spaces on brain magnetic resonance imaging (MRI).9,10 Perivascu-
lar spaces can become visible on brain MRI when enlarged. This enlargement, although 
still a poorly understood phenomenon,10,11 is deemed abnormal5 as high perivascular 
space load on MRI is associated with vascular and neurodegenerative pathologies, and 
a related increased risk of stroke and dementia.10,12-15 Impaired glymphatic clearance is 
also implicated in the pathophysiology of these diseases,4,5,16-19 suggesting that perivas-
cular space load on MRI could mark impaired glymphatic clearance.9-11
Several clinical and population-based studies determined the association of indica-
tors of poor sleep with higher perivascular space load on MRI. Studies reported asso-
ciations of lower sleep efficiency and shorter non-rapid eye movement (NREM) stage 3 
sleep,20 of obstructive sleep apnea,21 of shorter total sleep time,22 and of self-reported 
presence of interrupted sleep with higher perivascular space loads. Others reported no 
association.23,24One population-based study found a positive association of sleep effi-
ciency with perivascular space load in the basal ganglia in a 97 participants, but not with 
sleep quality or apnea.25 Considering these mixed results, it remains unknown to what 
extent sleep is important for brain waste clearance, as indicated by perivascular space 
load on brain MRI, in the general population. Determining this link may help support an 
etiological role of sleep disturbances, which are potentially amenable to treatment, in 
neurological diseases.
We explored the relation of sleep with perivascular space counts on MRI using data 
from middle-aged and elderly participants of the population-based Rotterdam Study 





Study setting and population
The Rotterdam Study cohort started in 1990 and aims to investigate common chronic 
diseases in the elderly.27 The cohort has since been expanded twice and includes 14,926 
participants aged 45 years and over. Examination rounds include a home interview and 
visits to the dedicated research center, and are repeated every 4-5 years.
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-
PG). All participants provided written informed consent to participate in the study and 
to have their information obtained from treating physicians.
Between 2011 and 2014, 2,135 persons were invited to participate in actigraphy 
substudy (1,773 agreed, 83%), and 1,750 persons were invited to participate in a poly-
somnography substudy (928 agreed, 53%). A total of 1,062 were invited to undergo 
both (656 agreed, 62%). No exclusion criteria were set except for being deemed able to 
understand instructions. In our main analysis, we included 561 individuals who had i) 
valid actigraphy for ≥4 days, ii) a valid 1-night polysomnography, and iii) a valid MRI-scan 
performed within a 2-year timeframe. Sensitivity analyses were performed in the full 
samples of 771 persons with valid polysomnography and MRI, and 1,228 persons with 
valid actigraphy and MRI.
Assessment of sleep
Participants wore an actigraph (Actiwatch, model AW4; Cambridge Technology, Cam-
bridge, UK, or Geneactiv, Activinsights Ltd, Kimbolton, UK), measuring acceleration ag-
gregated into activity counts per 30-second epochs.28,29 We used a previously described 
method to ensure comparability of estimates obtained from these devices.30,31 We 
instructed participants to wear the actigraph for 7 days and nights around the non-
dominant wrist, to remove it only while bathing (only for Actiwatch), and to keep a daily 
sleep diary.28
Sleep data per night were considered invalid if no data was recorded, if the participant 
had discontinued wearing the actigraph, if it coincided with daylight savings or followed 
daylight savings occurring during the recording, or if sleep diary information on bedtime 
and get-up time from which time in bed was derived was invalid or missing.31 Within the 
time in bed, the algorithm estimated the assumed sleep period based on sleep onset 
and sleep offset, as described previously.28,32 It also estimated sleep versus wakefulness 
per 30-second epoch using a validated algorithm with a threshold of 20 activity counts.32 
The algorithm calculated total sleep time (the sum of all sleep epochs within the as-




and estimated sleep onset), wake after sleep onset (sum of all wake epochs within the 
assumed sleep period) and sleep efficiency (total sleep time / time in bed * 100%). Sleep 
parameters were averaged over all available nights.
Mean actigraphy recording duration was a median 144 hours (IQR=144-168).
For polysomnography at home, device and sensors were applied according to the 
American Association of Sleep Medicine (AASM) criteria by trained research assistants.33 
Sensors included six electroencephalography (EEG) channels (F3/A2, F4/A1, C3/A2, C4/
A1, O1/A2, O2/A1), bilateral electro-oculography, chin electromyography, electrocardi-
ography, respiratory belts on the chest and abdomen, oximetry, and a nasal pressure 
transducer and oronasal thermocouple. We instructed individuals to spend the night as 
normal as possible, without restrictions on bedtimes, activities or diet.
Participants signaled the times of ‘lights out’ and getting up on the device, from 
which time in bed was calculated. Missing times were extracted from the sleep diary. All 
recordings were scored by a Registered Polysomnographic Technologist to determine 
wake, non-rapid eye movement (NREM) sleep stage 1 (N1), N2, N3, and REM sleep.33 We 
calculated total sleep time (sum of all sleep epochs regardless of stage), sleep onset 
latency (time from ‘lights out’ to the first epoch of sleep), wake after sleep onset (sum 
of wake epochs after sleep onset), and sleep efficiency (total sleep time / time in bed * 
100%), and sleep stage durations (sum of epochs per stage).
Neuroimaging
Brain imaging was performed on a 1.5T MRI scanner (Signa Excite II, GE Healthcare, 
Milwaukee, WI, USA) providing T1-contrast (T1), T2 and T2*-weighted gradient-recalled-
echo (T2*) sequences, as detailed previously.34
Perivascular spaces in the midbrain, hippocampi, basal ganglia and centrum semiovale 
were automatically classified, using a machine learning algorithm on T2-scans.35 This 
algorithm was developed on visual ratings, performed with a standardized protocol,10 
defining perivascular spaces as linear, ovoid or round-shaped hyperintensities on T2 
scans with a diameter of ≥1 mm, and <3 mm. Single slices were used to rate perivascular 
space counts in the centrum semiovale (1 cm above the uppermost part of the lateral 
ventricles) and the basal ganglia (slice involving the anterior commissure).36 Counts in 
hippocampus and midbrain were evaluated in whole volumes.
Preprocessing and model development was detailed previously.35 In short, prepro-
cessing included extracting target brain regions on T1 with Freesurfer and masking 
surroundings. Images were then processed by a convolutional neural network.37 This 
machine learning algorithm provides high reproducibility and low computation time, 
and is one of the most validated automated methods for quantifying enlarged perivas-
cular spaces. Networks were trained per region, considering region-specific shapes and 
mimics of perivascular spaces. Models were trained (n=1,200) and validated (n=400) 
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on independent sets of scans,35 and showed good performance based on specificity 
to perivascular spaces using attention maps, and agreement between automated and 
visual scores similar to human inter-observer agreement. Moreover, determinants of 
perivascular spaces were similar between using automatically calculated and visually 
rated counts.35
Covariates
We considered as potential confounders the following covariates: Age at sleep measure-
ment, sex, education (categorized as primary, secondary/lower vocational, intermediate 
vocational and higher vocational/university), the time interval between measurements 
of sleep and MRI scanning, smoking status (never, former, current), habitual alcohol 
consumption (gr/day), body mass index (kg/m2), presence of hypertension (resting 
blood pressure >140/90 mmHg, or use of blood pressure-lowering medication), pres-
ence of diabetes mellitus (serum glucose level ≥7.0 mmol/l [fasting] or ≥11.1 mmol/L 
[non-fasting], or use of glucose-lowering medication), a positive history of heart disease 
(myocardial infarction, heart failure, or coronary revascularization procedure), the sys-
temic immune-inflammation index (blood-based biomarker calculated by multiplying 
counts, in 109/L, of platelets with granulocytes, divided by lymphocytes),38 and napping 
(reported with the sleep diary during actigraphy recording as present versus absent per 
afternoon and evening, daily, i.e. ranging from 0 to 14). Measurements were performed 
during the home interview or center visits, unless stated otherwise.39
Additionally, we determined supratentorial intracranial volume, white matter hyper-
intensity volume, lacunar and cortical brain infarcts, and lobar cerebral microbleeds. 
Volumes were segmented automatically on T1-images and confirmed or corrected by 
trained raters.40 Trained raters also rated cortical infarcts (lesions involving cortical gray 
matter with tissue loss), lacunar infarcts (subcortical lesions ≥3 mm and <15 mm), and 
lobar microbleeds as focal parenchymal areas of low signal on T2* images not involving 
deep gray and white matter structures.40
With regard to sleep we further determined the polysomnography-derived apnea-
hypopnea index and desaturation rate (PRANA, PhiTools, Strasbourg, France), the apnea-
hypopnea index was automatically calculated as the number of apneas and hypopneas, 
defined accordance to guidelines,33 per hour of sleep. Similarly, desaturation rate was 
calculated as the number of desaturations of ≥3% from baseline, per hour of sleep.
Statistical analysis
We associated total sleep time, sleep onset latency, wake after sleep onset, and sleep ef-
ficiency, assessed with both actigraphy and polysomnography, with perivascular space 
counts in 4 regions. All sleep parameters were winsorized to 3 standard deviations from 




We used zero-inflated negative binomial regression models to account for excess zeros 
in the perivascular space count data.35 Analyses were adjusted for age, sex, education, 
and the time interval between measurements of sleep and MRI (model 1), and addition-
ally for smoking status, habitual alcohol consumption, body mass index, hypertension, 
diabetes mellitus, a history of heart disease, the systemic immune-inflammation index, 
and napping (model 2). We additionally adjusted for white matter hyperintensity vol-
ume and intracranial volume in persons with valid segmentations (model 3a),5,35 and 
separately also for apnea-hypopnea index and desaturation rate (model 3b).21
In addition, we investigated non-linearity in associations for total sleep time by model-
ing quadratic terms, as total sleep time may show a U-shaped relation to related poor 
health outcomes.41 Second, we investigated as determinants separate polysomnography-
derived sleep stages (N1, N2, N3, and REM), expressed proportional to total sleep time, 
which may relate differentially to perivascular spaces.20 Third, we restricted our analysis 
to persons without cortical or lacunar infarcts on brain MRI (n=497) to determine the 
influence of comorbid cerebrovascular disease and reduce potential misclassification of 
infarcts as perivascular spaces.35 Fourth, we restricted analyses to persons with a time 
interval between sleep and MRI measurement of ≤28 days to check the influence of the 
time interval in detecting cross-sectional associations. Lastly, we repeated analyses in 
the full samples of persons with valid data on either actigraphy and MRI, or polysomnog-
raphy and MRI, to reduce selective inclusion and increase statistical power.
Posthoc, we examined if centrum semiovale-specific vascular pathology drove the as-
sociation by additionally adjusting for lobar cerebral microbleeds, indicative of cerebral 
amyloid angiopathy.42-45
We considered associations at P<0.00198 as statistically significant correcting for mul-
tiple testing. This threshold was defined by first Bonferroni-correcting for testing 4 brain 
regions to P<0.0125, and then applying a Sidak correction using the number of effective 
tests46 (Meff=6.43) based on correlations amongst main analysis sleep parameters.
Missing values on covariates (median 0.4%, ranging from 0.2 to 9.4%, in n=561) were 
imputed using five multiple imputations with IBM SPSS Statistics version 24 (IBM Corp, 
Armonk, NY). All analyses were performed with R (package: glmmADMB).
RESULTS
We included 561 participants (mean age 62 ± 6, 52% female; Table 1). The absolute time 
interval between initiating actigraphy recording and MRI-scanning was a median 27 
days (IQR=10-67); for polysomnography, this interval was a median 20 days (IQR=8-46). 




Actigraphy-estimated higher sleep efficiency was associated with more perivascular 
spaces in the centrum semiovale in model 2 (Odds ratio [OR] per standard deviation 
increase 1.10, 95% confidence interval [CI] 1.04-1.16, P=0.0009; Table 2). For polysom-
nographic sleep parameters, we found no associations with perivascular space count in 
Table 1. Characteristics of study population
Characteristic (unit) Study population (N = 561)
Actigraphy Polysomnography
Age at sleep measurement (years) 62.3 ± 5.5 62.3 ± 5.5
Female 290 (52%) -
Medium or higher education 338 (61%) -
Absolute time interval sleep-MRI (days) 27 (10-67) 20 (8-46)
Never smoker 161 (29%) -
Body mass index (kg/m2) 27.4 ± 4.1 -
History of diabetes mellitus 62 (11%) -
History of hypertension 221 (39%) -
History of heart disease 15 (3%) -
Habitual alcohol consumption (grams/day) 8 (4-9) -
Systemic immune-inflammation index 449 (345-601) -
Naps during actigraphy recording 1 (0-2) -
White matter hyperintensity volume (cm3) 2.3 (1.4 – 4.3) -
Intracranial volume (cm3) 1,140 ± 115 -
Apnea-hypopnea index (events/hour) 11 (5-21) -
Desaturation rate (events/hour) 19 (9-30) -
No lacunar or cortical infarcts on brain MRI 497 (76%) -
Presence of lobar cerebral microbleeds 53 (9%) -
Total sleep time 6.2 ± 0.9 6.4 ± 1.0
N1 (%) 11 (9 – 17) NA
N2 (%) 54 ± 9 NA
N3 (%) 11 (4 – 19) NA
REM (%) 21 ± 5 NA
Sleep onset latency 13 (8-22) 14 (9-23)
Wake after sleep onset 0.9 ± 0.4 1.1 ± 0.7
Sleep efficiency 78 (72-83) 83 (78-89)
Perivascular space count
Centrum semiovale 6.1 (3.9-9.9) -
Basal ganglia 2.4 (1.8-3.3) -
Hippocampus 2.3 (1.0-4.3) -
Midbrain 1.3 (0.5-2.4) -




any region (Table 3). Model 1 estimates were similar (data not shown). The association 
of higher sleep efficiency with higher perivascular space count in the centrum semi-
ovale remained after additional adjustment for white matter hyperintensity volume and 
intracranial volume (model 3a: OR 1.12, 95% CI 1.06-1.18, P=0.00004), and for sleep-
disordered breathing parameters (model 3b: OR 1.09, 95% CI 1.04-1.16, P=0.001). Similar 
to model 2, we found no associations of other sleep parameters with perivascular space 
counts in model 3a and 3b.
Additional analyses demonstrated no non-linear associations of actigraphy-estimated 
or polysomnography-derived total sleep time by modeling quadratic terms (Supplemen-
tary Table 1). Polysomnography-derived separate sleep stages were also not associated 
with perivascular space counts (Supplementary Table 2). We observed the same asso-
ciations after restriction to persons without cortical or lacunar infarcts (Supplementary 
Table 3).
Table 2. Associations of actigraphy-estimated sleep parameters with perivascular space counts
Determinant (N=561) Rate ratio for association with perivascular space counts (OR [95% CI])
Centrum semiovale Basal ganglia Hippocampus Midbrain
Total sleep time 1.05 (0.99-1.11) 0.98 (0.93-1.03) 0.99 (0.92-1.07) 1.02 (0.94-1.10)
Sleep onset latency 0.91 (0.86-0.97) 1.02 (0.96-1.08) 0.91 (0.84-1.00) 0.97 (0.89-1.06)
Wake after sleep onset 0.96 (0.90-1.02) 1.03 (0.97-1.08) 1.01 (0.94-1.10) 0.98 (0.91-1.07)
Sleep efficiency 1.10 (1.04-1.16) 0.99 (0.94-1.05) 1.00 (0.93-1.08) 1.05 (0.98-1.13)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. Estimates were obtained with zero-inflated negative binomial 
regression, adjusted for age, sex, education, time interval between measurements of sleep and MRI, smok-
ing status, habitual alcohol consumption, body mass index, presence of hypertension, presence of diabetes 
mellitus, history of heart disease, systemic immune-inflammation index, and napping
Bold indicates statistical significance after correcting for multiple testing (P<0.00198).
Abbreviations: CI=Confidence Interval; N=Sample size; OR=Odds ratio.
Table 3. Associations of polysomnographic sleep parameters with perivascular space counts
Determinant (N=561) Rate ratio for association with perivascular space counts (OR [95% CI])
Centrum semiovale Basal ganglia Hippocampus Midbrain
Total sleep time 1.01 (0.96-1.08) 1.00 (0.95-1.06) 0.99 (0.92-1.07) 1.00 (0.92-1.08)
Sleep onset latency 0.92 (0.85-0.99) 0.96 (0.89-1.03) 0.96 (0.86-1.07) 0.96 (0.86-1.07)
Wake after sleep onset 0.94 (0.89-1.00) 1.01 (0.96-1.07) 1.00 (0.92-1.08) 1.03 (0.95-1.12)
Sleep efficiency 1.07 (1.01-1.13) 1.00 (0.94-1.06) 1.01 (0.93-1.09) 0.98 (0.91-1.07)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. Estimates were obtained with zero-inflated negative binomial 
regression, adjusted for age, sex, education, time interval between measurements of sleep and MRI, smok-
ing status, habitual alcohol consumption, body mass index, presence of hypertension, presence of diabetes 
mellitus, history of heart disease, systemic immune-inflammation index, and napping
Abbreviations: CI=Confidence Interval; N=Sample size; OR=Odds ratio.
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After restricting to persons with a time interval between sleep and MRI assessment of 
≤28 days, estimates for the association of higher sleep efficiency with higher perivascu-
lar space count in the centrum semiovale were similar, albeit non-significant (OR 1.12, 
95% CI 1.04-1.20, P=0.0029). Also, non-significant estimates across brain regions seemed 
consistently slightly more pronounced (Supplementary Table 4).
Repeated analyses in full samples of participants with valid actigraphy and MRI 
(n=1,228, mean age 65.3 ± 7.3, 51% women), or valid polysomnography and MRI data 
(n=771; mean age 63.0 ± 6.6, 54% women), were similar to the main analysis (Supple-
mentary Table 5). We observed a slightly attenuated, statistically significant association 
of higher actigraphy-estimated sleep efficiency with higher perivascular space count in 
the centrum semiovale (OR 1.07, 95% CI 1.03-1.11, P=0.0003).
Posthoc, we explored the association of sleep efficiency with higher perivascular space 
count in the centrum semiovale by additionally adjusting for presence of lobar cerebral 
microbleeds, which did not change estimates (OR 1.11, 95% CI 1.05-1.18, P=0.0001).
DISCUSSION
In this population-based study, we found that actigraphy-estimated sleep efficiency was 
associated with higher perivascular space count in the centrum semiovale.
We found no association of any other sleep parameters with higher perivascular 
space load in the basal ganglia, hippocampus or midbrain. Findings were not consistent 
with previous, mostly clinical studies who did suggest an association.20-22,26 Another 
population-based cohort also mostly reported null findings,24,25 except for the associa-
tion of higher sleep efficiency with lower perivascular space load in the basal ganglia 
in a subgroup undergoing polysomnography.25 Yet, as the authors noted, their findings 
may have had low generalizability.25
The direction of the association of higher sleep efficiency with perivascular space count 
was opposite to what we hypothesized based on aforementioned observations.20-22,25,26 
This could indicate that high sleep efficiency in our study did not represent good quality 
sleep but rather indicated short sleep opportunity accompanied by a high sleep pres-
sure. Although we could not determine to what extent habitual sleep opportunity was 
too short, adjusting for napping did not influence the association, nor did we find an 
association for the proportion of N3 sleep. Together with no relation of short total sleep 
time with perivascular space load, findings suggest that the association of higher sleep 
efficiency with higher perivascular space count is not likely to be explained by a short 
sleep opportunity.
Equally, it could be hypothesized that enlarged perivascular spaces, at least in the cen-




of pathology.5 Several findings, including ours, seem to indeed support alternative inter-
pretations. First, a higher hippocampal load of perivascular spaces was associated with 
better, not worse, memory performance in humans.47 Second, age did not determine 
perivascular space count in the centrum semiovale in our cohort, nor did most vascular 
risk factors,35 all of which are risk factors for brain pathology. Third, adjusting for lobar 
microbleeds, a marker of cerebral amyloid angiopathy associated with perivascular 
spaces in the centrum semiovale,44,48 did not influence our estimates. Fourth, a previous 
study in our cohort found that higher actigraphy-estimated sleep efficiency related to 
better white matter microstructural integrity, in regions overlapping with the centrum 
semiovale.29 Yet, we found the opposite relation to perivascular spaces, suggesting that 
perivascular space count, at least in relation to sleep, represents something else than 
vascular pathology. Together, these findings suggest that enlarged perivascular spaces 
in the centrum semiovale need not signal pathology per se.
Against the background of aforementioned considerations of how to interpret 
higher sleep efficiency and higher perivascular space count, different mechanisms 
may explain their association. One speculative explanation is that sleep state-related 
increases in fluid flow across the perivascular space1 enlarge the compartment, e.g. 
through repetitively exerting mechanical force. Yet, total sleep time was not related to 
perivascular space count, nor was the proportion of deep sleep in which glymphatic 
flow may be strongest.1,49 Vice versa, our cross-sectional association may also indicate 
that perivascular space caliber may help determine sleep. A higher caliber perivascular 
space may allow a higher rate of fluid exchange which, assuming that sleep functions 
to clear waste from the brain, offers a functional benefit and may increase the efficiency 
of waste clearance during sleep. In line with this interpretation, a recent study observed 
an association of functional genetic variation in aquaporin-4 (AQP4), an astrocytic water 
channel facilitating flow between perivascular space and interstitium,50 with slow-wave 
power during the night in humans.51 The functional importance of perivascular space 
caliber for waste clearance is also supported by another study in mice that showed that 
migraine-related closure of perivascular spaces could impair clearance.52 Lastly, sleep ef-
ficiency and perivascular space enlargement may also share common biological causes, 
e.g. those related to astrocytic structure or function.4,53
Future studies may consider investigating the direction of our association by investi-
gating determinants of perivascular space count in the centrum semiovale in humans, 
including glymphatic clearance, and investigate their relation with sleep, or investigate 
the temporality of our finding.
Several methodological considerations deserve mention. First, our algorithm was 
based on visually rated perivascular space counts as ground truth. Possibly, segmented 
volumes instead of counts may have better represented subtle caliber changes relevant 
for glymphatic functioning. Second, a 1.5-Tesla MRI scanner detects only the ‘tip of the 
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iceberg’ of perivascular space enlargement. Perivascular spaces detected with a 7-Tesla 
scanner may better represent physiological aspects,54 potentially relevant to sleep. 
Third, we could not exclude that the visibility of perivascular spaces on MRI could have 
been influenced by sleeping during MRI-acquisition. As sleep strongly alters interstitial 
space volume and fluid exchange in mice,1 perivascular space caliber may increase dur-
ing sleep, which quickly and commonly occurs during scanning in the MRI.55 Although 
speculative and untested in humans, such effects may have led to underestimation of 
our association. Study strengths include using two different modalities to objectively 
measure sleep, determining associations across several brain regions, and accounting 
for various potential confounding factors.
We conclude that the association of sleep with perivascular space counts in the mid-
dle-aged and elderly population remains limited to that of higher actigraphy-estimated 
sleep efficiency with higher perivascular space load in the centrum semiovale. Further 
work is needed to determine the significance of this association to glymphatic clear-
ance, and sleep.
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Supplementary Table 1. Quadratic associations of total sleep time with perivascular space counts
Modeled total 
sleep time terms 
(N=561)
Centrum semiovale Basal ganglia Hippocampus Midbrain
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Actigraphy-estimated total sleep time
Main term 1.01 (1.00-1.02) 0.03 1.00 (0.99; 1.01) 0.88 1.00 (0.99-1.01) 0.91 1.00 (0.99-1.02) 0.67
Quadratic term 1.00 (1.00-1.00) 0.04 1.00 (1.00; 1.00) 0.80 1.00 (1.00-1.00) 0.93 1.00 (1.00-1.00) 0.71
Polysomnography-derived total sleep time
Main term 1.00 (1.00-1.01) 0.35 1.00 (0.99-1.01) 0.97 0.99 (0.98-1.00) 0.04 1.00 (0.99-1.01) 0.76
Quadratic term 1.00 (1.00-1.00) 0.37 1.00 (1.00-1.00) 0.97 1.00 (1.00-1.00) 0.04 1.00 (1.00-1.00) 0.75
Estimates were obtained by modeling a main term of total sleep time that was not transformed nor stan-
dardized, and adding a quadratic term of total sleep time to the model. Estimates are expressed as the 
relative increase in odds of the enlarged perivascular spaces count per unit increase in total sleep time, i.e. 
hours. Estimates were obtained with zero-inflated negative binomial regression, adjusted for age, sex, edu-
cation, time interval between measurements of sleep and MRI, smoking status, habitual alcohol consump-
tion, body mass index, presence of hypertension, presence of diabetes mellitus, history of heart disease, 
systemic immune-inflammation index, and napping. Abbreviations: CI=Confidence Interval; N=sample 
size; OR=Odds ratio.
Supplementary Table 2. Association of separate sleep stages derived from polysomnography with peri-
vascular space counts
Sleep stage duration expressed 
as
Rate ratio for association with perivascular space counts (OR [95% CI])
% of total sleep time (N=561) Centrum semiovale Basal ganglia Hippocampus Midbrain
N1 0.97 (0.91; 1.03) 1.02 (0.96; 1.08) 0.97 (0.89; 1.06) 1.06 (0.98; 1.15)
N2 0.99 (0.94; 1.04) 1.00 (0.95; 1.05) 1.01 (0.94; 1.09) 0.97 (0.90; 1.04)
N3 1.02 (0.97; 1.08) 0.99 (0.93; 1.04) 1.01 (0.93; 1.09) 0.98 (0.91; 1.06)
REM 1.02 (0.97; 1.08) 1.00 (0.95; 1.05) 0.99 (0.92; 1.07) 1.03 (0.96; 1.10)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. We investigated relative sleep stage durations, i.e. as propor-
tion of total sleep time. Estimates were obtained with zero-inflated negative binomial regression, adjusted 
for age, sex, education, time interval between measurements of sleep and MRI, smoking status, habitual 
alcohol consumption, body mass index, presence of hypertension, presence of diabetes mellitus, history of 
heart disease, systemic immune-inflammation index, and napping. Abbreviations: CI=Confidence Interval; 




Supplementary Table 3. Associations of actigraphy-estimated and polysomnographic sleep parameters 
with perivascular space counts, restricted to persons without lacunar of cortical brain infarcts on MRI
Determinant (N=497) Rate ratio for association with perivascular space counts (OR [95% CI])
Centrum semiovale Basal ganglia Hippocampus Midbrain
Actigraphy
Total sleep time 1.07 (1.01-1.14) 0.98 (0.92-1.04) 1.02 (0.93-1.11) 1.01 (0.93-1.10)
Sleep onset latency 0.91 (0.85-0.97) 1.02 (0.95-1.09) 0.89 (0.81-0.98) 0.98 (0.89-1.08)
Wake after sleep onset 0.95 (0.89-1.01) 1.03 (0.96-1.09) 0.99 (0.91-1.09) 0.99 (0.90-1.08)
Sleep efficiency 1.13 (1.06-1.19) 0.99 (0.93-1.05) 1.04 (0.96-1.13) 1.05 (0.96-1.13)
Polysomnography
Total sleep time 1.02 (0.96-1.08) 1.01 (0.95-1.07) 0.98 (0.90-1.06) 0.99 (0.91-1.08)
Sleep onset latency 0.93 (0.86-1.00) 0.96 (0.89-1.04) 0.96 (0.86-1.07) 0.96 (0.86-1.07)
Wake after sleep onset 0.93 (0.87-0.99) 1.01 (0.94-1.07) 1.00 (0.92-1.09) 1.05 (0.96-1.15)
Sleep efficiency 1.07 (1.01-1.14) 1.01 (0.95-1.08) 1.00 (0.91-1.09) 0.97 (0.89-1.06)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. Estimates were obtained with zero-inflated negative binomial 
regression, adjusted for age, sex, education, time interval between measurements of sleep and MRI, smok-
ing status, habitual alcohol consumption, body mass index, presence of hypertension, presence of diabetes 
mellitus, history of heart disease, systemic immune-inflammation index, and napping. Bold indicates sta-
tistical significance after correcting for multiple testing (P<0.00198). Abbreviations: CI=Confidence Interval; 
MRI=Magnetic resonance imaging; N=Sample size; OR=Odds ratio
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Supplementary Table 4. Associations of actigraphy-estimated and polysomnographic sleep parameters 
with perivascular space counts, restricted to persons with a time interval of ≤28 days between sleep and 
MRI measurements
Determinant (N [% of 561]) Rate ratio for association with perivascular space counts (OR [95% CI])
Centrum semiovale Basal ganglia Hippocampus Midbrain
Actigraphy (N=350 [62%])
Total sleep time 1.04 (0.96-1.12) 0.97 (0.90-1.04) 1.00 (0.90-1.11) 1.00 (0.90-1.11)
Sleep onset latency 0.90 (0.83-0.99) 1.02 (0.94-1.10) 0.95 (0.85-1.07) 0.94 (0.83-1.05)
Wake after sleep onset 0.91 (0.84-1.00) 0.98 (0.91-1.07) 1.03 (0.91-1.16) 0.94 (0.84-1.06)
Sleep efficiency 1.12 (1.04-1.20) 1.01 (0.94-1.08) 0.98 (0.89-1.09) 1.01 (0.91-1.12)
Polysomnography (N=288 [51%])
Total sleep time 1.01 (0.94-1.08) 0.99 (0.93-1.06) 0.96 (0.87-1.06) 1.00 (0.91-1.10)
Sleep onset latency 0.87 (0.79-0.96) 0.93 (0.85-1.03) 0.92 (0.80-1.06) 0.89 (0.78-1.02)
Wake after sleep onset 0.95 (0.88-1.02) 1.02 (0.95-1.10) 1.03 (0.92-1.16) 1.03 (0.93-1.14)
Sleep efficiency 1.08 (1.00-1.16) 1.00 (0.93-1.08) 0.98 (0.88-1.10) 1.01 (0.91-1.12)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. Estimates were obtained with zero-inflated negative binomial 
regression, adjusted for age, sex, education, time interval between measurements of sleep and MRI, smok-
ing status, habitual alcohol consumption, body mass index, presence of hypertension, presence of diabetes 
mellitus, history of heart disease, systemic immune-inflammation index, and napping. Please note that 
number of participants for analyses restricted on time intervals differed across modalities, as the start of 
actigraphy recording differed slightly from the date on which polysomnography was performed. Abbrevia-




Supplementary Table 5. Associations of sleep parameters with enlarged perivascular space counts, sepa-
rately for polysomnography and actigraphy in partly overlapping samples
Determinant Rate ratio for association with perivascular space counts (OR [95% CI])
Centrum semiovale Basal ganglia Hippocampus Midbrain
Actigraphy (n=1,228)
Total sleep time 1.04 (1.00-1.08) 1.04 (1.00-1.08) 1.02 (0.97-1.08) 1.01 (0.96-1.06)
Sleep onset latency 0.96 (0.92-1.00) 1.01 (0.97-1.05) 0.94 (0.89-1.00) 1.00 (0.95-1.06)
Wake after sleep onset 0.95 (0.91-0.98) 1.00 (0.97-1.04) 0.98 (0.93-1.03) 0.97 (0.92-1.03)
Sleep efficiency 1.07 (1.03-1.11) 1.02 (0.98-1.05) 1.02 (0.97-1.08) 1.02 (0.97-1.07)
Polysomnography (n=771)
Total sleep time 1.03 (0.98-1.07) 1.02 (0.98-1.06) 1.00 (0.94-1.06) 1.01 (0.95-1.08)
Sleep onset latency 0.96 (0.90-1.01) 0.96 (0.90-1.02) 0.99 (0.91-1.07) 1.01 (0.93-1.10)
Wake after sleep onset 0.95 (0.90-0.99) 1.00 (0.96-1.05) 1.00 (0.93-1.07) 0.97 (0.91-1.04)
Sleep efficiency 1.05 (1.01-1.10) 1.01 (0.97-1.06) 1.00 (0.94-1.07) 1.02 (0.95-1.09)
Estimates are expressed as the relative increase in odds of the enlarged perivascular spaces count per stan-
dard deviation increase of the determinant. Estimates were obtained with zero-inflated negative binomial 
regression, adjusted for age, sex, education, time interval between measurements of sleep and MRI, smok-
ing status, habitual alcohol consumption, body mass index, presence of hypertension, presence of diabetes 
mellitus, history of heart disease, and systemic immune-inflammation index, and napping (polysomnog-
raphy-derived sleep parameters were not adjusted for napping, which was assessed during actigraphy re-
cordings).
Bold indicates statistical significance after correcting for multiple testing (P<0.00198). Abbreviations: 

















Sleep and resting-state functional MRI connectivity in middle-aged adults and elderly: A 




Sleep problems increase with aging. Increasing evidence suggest that sleep problems 
are not only a consequence of the aging process, but may independently contribute to 
developing vascular or neurodegenerative brain disease. Yet, it remains unclear what 
mechanisms underlie the impact sleep problems may have on brain health in the gen-
eral middle-aged and elderly population.
Here, we studied sleep’s relation to specifically brain functioning in 621 participants 
(median age 62 years, 55% women) from the population-based Rotterdam Study. We 
investigated cross-sectional associations of polysomnographic and subjectively mea-
sured aspects of sleep with intrinsic neural activity measured with resting-state func-
tional magnetic resonance imaging on a different day. We investigated both functional 
connectivity between regions and brain activity (blood-oxygen-level-dependent signal 
amplitude) within regions, hierarchically towards smaller topographical levels.
We found that longer polysomnographic total sleep time is associated with lower 
blood-oxygen-level-dependent signal amplitude in (pre)frontal regions. No objective or 
subjective sleep parameters were associated with functional connectivity between or 
within resting-state networks.
Findings may indicate a pathway through which sleep, in a ‘real-life’ population set-
ting, impacts brain activity or regional brain activity determines of total sleep time.
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INTRODUCTION
Sleep is a homeostatic process serving vital functions for the brain to support perfor-
mance the next day. As adults age, they increasingly experience sleep problems.1 Sleep 
problems have been hypothesized to impair brain health, as they are associated with 
developing stroke2 and dementia.3 It is therefore important that we increase our un-
derstanding how sleep, beyond its homeostatic, night-to-day effect, may impact brain 
health in the general middle-aged and elderly population.
How sleep affects the brain can be investigated well by studying brain functional con-
nectivity. Brain functional connectivity can be studied non-invasively with functional MRI 
(fMRI), which measures intrinsic neural activity indirectly through blood oxygenation. 
Applying fMRI when individuals are not engaged in a task (‘resting-state’ fMRI (rs-fMRI)) 
reveals how brain regions spontaneously communicate with each other in connected 
networks.4 Intrinsic neural activity as measured with rs-fMRI can provide measures of 
activity between cortical regions, or within them. The organization of intrinsic neural 
activity in networks is remarkably robust and present across various conditions.5
That sleep is relevant for waking rs-fMRI neural activity has been shown using various 
approaches. Experimental sleep deprivation studies showed immediate widespread 
changes in functional connectivity during subsequent wakefulness6,7 including an 
increase of global fMRI-signal variability,8 also known as signal amplitude. Importantly, 
observational studies that associated habitual sleep quality or duration, or a sleep dis-
order such as insomnia with rs-fMRI measures suggest that sleep may impact intrinsic 
neural activity beyond the short term.9-14 Yet, only few studies measured sleep objec-
tively to minimize misclassification or used large samples to increase statistical power 
and decrease the chance that significant associations are overestimated. Findings from 
large-scale, population-based studies are more equivocal, reporting no associations of 
sleep quality with connectivity between networks15 or of self-reported sleep duration 
with signal amplitude in the often-studied ‘default mode’ network.12
It is therefore unclear if variations in sleep, including total sleep time and duration of 
individual sleep stages, are related to intrinsic neural activity during daytime, measured 
as functional connectivity between or neural activity within different brain regions, in the 
general middle-aged and elderly population. We aimed to fill this knowledge gap using 
sleep parameters measured with polysomnography and the Pittsburgh Sleep Quality 
Index, and rs-fMRI measures from the population-based Rotterdam Study cohort. We 
explored associations between sleep and intrinsic neural activity using a hierarchical 
approach from global to more spatially-specific analyses, and subsequently examined 





The Rotterdam Study, starting in 1990, is a prospective population-based cohort of 
inhabitants of a suburban district in Rotterdam aged 45 years or over.16 Participating 
inhabitants were interviewed at home and subsequently visited the research center. 
These examination rounds were repeated every 4-5 years. The cohort was expanded 
twice, in 2000 with persons aged ≤55, and in 2006 with persons aged ≤45. We studied 
individuals from all three inclusion rounds who participated in a polysomnography 
(PSG) study between January 2012 to September 2014, and also underwent a resting 
state fMRI (rs-fMRI) scan. Rs-fMRI was implemented routinely since 2012.17
The Rotterdam Study (RS) has been approved by the Medical Ethics Committee of the 
Erasmus MC (registration number MEC 02.1015) and by the Dutch Ministry of Health, 
Welfare and Sport (Population Screening Act WBO, license number 1071272-159521-
PG). The RS has been entered into the Netherlands National Trial Register (NTR; www.
trialregister.nl) and into the WHO International Clinical Trials Registry Platform (ICTRP; 
www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831. 
The study was conducted in accordance with the guideline proposed in the World 
Medical Association Declaration of Helsinki. All participants provided written informed 
consent to participate in the study and to have their information obtained from treating 
physicians.
Study sample
We invited 1,750 persons that visited the research center for in-home PSG; 928 con-
sented. Invitees were deemed able to understand study purpose and instructions. 
Twenty-seven recordings failed or were of insufficient quality for sleep scoring. Of these, 
724 persons without MRI contra-indications also underwent rs-fMRI. We excluded par-
ticipants with poor quality17 rs-fMRI data (n=49), cortical brain infarcts (n=20) or with 
prevalent dementia or missing dementia screening (n=2). From the remaining 653, we 
included in our main analyses 621 participants with a time interval between PSG and rs-
fMRI of one year or less. From this population, we included 560 participants for analyses 
of PSG spectral power due to failure of critical EEG-leads in 61 individuals. Similarly, we 
included 603 participants for analyses on global PSQI score due to missing data of more 
than one component (see Sleep assessments below).
Sleep assessments
We recorded one night of PSG at home during weeknights. Polysomnography was 
applied by trained research assistants according to the American Association of Sleep 
Medicine (AASM) criteria,18 including six electroencephalography (EEG) channels (F3/A2, 
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F4/A1, C3/A2, C4/A1, O1/A2, O2/A1), bilateral electro-oculography, chin electromyog-
raphy, electrocardiography, respiratory belts on the chest and abdomen, oximetry, and 
a nasal pressure transducer and oronasal thermocouple. Participants were instructed 
to spend the night as normal as possible, without restrictions on bedtimes and use of 
alcohol, coffee or sleep medication. They pressed a button to signal when intending to 
go to sleep (“lights out”) and getting out of bed (“lights on”).
Sleep was scored18 by a Registered Polysomnographic Technologist to determine 
total sleep time (TST), sleep onset latency (SOL), wake after sleep onset (WASO), sleep 
efficiency (SE), and the duration of the sleep stages non-rapid eye movement (NREM) 1 
(N1), N2, N3 and REM.
We calculated spectral power and spindles in the C3/A2 derivation, using PRANA soft-
ware (PhiTools, Strasbourg, France). For spectral power, band-pass filtering (0.125-128 
Hz) and automated removal of artifacts were applied. Spectral analysis was performed 
using 4-second epochs with 50% overlap, averaged over 30-second epochs. We calcu-
lated the absolute spectral power in the delta (0.75-4.00 Hz), beta (15.50-22.50 Hz) and 
gamma (22.50-40.00 Hz) frequency bands.
Apneas were defined as an airflow reduction of ≥90% of baseline for ≥10 seconds, and 
a hypopnea was defined as an airflow reduction of ≥30% of baseline for ≥10 seconds 
and a desaturation of ≥3% from baseline or an arousal.18 The apnea-hypopnea index 
(AHI) was automatically calculated as the number of apneas and hypopneas per hour 
of sleep.
Subjective sleep quality during the past 4 weeks was measured with the PSQI during 
the home interview. The PSQI has good test-retest reliability and validity in a non-clinical 
sample of older adults.19 Items, including self-reported sleep duration, were scored to 
provide a global PSQI score ranging from 0-21. Higher scores indicate poorer sleep qual-
ity. We weighted the PSQI score for 36 out of 603 individuals with one component score 
missing, by multiplying scores by 7/6.
To validate our findings for polysomnography sleep measure and assess a possible 
first night effect we used actigraphy.20 The night of polysomnography, participants also 
wore an actigraph (ActiWatch model AW4, Cambridge Technology Ltd), and were invited 
to wear it for 7 days and also keep a sleep diary. Of 621 participants, 428 completed at 
least 4 consecutive nights (recording duration: 153±16 hours [median=144]). We used 
diary-derived times of ‘lights out’ and getting up the next morning to estimate time in 
bed. Within the time in bed, total sleep time was estimated using a validated algorithm 
with a threshold of 20 activity counts, and was averaged over all available nights per 




Brain imaging was performed with a 1.5-tesla MRI scanner (Signa Excite II, GE Healthcare, 
Milwaukee, WI, USA) at the research center. Resting state fMRI acquisition time was 
7m44s (TR= 2900 ms, TE= 60ms, Field of View= 21 cm2, 31 axial slices, matrix size=64x64, 
slice thickness= 3.3 mm, 165 volumes). Details of rs-fMRI preprocessing and connectivity 
analyses are provided elsewhere.17 In brief, participants were prompted before the start 
of the fMRI-sequence to lie still, keep their eyes open, and stay awake. Preprocessing 
of resting-state data was performed with the FMRIB Software Library FEAT package.21 
Subject-specific artifact removal was conducted using independent components which 
were automatically classified. We excluded scans that showing absolute head displace-
ment >3 mm and/or mean relative frame-wise displacement >0.2 mm. Also, as mild 
ghosting artefacts were introduced during rs-fMRI acquisition, we did not include scans 
with a ghost-to-signal ratio>0.1 and added this ratio as a covariate in analyses.17
For functional connectivity analyses, we generated a study-specific functional parcel-
lation using independent component analysis17,22 resulting in 50 components of inter-
est, or functional nodes (hereafter: nodes). A node thus is a region where voxels show 
the same temporal BOLD-signal pattern. This template was used to derive node-level 
time series and obtain values for the full temporal correlations per subject for all nodes. 
Using hierarchical clustering of the group-level node correlations,22 we concatenated 
these nodes into 9 large-scale networks, labeled anterior default mode, posterior de-
fault mode, frontoparietal, dorsal attention, ventral attention, sensorimotor, visual, 
subcortical, and temporal network.17 Networks thus contain multiple nodes showing 
similar temporal patterns. Defining small nodes and clustering them into networks al-
lowed studying with more detail the functional specialization within networks, as well 
as large-scale networks as a whole.23
Using the functional parcellation of 50 nodes, we calculated functional connectivity 
between node regions, and brain activity within node regions. For functional connectiv-
ity, we calculated correlations between the BOLD-signal time-series of each of the 50 
nodes with all others. At the network level, we obtained between-network functional 
connectivity by averaging correlation values between all nodes from one network with 
all nodes from the other network, for 9x9 networks. Within-network functional connec-
tivity was thus defined by averaging correlations of node pairs within that network. We 
investigated brain activity within regions as the variability of that region’s BOLD-signal, 
by calculating the standard deviation (SD) of each node’s time series (hereafter: signal 
amplitude). Analogous to functional connectivity, network-level signal amplitude was 
obtained by averaging amplitudes across nodes within that network. Global signal 
amplitude was obtained by averaging over all 50 nodes.
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Potential confounders
We adjusted for potential confounders selected based on relevant publications17,24: Age, 
sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between 
sleep and rs-fMRI measurement, habitual alcohol consumption, physical activity, systolic 
blood pressure, body mass index, history of diabetes mellitus, supratentorial gray matter 
volume and total intracranial volume.
The sensitivity analysis included additionally adjusting the main analyses for depres-
sive symptoms and use of any antidepressant or hypnotic medication during PSG. 
Details of measurement are provided in the Supplementary Text.
Statistical analyses
Details are described in the Supplementary Text. We investigated cross-sectional as-
sociations of 12 sleep determinants (TST, WASO, SOL, SE, duration of stages N1, N2, N3, 
REM, spectral delta, beta and gamma power, and global PSQI score) with both functional 
connectivity between regions (and within where possible), and signal amplitude within 
regions. We used non-parametric permutation testing (n=5,000) implemented in FSL’s 
‘randomise’, with family-wise error (FWE) corrected P-values.
We hierarchically tested associations to examine regional heterogeneity if significant 
at a global level: We investigated associations with functional connectivity at the network 
level, and further analyzed node-level associations if nominally significant. Similarly, we 
first investigated associations with mean signal amplitude on a global level, and further 
analyzed the nominally significant associations on a network level. Furthermore, we 
investigated significant network-level associations on a node level.
As tests in ‘randomise’ are by default performed one-sided, we further Bonferroni-
corrected the alpha level of 0.05 to PFWE-corrected<0.025 (nominal significance level). As we 
tested multiple sleep determinants, we defined a more stringent threshold for signifi-
cance at PFWE-corrected<0.00277 (number of effective independent tests=9.23).
As sensitivity analysis, we repeated the analyses in persons with a shorter time interval 
between imaging and sleep measurements (<1 month for PSG parameters; <6 months 
for PSQI score). Also, we additionally adjusted analyses for i) depressive symptoms and 
use of any antidepressant or hypnotic medication during PSG; ii) AHI.
In post-hoc analyses based on initial findings for total sleep time, we i) explored as-
sociations of separate sleep stages with amplitude on a node level; ii) assessed possible 
non-linearity by analyzing 5 equal-sized categories (quintiles) of total sleep time and 
modeling a quadratic term; iii) repeated analyses with actigraphy-estimated total sleep 





We included 621 participants (median age=62 years [range 52-95 years], 55% women). 
The median absolute time interval between PSG and rs-fMRI was 17 days. Excluded 
participants did not differ by age, sex, head motion parameters or sleep stages dura-
tion from included participants. Correlations amongst sleep and fMRI parameters are 
provided in Supplementary Table 1.
We found no associations of objective or subjective sleep parameters with functional 
connectivity between or within resting state networks (all PFWE-corrected >0.025; Fig. 1).
We observed an association of longer total sleep time with lower mean global signal 
amplitude (beta per SD increase: -0.025 (95% CI -0.044; -0.006); P=5.0e-3; Table 2).
Investigating the regional heterogeneity of this association at a network level, we 
found it was present in the ventral attention, sensorimotor, subcortical, and temporal 
network (Table 3). In the ventral attention network, the association remained after 
correcting for testing multiple sleep parameters (-0.051 (95% CI -0.077; -0.024); PFWE-
corrected=1.2e-3; Supplementary Figure 1).
We further investigated associations of total sleep time with signal amplitude within 
aforementioned networks at the node level. We only observed associations of longer 
total sleep time with lower signal amplitude in nodes of the ventral attention network, 
distributed mainly in (pre)frontal regions (Fig. 2). The association in ‘node 32’ remained
after correcting for multiple testing (-0.051 (95% CI -0.075;-0.027); PFWE-corrected=1.6e-3). 
This node corresponds bilaterally to the anterior cingulate gyrus, and the juxtapositional 
lobule cortex (formerly: Supplementary motor cortex; Fig. 2).
Other sleep parameters were not associated with mean global signal amplitude, yet 
direction of effect sizes were mostly congruent with indicating ‘poor’ sleep (e.g. sleep 
onset latency, beta spectral power) versus ‘good’ sleep (e.g. sleep efficiency).
Restricting associations to persons with a shorter time interval between sleep and rs-
fMRI measurement showed more pronounced effect sizes for the association of longer 
total sleep time with lower mean signal amplitude (n=450, Supplementary Table 2). 
Associations remained statistically significant in ‘node 32’ (-0.063 (95% CI -0.091; -0.034); 
PFWE-corrected=1.0e-3), and ‘node 23’ (-0.080 (95% CI -0.120; -0.040); PFWE-corrected=2.0e-3) cor-
responding mainly to the frontal pole and the anterior cingulate gyrus (Fig. 2). Longer 
stage N2 sleep related with lower global mean signal amplitude, driven mostly by the 
ventral attention and temporal networks (Supplementary Table 2), yet no node-level 
associations survived multiple testing correction.
In the total sample of n=621, additional adjustment for depressive symptoms and 
use of antidepressant and hypnotic medication during PSG did not change estimates 
on the global level (-0.025 (95% CI 0.044;-0.006); P=5.0e-3), or network level (ventral 
attention network: -0.051 (95% CI -0.078; -0.025); PFWE-corrected=1.2e-3; other networks: all 
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Table 1. Characteristics of the study population
Characteristics (unit) Value
Age (years) 62 (58; 66)
Female 340 (55%)
Time interval MRI-PSG (days) 6 (-12; 22)
No. of participants <1 month 450 (72%)
Time interval MRI-PSQI (days) 150 (104; 191)
No. of participants <6 months 438 (69%)
Habitual alcohol consumption (gr/day) 8 (4; 11)
Physical activity (MET-hours/week) 50 (24; 78)
Systolic blood pressure (mm Hg) 133 ± 18
Body mass index (kg/m2) 27 ± 4
History of diabetes mellitus 73 (12%)
Supratentorial gray matter volume (cm3) 538 ± 55
Intracranial volume (cm3) 1,141 ± 115
Depressive symptoms (CES-D score) 12 (10; 15)
Use antidepressants/hypnotics during PSG 29 (5%)
Self-reported sleep duration (minutes) 408 ± 73
Apnea-hypopnea index (events/hour of sleep) 9 (5; 13)
Sleep parameters
Total sleep time (minutes) 380 ± 65
Sleep onset latency (minutes) 14 (8; 23)
Wake after sleep onset (minutes) 71 ± 48
Sleep efficiency (%) 81% ± 11
Sleep stage duration (minutes)
N1 49 ± 25
N2 203 ± 52
N3 48 ± 37
REM 79 ± 26
Absolute spectral power (µV2/Hz)
Delta (range: 0.75 - 4.50 Hz) 106 (72; 155)
Beta (range: 15.50 - 22.50 Hz) 2.5 (1.7; 3.7)
Gamma (range: 22.50 – 40.00 Hz) 1.9 (1.3; 2.9)
Missing 61 (10%)
Subjective sleep quality (PSQI score) 3 (1; 6)
Missing 18 (3%)
Values are frequency (%) for categorical variables, and mean ± standard deviation or median (1st quartile; 
3rd quartile) for continuous variables, calculated over 621 participants unless specified otherwise. Values 
include imputed values for covariates.
Abbreviations: CES-D=Center for Epidemiological Studies – Depression Scale; MET=Metabolic equivalent 
of task; MRI=Magnetic resonance imaging; N=sample size; N[x]=non-REM stage x; PSG=polysomnography; 
PSQI=Pittsburgh Sleep Quality Index; REM=rapid-eye movement; TST=Total Sleep Time.
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Figure 1. Associations of sleep parameters with functional connectivity between networks
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Colors and sizes of blocks correspond to beta coefficients: Red indicates positive, and blue indicates nega-
tive associations. Values are obtained using linear regression, adjusted for age, sex, mean frame-wise head 
displacement, ghost-to-signal ratio, time interval between sleep and rs-fMRI measurement, habitual alco-
hol consumption, physical activity, systolic blood pressure, body mass index, history of diabetes mellitus, 
supratentorial gray matter volume and total intracranial volume. No associations were significant at the 
level of PFWE-corrected < 0.025. Abbreviations: DMNa=anterior default mode network; DMNp=posterior 
default mode network; DAN=dorsal attention network; FPN=frontoparietal network; N[x]=non-REM sleep 
stage x; PSQI=Pittsburgh Sleep Quality Index; REM=rapid eye movement; SMN=sensorimotor network; 
Subcort=subcortical network; Temp=temporal network, Vis=visual network; VAN=ventral attention net-
work.
Table 2. Associations of sleep parameters with global mean signal amplitude
Sleep measures Beta (95% CI) P-value
Objective
Sleep continuity measures
Total sleep time -0.025 (-0.044; -0.006) 5.0e-3
Sleep onset latency 0.015 (-0.020; 0.049) 0.19
Wake after sleep onset -0.001 (-0.022; 0.019) 0.45
Sleep efficiency -0.014 (-0.038; 0.010) 0.14
Sleep stage duration
N1 -0.013 (-0.034; 0.007) 0.10
N2 -0.013 (-0.032; 0.005) 0.08
N3 -0.009 (-0.030; 0.013) 0.21
REM -0.015 (-0.034; 0.004) 0.05
Spectral power
Delta power 0.004 (-0.024; 0.032) 0.39
Beta power 0.013 (-0.013; 0.038) 0.16
Gamma power 0.003 (-0.023; 0.029) 0.41
Subjective
Sleep complaints (global PSQI score) 0.009 (-0.010; 0.028) 0.18
Values represent difference (95% CI) in mean signal amplitude on a whole-brain level, per standard devia-
tion increase in the determinant. Estimates are obtained using linear regression models adjusted for age, 
sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between sleep and rs-fMRI 
measurement, habitual alcohol consumption, physical activity, systolic blood pressure, body mass index, 
history of diabetes mellitus, supratentorial gray matter volume and total intracranial volume.
Bold values indicate statistical significance at P<0.025. Please note that P-values were uncorrected as only 
the ‘global’ region was tested. Abbreviations: PSQI=Pittsburgh Sleep Quality Index; Nx=non-REM sleep 
stage x; REM=Rapid eye-movement.
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PFWE-corrected>8.6e-3). Additionally adjusting analyses for AHI did not influence global and 
network-level associations (Supplementary Table 3), and the association within ‘node 32’ 
remained highly similar (-0.051 (95% CI -0.075;-0.027); PFWE-corrected=1.2e-3).
Posthoc, we explored the contribution of individual sleep stages to the association of 
total sleep time with mean signal amplitude found in four networks, at both the network 
and node level. As most of total sleep time was spent in stages REM and N2, these stages 
contributed most to the association (Fig. 3), yet no association survived multiple testing 
correction.
Analyzing categorized total sleep time did not suggest non-linearity in the relation 
with signal amplitude at a global or network level (Supplementary Table 4), supported 
by testing quadratic terms of total sleep time (global: P=0.27; networks: all PFWE-correct-
ed>0.025).
Actigraphy-estimated longer total sleep time was also associated with lower mean 
signal amplitude at a global level, driven by similar networks as when derived from PSG 
(Supplementary Table 5).
Self-reported sleep duration was not associated with mean signal amplitude on 
a global level (-0.011 (95% CI -0.028; 0.004); P=0.07), nor on a network level (all PFWE-
corrected>0.025).
Table 3. Associations of total sleep time and mean signal amplitude in networks
Total sleep time Beta (95% CI) P-value PFWE-corrected
Networks
1: Default Mode - anterior -0.046 (-0.083; -0.010) 5.8e-3 0.04
2: Default Mode - posterior -0.017 (-0.039; 0.006) 0.08 0.30
3: Fronto-parietal -0.013 (-0.040; 0.013) 0.16 0.49
4: Dorsal Attention -0.014 (-0.041; 0.013) 0.15 0.48
5: Ventral Attention -0.051 (-0.077; -0.024) 4.0e-4 1.2e-3
6: Sensorimotor -0.030 (-0.049; -0.010) 1.6e-3 8.8e-3
7: Visual -0.013 (-0.033; 0.008) 0.12 0.39
8: Subcortical -0.021 (-0.036; -0.005) 4.2e-3 2.5e-2
9: Temporal -0.032 (-0.053; -0.011) 1.2e-3 8.4e-3
Values represent difference (95% CI) in mean signal amplitude on a network level, per standard deviation 
increase in total sleep time. Estimates are obtained using linear regression models and permutation tests, 
adjusted for age, sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between 
sleep and rs-fMRI measurement, habitual alcohol consumption, physical activity, systolic blood pressure, 
body mass index, history of diabetes mellitus, supratentorial gray matter volume and total intracranial vol-
ume. Bold indicates statistical significance at P<0.025.
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Figure 2. Topographical view of associations of total sleep time with signal amplitude within nodes of the 
ventral attention network
Negative associations of total sleep time with signal amplitude are shown for all 5 nodes of the ventral at-
tention network on inflated right and left hemispheres, from a lateral (top row) and medial (bottom row) 
perspective. Lighter colors correspond to larger negative effect sizes (beta coefficients). Asterisks denote 
statistical significance as: *PFWE-corrected<0.025; **PFWE-corrected<0.00277. Please note that significance levels dif-
fer from effect sizes. Values represent difference in signal amplitude in that node per standard deviation in-
crease in total sleep time, and are obtained through linear regression and permutation testing. Coefficients 
are adjusted for age, sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between 
sleep and rs-fMRI measurement, habitual alcohol consumption, physical activity, systolic blood pressure, 
body mass index, history of diabetes mellitus, supratentorial gray matter volume and total intracranial vol-
ume. Nodes correspond to the following regions (labeled using the probabilistic Harvard-Oxford cortical 
atlas found at https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases; top three overlapping regions): Node 14=Parietal 
operculum (16%), Posterior (16%) and Anterior (16%) Supramarginal cortex; Node 36= Superior Temporal 
cortex (21%), Temporal Pole (9%), Central Opercular cortex (9%); Node 25= Frontal Orbital cortex (28%), In-
sular cortex (17%), and Frontal Pole (8%); Node 23= Frontal pole (29%), Cingulate cortex - anterior division 
(9%), and Paracingulate cortex (6%); Node 32= Cingulate cortex – anterior division (24%), Juxtapositional 
Lobule (formerly: Supplementary Motor cortex) (13%), and Paracingulate cortex (5%). Threshold of node 
borders was set at z=5.0.
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Figure 3. Associations of total sleep time, and duration of sleep stages, with signal amplitude within signifi-
cant networks, and within their nodes
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DISCUSSION
In this population-based study, we found that PSG-determined longer total sleep time 
was associated with a lower mean BOLD-signal amplitude during daytime, primarily in 
the ventral attention network. In contrast, no objective or subjective sleep parameter 
was associated with functional connectivity between or within networks.
No study previously investigated the relation of objectively measured sleep with 
intrinsic neural activity measured at median 17 days apart, using a population-based 
design. In a large-scale study using UK biobank data, self-reported total sleep time 
was negatively correlated with signal amplitude in networks labeled as sensory/motor, 
not attentional networks.12 We found no association for self-reported sleep duration 
assessed with the PSQI, but to the extent that PSG-derived total sleep time measured 
a similar construct, differences in study-specific parcellation, attributing the same func-
tional node to different networks, may explain regional differences between studies.
We measured both sleep and rs-fMRI not within a 24-hour timeframe, which makes 
the association more robust to biases due to variable recording conditions of PSG and 
rs-fMRI. The association was more pronounced in persons who underwent measure-
ments within a shorter, 1-month time interval, suggesting that effects were short-
lived. Yet, both sleep25,26 and resting state measures27,28 exhibit ‘trait’-like, time-stable 
properties, supporting that our association may extend beyond a night-to-day effect. 
Our findings were specific to BOLD-signal amplitude. Momentary increases in BOLD-
signal may reflect local, task-triggered neural activity.29 This amplitude does not refer 
to momentary increases but to increased fluctuations over time. Although its correlates 
have not been well characterized several observations suggest it is representative of a 
sleep-deprived state or lower vigilance.7,30,31 After sleep deprivation, increased lapses in 
attentional maintenance can be observed32 and such lapses may be accompanied by 
repeated intrusions of sleep.30
Associations of total sleep time and sleep stages with (mean) signal amplitude are shown for the four net-
works with a statistically significant relation. Corresponding nodes are depicted in the axial plane (right = 
anatomical left) at the level of highest node intensity. Colors and sizes of blocks correspond to effect sizes 
(beta coefficients): red indicates positive, and blue indicates negative associations.
Values are obtained through linear regression and permutation testing. Coefficients represent difference in 
signal amplitude in that network or node per standard deviation increase in the sleep parameter, adjusted 
for age, sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between sleep and 
rs-fMRI measurement, habitual alcohol consumption, physical activity, systolic blood pressure, body mass 
index, history of diabetes mellitus, supratentorial gray matter volume and total intracranial volume. FWE-
corrected P-values for networks were corrected over all 9 networks, and for nodes were corrected for all 50 
nodes. Symbols denote: + PFWE-corrected<0.025; *PFWE-corrected<0.00277. Please note that significance levels differ 
from effect sizes. Abbreviations: Nx= non-REM sleep stage x; REM=rapid eye movement.
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Alternatively, the amount of wakefulness could equally well underlie the association 
of total sleep time and signal amplitude as it was not driven by a specific sleep stage, 
and was also found when using actigraphy-estimated habitual total sleep time. Ex-
tended wakefulness increases synaptic potentiation,33 and low-frequency EEG power34 
indicative of more synchronized activity. This power increase is most pronounced 
medio-frontally as was our association. Also, high amplitude activity on EEG observed in 
deep sleep indicates more synchronized fluctuations in membrane potential.35 Against 
this background, we speculate that the association with BOLD-signal amplitude may 
also result from more synchronized, infra-slow neural activity during wakefulness.
Although we could not assess temporality in our cross-sectional study, these potential 
mechanisms favor a temporal association from sleep, or wakefulness, to brain intrinsic 
neural activity. Yet, the topographical overlap of our findings to the regions involved 
in the generation and propagation of sleep itself36,37 may also suggest that signal am-
plitude determines total sleep time in a population-based, ‘non-laboratory’ setting. The 
temporality of the association of objectively estimated total sleep time and regional 
brain activity, or shared causes, should be studied further.
No sleep parameter was associated with network functional connectivity, in line 
with previous findings for the PSQI score.15 Findings differ from experimental sleep 
deprivation studies that show a consistent impact on subsequent e.g. within-network 
connectivity of the default mode network.6 Possibly, sleep deprivation effects may be 
too short-lived to be detected here. Furthermore, such effects inherently differ from 
our sleep measures which are more indicative of chronic, stable aspects of sleep. Im-
portantly, methodological heterogeneity in e.g. study design, imaging processing, or 
modelling approaches may also explain finding null results in contrast to literature, as 
concluded recently for insomnia neuroimaging findings.38 Also, bias by lack of adequate 
control for potential confounders or use of seed-based approaches38 may have made 
previous studies more prone to finding false-positive results.
Several methodological considerations deserve mention. First, we did not monitor 
sleep during rs-fMRI acquisition and cannot rule out contamination of our measures by 
sleep.39 Even light sleep stages40 involve increases in global signal amplitude, consistent 
over networks. Individuals with a short total sleep time may have been at increased like-
lihood of falling asleep in the scanner, which may have biased our estimates. However, 
several observations suggest that contamination less likely explains our findings: i) We 
found no non-linearity in our associations for total sleep time, indicating that results 
were not driven by short sleepers only; ii) Total sleep time was not correlated with head 
motion, which may indicate sleepiness in the scanner41; iii) Even light stages of sleep 
involve substantially altered network connectivity.39,42 This suggests that, if sleeping in 
the scanner drove our results for signal amplitude, one might expect to also find as-
sociations with functional connectivity between or within networks. Yet, we found none, 
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indicating that likely few participants slept during rs-fMRI acquisition. We ensured, by 
addressing participants, that they were awake at the start of rs-fMRI acquisition. Further 
vigilance monitoring with concomitant EEG was not deemed necessary nor feasible due 
to the population-based nature of our study. Second, we could not assess the influence 
of sleep the night preceding rs-fMRI acquisition. Third, performing fMRI at 1.5T instead of 
higher field strengths, and not controlling for variable conditions during rs-fMRI acquisi-
tion, may have reduced our sensitivity to detect associations. Similarly, retrospective 
assessment of sleep with the PSQI over the previous 4 weeks may have reduced chances 
to detect cross-sectional associations for PSQI-derived measures. Third, we could not 
assess how local differences in gray matter influenced our estimates beyond global 
volume. Study strengths include using PSG to study sleep over a broad and ‘real-life’ 
spectrum in a population-based study population, having substantial statistical power 
to detect small effect sizes, and adjusting for multiple potential confounders.
We conclude that, in the general middle-aged and elderly population, total sleep time 
affects the repertoire of (pre)frontal brain activity, or vice versa, beyond a night-to-day 
effect. At the same time, our results suggest there is no clear association of objective and 
subjective measures of sleep with functional connectivity between or within resting-
state networks.
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Supplementary Table 1. Correlations amongst sleep parameters and MRI quality parameters
TST TST
SOL -0.20 SOL
WASO -0.30 0.14 WASO
SE 0.52 -0.48 -0.85 SE
N1 0.08 -0.03 0.33 -0.20 N1
N2 0.69 -0.17 -0.26 0.41 0.02 N2
N3 0.18 -0.01 -0.19 0.19 -0.42 -0.33 N3
REM 0.63 -0.14 -0.29 0.42 -0.08 0.30 0.06 REM
Delta 0.15 0.01 -0.10 0.11 -0.44 -0.07 0.58 0.03 Delta
Beta -0.04 0.09 0.15 -0.13 -0.17 -0.14 0.26 -0.04 0.53 Beta
Gam -0.06 0.11 0.17 -0.15 -0.11 -0.17 0.22 -0.06 0.50 0.84 Gam
PSQI -0.06 0.06 0.08 -0.11 -0.09 -0.02 0.06 -0.09 0.12 0.17 0.14 PSQI
Gh 0.01 -0.06 0.02 0.03 0.11 0.07 -0.17 0.00 -0.12 -0.13 -0.16 -0.14 Gh
FD 0.02 -0.03 0.00 0.01 0.08 0.01 -0.01 -0.02 -0.05 -0.12 -0.10 0.06 -0.04 FD
Spearman correlation values for polysomnography-derived parameters (sleep continuity measures, abso-
lute sleep stage duration, spectral powers in three frequency bands), global PSQI score, and two MRI quality 
parameters. Values are obtained for complete case pairwise comparisons, using original variable distribu-
tions. Comparisons between spectral power frequency bands (n=560) and global PSQI score (n=603) were 
calculated in=543. Bold indicates statistical significance at P<0.001.
Abbreviations: Delta/Beta/Gam=Absolute spectral power in the delta/beta/gamma frequency band; 
FD=Frame-wise head displacement; Gh=ghost-to-signal ratio; Nx=non-REM sleep stage x sleep duration; 
PSQI=Global Pittsburgh Sleep Quality Index score; REM=Rapid eye movement sleep duration; SE=Sleep 
efficiency; SOL=Sleep onset latency; TST=Total sleep time; WASO=Wake after sleep onset
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Supplementary Figure 1. Scatterplot of association of total sleep time with mean signal amplitude in the 
ventral attention network
The data points graphically depict the relation of longer total sleep time with mean signal amplitude in 
the ventral attention network. The regression line and corresponding shaded 95% confidence interval (CI) 
show the average relation obtained after linear regression. The multivariate adjusted linear association was 
statistically significant association after correcting for multiple testing only in this network (per standard 
deviation increase of total sleep time: -0.051 mean difference in signal amplitude (95% CI -0.077l -0.024); 
PFWE-corrected=1.2e-3. Total sleep time is depicted in hours.
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Supplementary Table 2. Associations of sleep parameters with mean signal amplitude at the global and 
network level, restricted to participants with a shorter time interval between sleep and rs-fMRI measure-
ment
Level Sleep parameters Beta (95% CI) P PFWE-corrected
Global Total sleep time -0.033 (-0.055; -0.011) 2.4e-3 -
Sleep onset latency -0.009 (-0.050; 0.032) 0.35 -
Wake after sleep onset -0.001 (-0.025; 0.023) 0.47 -
Sleep efficiency -0.005 (-0.033; 0.024) 0.38 -
Stage N1 duration -0.010 (-0.034; 0.014) 0.19 -
Stage N2 duration -0.024 (-0.046; -0.003) 1.2e-2 -
Stage N3 duration -0.007 (-0.031; 0.018) 0.30 -
Stage REM duration -0.016 (-0.038; 0.006) 0.08 -
Spectral delta power -0.003 (-0.031; 0.026) 0.44 -
Spectral beta power 0.011 (-0.020; 0.041) 0.24 -
Spectral gamma power -0.009 (-0.041; 0.023) 0.31 -
Global PSQI score 0.014 (-0.009; 0.037) 0.12 -
Network Total sleep time
1: Default mode – anterior -0.058 (-0.100; -0.015) 5.2e-3 2.9e-2
2: Default mode – posterior -0.025 (-0.051; 0.002) 0.04 0.17
3: Frontoparietal -0.024 (-0.054; 0.006) 0.06 0.25
4: Dorsal attention -0.023 (-0.055; 0.009) 0.07 0.29
5: Ventral attention -0.062 (-0.094; -0.030) 6.0e-4 1.6e-3
6: Sensorimotor -0.039 (-0.061; -0.017) 4.0e-4 2.4e-3
7: Visual -0.011 (-0.034; 0.012) 0.17 0.51
8: Subcortical -0.029 (-0.047; -0.012) 6.0e-4 4.8e-3
9: Temporal -0.045 (-0.070; -0.020) 8.0e-4 2.2e-3
Stage N2 duration
1: Default Mode – anterior -0.039 (-0.082; 0.003) 0.03 0.16
2: Default Mode – posterior -0.023 (-0.049; 0.004) 0.05 0.20
3: Fronto-parietal -0.025 (-0.055; 0.004) 0.04 0.20
4: Dorsal Attention -0.008 (-0.039; 0.023) 0.30 0.71
5: Ventral Attention -0.049 (-0.081; -0.017) 1.2e-3 9.4e-3
6: Sensorimotor -0.025 (-0.047; -0.003) 1.3e-2 0.07
7: Visual -0.003 (-0.026; 0.019) 0.39 0.79
8: Subcortical -0.023 (-0.041; -0.006) 4.0e-3 2.6e-2
9: Temporal -0.038 (-0.063; -0.013) 1.6e-3 9.8e-3
We analyzed associations at the global level, and further explored significant sleep parameters (total sleep 
time and stage N2 duration) at the network level. The absolute time interval between sleep and rs-fM-
RI measurement was ≤1 month for polysomnography (n=450 [72%], n=406 for spectral power variables 
[65%]), and ≤6 months for PSQI (n= 430 [69%]). Values represent difference (95% CI) in mean signal ampli-
tude per standard deviation increase in the sleep parameter. Estimates are obtained using linear regression 
models and permutation tests, adjusted for age, sex, mean frame-wise head displacement, ghost-to-signal 
ratio, time interval between sleep and rs-fMRI measurement, habitual alcohol consumption, physical activi-
ty, systolic blood pressure, body mass index, history of diabetes mellitus, supratentorial gray matter volume 
and total intracranial volume. Bold indicates statistical significance at P<0.025. Please note that P-values 
at the global level were uncorrected as only the ‘global’ region was tested. Abbreviations: N=sample size; 
Nx=non-REM sleep stage x; PSQI=Pittsburgh Sleep Quality Index; REM=rapid eye movement
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Supplementary Table 3. Associations of sleep parameters with mean signal amplitude at the global and 
network level, additionally adjusted for apnea-hypopnea index
Level Sleep parameter Beta (95% CI) P PFWE-corrected
Global Total sleep time -0.025 (-0.044; -0.006) 5.2e-3 -
Sleep onset latency 0.014 (-0.020; 0.049) 0.20 -
Wake after sleep onset -0.001 (-0.022; 0.019) 0.45 -
Sleep efficiency -0.014 (-0.038; 0.011) 0.14 -
Stage N1 duration -0.013 (-0.034; 0.007) 0.10 -
Stage N2 duration -0.013 (-0.032; 0.005) 0.08 -
Stage N3 duration -0.009 (-0.030; 0.012) 0.21 -
Stage REM duration -0.015 (-0.034; 0.004) 0.06 -
Spectral delta power 0.004 (-0.024; 0.031) 0.40 -
Spectral beta power 0.014 (-0.011; 0.039) 0.14 -
Spectral gamma power 0.006 (-0.020; 0.032) 0.33 -
Global PSQI score 0.009 (-0.010; 0.028) 0.18 -
Network Total sleep time
1: Default mode – anterior -0.047 (-0.083; -0.01) 5.6e-3 0.04
2: Default mode – posterior -0.016 (-0.039; 0.007) 0.09 0.32
3: Frontoparietal -0.013 (-0.040; 0.013) 0.16 0.50
4: Dorsal attention -0.014 (-0.042; 0.013) 0.15 0.47
5: Ventral attention -0.051 (-0.078; -0.025) 4.0e-4 1.0e-3
6: Sensorimotor -0.030 (-0.049; -0.010) 1.6e-3 8.8e-3
7: Visual -0.012 (-0.033; 0.008) 0.12 0.40
8: Subcortical -0.020 (-0.036; -0.005) 5.0e-3 0.03
9: Temporal -0.032 (-0.052; -0.011) 1.6e-3 9.2e-3
We analyzed associations at the global level, and further explored significant sleep parameters (total sleep 
time) at the network level. Values represent difference (95% CI) in mean signal amplitude per standard de-
viation increase in the sleep parameter. Estimates are obtained using linear regression models and permu-
tation tests, adjusted for age, sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval 
between sleep and rs-fMRI measurement, habitual alcohol consumption, physical activity, systolic blood 
pressure, body mass index, history of diabetes mellitus, supratentorial gray matter volume and total intra-
cranial volume. Bold indicates statistical significance at P<0.025. Please note that P-values at the global 
level were uncorrected as only the ‘global’ region was tested.




Supplementary Table 4. Effect sizes of associations of categorized total sleep time with mean signal am-
plitude, at both the global and network level
Level Categories (quintiles) of total sleep time in hours
<5.6 5.6-6.2 6.2-6.6 6.6-7.2 >7.2
Global 0.035 0.006 0.000 (ref ) -0.046 -0.035
Network
1: Default mode - anterior 0.020 -0.041 0.000 (ref ) -0.096 -0.116
2: Default mode - posterior 0.047 0.042 0.000 (ref ) -0.014 0.014
3: Frontoparietal 0.031 0.006 0.000 (ref ) -0.029 -0.017
4: Dorsal attention 0.002 -0.047 0.000 (ref ) -0.074 -0.060
5: Ventral attention 0.066 0.031 0.000 (ref ) -0.067 -0.055
6: Sensorimotor 0.052 0.016 0.000 (ref ) -0.031 -0.031
7: Visual 0.004 0.000 0.000 (ref ) -0.048 -0.035
8: Subcortical 0.031 -0.001 0.000 (ref ) -0.041 -0.025
9: Temporal 0.055 0.017 0.000 (ref ) -0.043 -0.025
Associations of categories (quintiles) of total sleep time with mean signal amplitude at the global level, and 
the network level. Values represent difference in mean signal amplitude for that quintile of total sleep time, 
referenced to the middle quintile. Values are obtained through linear regression adjusted for age, sex, mean 
frame-wise head displacement, ghost-to-signal ratio, time interval between sleep and rs-fMRI measure-
ment, habitual alcohol consumption, physical activity, systolic blood pressure, body mass index, history of 
diabetes mellitus, supratentorial gray matter volume and total intracranial volume.
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Supplementary Methods
Measurement of potential confounders and effect-modifiers
Potential confounders were selected based on impacting sleep derived from PSG, the 
neurovascular process underlying the fMRI BOLD-signal, or both.1,2 Covariates, unless 
mentioned otherwise, were measured at the home interview or center visit, mostly 
before PSG. Age was determined at the polysomnography measurement. Values for 
ghost-to-signal ratio and mean frame-wise head displacement were obtained during 
fMRI preprocessing. Educational attainment was self-reported in four levels, expressed 
in corresponding average years (7, 9, 13, or 19). Habitual alcohol consumption was 
quantified with the Food Frequency Questionnaire3 as grams/day intake. Physical 
activity was queried4 and quantified in standardized measures of activity intensity 
(metabolic activity of task per week).5 Systolic blood pressure in mm Hg was the aver-
age of two right-arm measurements when sitting up. Body mass index was calculated 
from measured weight and height (kg/m2). Diabetes mellitus was defined as a fasting 
serum glucose level ≥7.0 mmol/L and/or self-reported use of anti-diabetic medication. 
Intracranial and supratentorial gray matter volume were obtained from structural MRI 
Supplementary Table 5. Associations of actigraphy-estimated sleep parameters with mean signal ampli-
tude at the global and network level, in n=428 persons
Level Sleep parameters Beta (95% CI) P PFWE-corrected
Global Total sleep time -0.025 (-0.048; -0.001) 2.3e-2 -
Network Total sleep time
1: DMN – anterior -0.068 (-0.113; -0.023) 1.0e-3 8.6e-3
2: DMN – posterior 0.000 (-0.029; 0.029) 0.50 0.87
3: Frontoparietal -0.006 (-0.038; 0.027) 0.35 0.75
4: Dorsal attention -0.034 (-0.069; 0.000) 0.03 0.12
5: Ventral attention -0.048 (-0.080; -0.016) 1.0e-3 9.4e-3
6: Sensorimotor -0.031 (-0.055; -0.007) 5.2e-3 3.6e-2
7: Visual -0.005 (-0.032; 0.021) 0.33 0.73
8: Subcortical -0.032 (-0.050; -0.014) 4.0e-4 2.2e-3
9: Temporal -0.024 (-0.051; 0.003) 0.04 0.18
We analyzed associations at the global level, and further explored total sleep time at the network level. 
Values represent difference (95% CI) in mean signal amplitude per standard deviation increase in the sleep 
parameter. Estimates are obtained using linear regression models and permutation tests, adjusted for age, 
sex, mean frame-wise head displacement, ghost-to-signal ratio, time interval between sleep and rs-fMRI 
measurement, habitual alcohol consumption, physical activity, systolic blood pressure, body mass index, 
history of diabetes mellitus, supratentorial gray matter volume and total intracranial volume.
Bold indicates statistical significance at P<0.025. Please note that P-values at the global level were uncor-
rected as only the ‘global’ region was tested. Abbreviations: DMN=Default mode network; N=sample size; 
Nx=non-REM sleep stage x; PSQI=Pittsburgh Sleep Quality Index; REM=rapid eye movement
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(T1-weighted sequence) segmentations.6 Depressive symptoms were assessed with the 
validated Dutch version7 of the Centre for Epidemiological Studies Depression Scale.8 
Self-reported use of any antidepressant or hypnotic medication during the night of PSG 
was queried in an accessory sleep diary.
Statistical analysis
First, we calculated pair-wise correlations between all sleep determinants, and included 
frame-wise head displacement and ghost-to-signal ratio to examine how sleep related 
to MRI-parameters.9 Main analyses were performed using general linear models with the 
intrinsic neural activity parameter as a dependent variable. We used group-level non-
parametric permutation testing (n=5,000) implemented by FSL’s randomise with family-
wise error (FWE) corrected P-values to evaluate significance when testing associations 
in multiple regions within one topographical scale (i.e. at the network- or node-level). 
We chose sleep determinants informed by prior research.10,11 Spectral power in the delta, 
beta and gamma bands were chosen based on the role of slow-wave activity on synaptic 
potentiation12,13 and the role of high frequency bands as potential electrophysiological 
markers of hyperarousal in insomnia.14-16 Lastly, we investigated global PSQI score as a 
measure of subjective sleep quality.
Thresholds for statistical significance and further exploring regional effects were a 
compromise between missing regional effects that may be ‘averaged out’ on a larger 
scale and type I error: Associations were regionally explored with PFWE-corrected<0.025, 
halving the alpha of 0.05, as tests were performed one-tailed. A second, more stringent, 
significance threshold was defined to account for testing multiple sleep aspects in 
this study. For this, we computed the number of effective tests17 (Meff=9.23) based on 
Pearson correlations between the 12 sleep determinants, subsequently applied a Sidak 
correction,18 and halved the new alpha level for two-tailed tests (P<0.00277).
In sensitivity analyses, we tested the robustness of findings by repeating the main 
analyses after including only participants with PSG and rs-fMRI measurements <1 
month apart (n=450 for sleep stage scoring, n=425 for spectral analysis), or <6 months 
apart for PSQI (n=438). We additionally adjusted analyses for depressive symptoms and 
self-reported use of any versus no antidepressant or hypnotic medication at the night of 
PSG considering these factors may relate to both sleep and rs-fMRI parameters.19,20 We 
also adjusted analyses for the apnea-hypopnea index, a prevalent indicator of potential 
obstructive sleep apnea in our study population.21
Posthoc, exploratory analyses included modeling a quadratic term of total sleep time 
(TST*TST), which was added besides the main effects term of TST, to statistically test 
potential non-linearity.
To minimize the effect of outliers, we winsorized outliers (changed to approach the 
mean) to 3 standard deviations from the mean. Sleep parameters were then standard-
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ized (subtracting the sample mean and dividing by the standard deviation) to facilitate 
comparison of effect sizes. Missing data on covariates (mean=3%) were imputed using 
5 multiple imputations, based on all analysis variables. Missing values imputation was 
performed with IBM SPSS Statistics version 22.0 (IBM Corp, Armonk, NY). Brain topo-
graphical depictions were created using Freesurfer Freeview. Figures including heat 
maps were created using R.
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Ik dacht eens beter een nachtje niet
dan dat ik een nacht geniet
dus beter een dagje niet, dacht je niet?














This thesis discusses the role of sleep in neurodegenerative diseases and related brain 
outcomes, studied from a population perspective. Here I will discuss the main findings 
across studies, and highlight several methodological considerations relevant for inter-
preting our findings.
REVIEW OF FINDINGS
Sleep in the general population
We described self-reported sleep characteristics across all ages using population-based 
cohorts from the Netherlands, investigated their potential determinants and compared 
these sleep characteristics across countries and assessment methods (see Chapter 2.1). 
Using the National Sleep Foundation sleep duration recommendations1 as a benchmark, 
we concluded that most people sleep for an acceptable duration. More importantly, 
sleep complaints or impaired sleep quality were more common than deviations of self-
reported total sleep time from age-appropriate recommendations, across countries. 
Also, sleep characteristics assessed objectively through physiologic data systematically 
differed from subjective assessments.
Focusing on middle-aged and elderly individuals, an increased focus of research and 
public health professionals to increase sleep quality, not only duration,2 seems relevant 
to improve sleep, and potentially related ‘cognitive, physical and emotional health prob-
lems’1 that may arise from poor sleep. However, we found that poor subjective sleep 
quality did not increase the risk of dementia in an elderly population. Recent studies 
showed that treating insomnia symptoms in adults through digital cognitive behav-
ioral therapy for insomnia can reduce mental health problems,3,4 of which application to 
older adults should be further studied. However, findings suggest that sleep problems 
when assessed subjectively are not necessarily related to an increased risk of all-cause 
dementia or Alzheimer’s disease (see Chapter 3.1). This is not to say that ameliorating 
insomnia symptoms, or improving sleep quality, has no value.
Although most persons report a sleep duration deemed acceptable for their age, 
we could not adequately address questions regarding sleep deprivation, sleep debt or 
chronic sleep loss at a population level. These constructs are well not captured by one 
measurement of self-reported sleep characteristics. But more importantly, the discrep-
ancy between self-reported and objective measurements5 indicates that we are prob-
ably looking at more than sleep per se when judging self-reports on a population-based 
scale (also see Methodological considerations, paragraph on ‘Subjective versus objec-
tive measurements’). Sleep characteristics that can be quantified using physiologic data, 
e.g. total sleep time, may be less adequately assessed using subjective, self-reported 
measurements.5,6 It suggests we need to either recalibrate the whole debate to objec-
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tive measures, or shift our focus more towards the constructs that are inherently validly 
measured through subjective appraisal.
Further research should investigate to what extent targeting individuals that report 
extreme durations or time in bed for their age and sex, or certain subgroups as those 
identified in this chapter, may yield improvement in sleep and well-being, and in health 
outcomes.
Sleep and dementia
We found no association of subjective sleep quality, measured with the Pittsburgh Sleep 
Quality Index (PSQI), with the risk of all-cause or Alzheimer’s disease dementia over 13 
years of follow-up (see Chapter 3.1). Moreover, PSQI components, including the often-
investigated parameters of self-reported sleep duration and efficiency, were also not 
related to dementia risk. We discussed that potential biases do not seem to explain our 
negative findings, which are, however, largely inconsistent with meta-analyzed results.7-9 
On the one hand this suggests that chance may have played a role, on the other hand 
meta-analysis authors have cautioned for potential publication bias.7 Interestingly, the 
most recent meta-analysis showed that there was no association of poor sleep with risk 
of cognitive disorders including dementia when the analysis was restricted to longer 
follow-up studies (>10 years). This suggests reverse causation, or the effect of preclinical 
or prodromal dementia on sleep at baseline, may have driven the largely positive results. 
Repeating survival analysis across studies, using our approach of time-stratified analyses 
on individual-level data may be an important next step to assess such effects (see Meth-
odological considerations, paragraph ‘Reverse causation’).
While self-reported sleep quality was not associated with dementia risk, we found a 
relation of having objectively disturbed sleep with increased dementia risk (see Chapter 
3.2). Evidently, subjective and objective measurements of sleep differ. Finding only an 
association using actigraphy-estimated sleep suggests that some disturbances are not 
recognized or not experienced as problematic by participants. Presence of prodromal 
subtle cognitive problems may hinder recognizing poor or short sleep, or contribute 
to downplaying issues with sleep, possibly to avoid further enquiry.10 Yet, we cannot 
exclude that participants or their spouses may be aware of sleep problems relevant to 
dementia risk. Beyond awareness of sleep problems, we could also not determine to 
what extent prioritizing sleep, or negligence of sleep, contributed to increased demen-
tia risk.
Besides sleep, we also investigated actigraphy-estimated 24-hour activity rhythms in 
relation to risk of dementia, identified as a knowledge gap in Chapter 2.2.11-13 We found 
no relation of fragmented or unstable 24-hour activity rhythms with incident dementia 
or Alzheimer’s disease. Yet, we found associations of a phase advance of sleep with inci-




earlier ‘lights out’ time with incident dementia in short versus longer follow-up durations. 
These findings suggest that underlying neurodegeneration, or concomitant behavioral 
or neuropsychiatric disease features disturb the 24-hour activity rhythm closely before 
the diagnosis, not vice versa. This is not in line with prevailing interpretations of mostly 
cross-sectional data in previous reviews.11-13 We feel repeated studies similar to ours are 
necessary. Also, future studies may consider investigating determinants of ‘lights out’ 
time as a novel indicator of dementia risk, with the objective to determine whether this 
symptom is indicative of behavior choices or of underlying circadian disruption.14
We discussed which neurobiological correlates may potentially confound the as-
sociations of actigraphy-estimated nighttime wakefulness and higher risk of dementia, 
especially Alzheimer’s disease (see Chapter 3.2). Here, I provide a brief background for 
one potentially important factor hypothesized to have a bidirectional relation with sleep 
disturbances: Disease-related neurodegenerative pathology.
Alzheimer’s disease is characterized pathologically by plaques of beta-amyloid and 
tau neurofibrillary tangles. When Alzheimer’s disease is clinically diagnosed, patients 
(or relatives) often also report sleep or circadian disturbances. Such disturbances are 
not only a consequence of the disease but have been hypothesized to independently 
contribute to development of progression or the disease.11-13,15-17 Studies have especially 
focused on the role of sleep, and extended wakefulness, in beta-amyloid metabolism. 
Animal studies show that beta-amyloid concentrations in interstitial fluid fluctuate with 
sleep and wake.18 Sleep has been hypothesized to drive beta-amyloid clearance,19 while 
wakefulness drives beta-amyloid production through neuronal activity.20,21 Human 
observational and experimental studies mostly confirm this regulatory role of sleep on 
beta-amyloid concentrations,22-28 and also sleep’s role in regulating concentrations of 
pathological tau proteins relevant to Alzheimer’s disease pathogenesis.29-33 The relation 
of sleep disturbances with Alzheimer’s disease pathology is likely bidirectional.15
Against this background, determining an association of sleep with incident neurode-
generative disease requires accounting for neurodegenerative pathology at baseline to 
obtain unbiased results. We discussed the possibility of such confounding (see Chapter 
3.2), and addressed it by investigating the cross-sectional relation of sleep with biomark-
ers of neurodegenerative disease (see Chapter 4.1). Interestingly, we found that sleep 
and biomarkers were unrelated. This seemed unattributable to poor validity of our bio-
markers measurements, as another recent study in our cohort found that higher NfL and 
lower Ab-42 in plasma were associated with an increased risk of all-cause dementia and 
Alzheimer’s disease in non-demented individuals.34 We do not know to what extent our 
plasma-based measurements may have not picked up small, strategic neurodegenera-
tive changes in sleep-wake regulating regions in brainstem and prefrontal regions.16,35,36 
Further research may focus on such local lesions using neuroimaging methods. Never-
theless, findings suggests that neurodegenerative pathologies including those related 
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to Alzheimer’s disease were not likely a confounder, or a mediator, of the association of 
actigraphy-estimated sleep disturbances with dementia risk. Thus, at the same time, to 
explain the link between sleep disturbances and dementia risk we feel it is warranted to 
look beyond Alzheimer’s disease pathology.16 After all, beta-amyloid and tau pathology 
are not sufficient37 causes for developing clinical Alzheimer’s disease dementia.38,39 Also, 
other pathophysiological processes in the brain play a role in dementia,32,40 that may also 
disturb sleep. Interestingly, some of these processes have also been described to occur 
as a consequence of disturbed sleep, e.g. excitotoxic activity or hyperexcitability, neuro-
inflammation, DNA damage, oxidative stress, or impaired glucose metabolism.41-46 This 
overlap argues that we further investigating these factors as potential confounders, or 
mediators, of the link of sleep disturbances with risk of dementia in the general popula-
tion.
This thesis further studied two such neurobiological correlates. We first determined 
sleep’s relation with glymphatic functioning as indicated by the structural appearance 
of the perivascular space on magnetic resonance imaging (MRI; see Chapter 4.2). Similar 
to findings for plasma biomarkers, we found no consistent associations of poor sleep 
with higher perivascular space burden on MRI. Contrary to findings from the small num-
ber of previous studies on this topic, we found an association of higher sleep efficiency 
with higher perivascular space count in the centrum semiovale, i.e. an association in 
the opposite direction. Results could be explained by, among others, perivascular space 
count indicating brain physiological aspects beneficial to sleep, and we suggest further 
study of this surprising finding.
We also determined the association of sleep with brain functioning measured with 
resting-state fMRI (see Chapter 4.3). This method probes the functional organiza-
tion of the brain and may represent subtle global or regional brain changes possibly 
relevant to neurodegeneration.47-49 We found that longer total sleep time, measured 
with polysomnography and also actigraphy, was associated with a lower BOLD-signal 
amplitude, driven by prefrontal brain regions. The significance of this finding to risk of 
neurodegenerative disease remains unclear, although it seems limited as the absolute 
amount of actigraphy-estimated total sleep time was not associated with dementia risk 
(see Chapter 3.2).
Together, the neurobiological correlates investigated in chapter 4 could not explain 
the relation of actigraphy-estimated poor sleep with increased dementia risk (see 
Chapter 3.2). Further study of neurobiological correlates potentially confounding or 
mediating the sleep-dementia link is needed to learn what sleep characteristics, if any, 




Sleep and Parkinson’s disease
We found that poor sleep quality and short sleep duration increase the risk of Parkin-
son’s disease only in the first 2 years of follow-up, but not thereafter (see Chapter 3.3). 
Analyses over repeated measurements of sleep showed that a deterioration of sleep, i.e. 
a shortening of duration and a decrease in quality, was related to developing Parkin-
son’s disease. These observations are congruent with sleep being a prodromal feature 
of Parkinson’s disease. This interpretation also fits with neuropathological findings in 
the model proposed by Braak and colleagues, stating the involvement of sleep-wake 
regulating brain regions before onset of motor symptoms.50-53
We could not determine if specific sleep disorders drove our findings. Rapid eye move-
ment sleep behavior disorder (RBD) may be considered a likely candidate as it occurs 
in around 30% of patients around diagnosis54,55 and is highly specific to developing 
Parkinson’s disease or related synucleinopathies.56 Yet, current limited evidence sug-
gests persons with RBD in the general population do not report their sleep as shorter 
or poorer than otherwise healthy individuals,57 and may even report longer sleep du-
rations. If, however, RBD precedes Parkinson’s disease by over a decade, it could be 
involved in higher baseline levels of self-reported sleep duration and quality that make 
for steeper declines in these constructs when prodromal disease sets in. Alternatively, 
obstructive sleep apnea (OSA) has also been reported to precede Parkinson’s disease in 
registry-based studies.58 We feel further study of the involvement of OSA in the etiology 
of Parkinson’s disease, and as driver of our findings is warranted based on several ob-
servations. First, the etiology of obstructive respiratory events strongly involves factors 
related to the airways, and not only central nervous system integrity. It may therefore 
be less susceptible to potential reverse causation effects than other sleep disorders in 
its relation to risk of neurodegenerative disease. Second, sequelae of OSA may poten-
tially impact Parkinson’s disease and its pathological features.59,60 Third, a meta-analysis 
showed that OSA may be less prevalent in early Parkinson’s disease cases versus con-
trols,61 which seems incongruent with Parkinson’s disease as the primary cause of OSA. 
This has been attributed to increased rigidity in the upper airway reduces sleep-related 
collapse and obstructive events around the time of diagnosis.58 However, most studies 
reporting a link of OSA and incident Parkinson’s disease are registry-based studies which 
may be prone to diagnostic bias,58 supporting the need for population-based prospec-
tive cohort studies implementing multimodal ascertainment of Parkinson’s disease.
Further research into the role of sleep disturbances as marker of prodromal Parkinson’s 
disease, or as potential risk factors to disease development seems warranted. To this 
end, population-based, prospective cohort studies such as the Rotterdam Study, that 
implement aforementioned ascertainment for incident disease as well as measurement 
of endophenotypes such as gait or symptoms of brady- or hypokinesia or rigidity, may 
well complement findings from cohort with individuals with RBD. Future studies may 
226
CHAPTER 5
also want to determine to what extent our results are generalizable to patients with 
early-onset Parkinson’s disease.
METHODOLOGICAL CONSIDERATIONS
Sleep seems to be a highly variable phenomenon between persons and over time (see 
Chapter 2.1).1,62 As hinted on in the ‘General introduction’ of this thesis, how normal we 
think sleep is contrasts sharply with how poorly we understand sleep in terms of its 
causes and consequences. This lack of knowledge is what makes sleep an interesting 
topic to study, especially in a population-based setting. At the same time, this inherently 
involves making several assumptions, some of which are not explicitly mentioned in the 
discussion sections of each chapter. The focus of this thesis was mainly on determining 
sleep’s consequences. Here I further discuss sleep’s neurobiological underpinnings and 
measurements, and how these are relevant to interpret the link with risk of neurodegen-
erative disease.
Multidimensionality of sleep
Sleep is a complex process or state, involving the orchestrated activity of diverse neu-
ronal populations across the entire brain.50,63,64 The dominant model for understanding 
how sleep and wake fluctuate at a systems level is the two-process model: Sleep depends 
on an interaction between a sleep homeostatic process and a circadian timing process.65 
Sleep homeostasis compensates sleep loss with extra sleep, operates throughout the 
brain and is indicated by slow-wave activity on the sleep electroencephalogram. Cir-
cadian timing is characterized at a cellular level by expression of proteins that inhibit 
their own production, fluctuating with a period of about 24-hours.11 The master clock 
in the hypothalamic suprachiasmatic nucleus integrates circadian rhythms throughout 
the body.66 Various brain nuclei and projections throughout the brainstem, frontal lobe 
and limbic system, using different neurotransmitter and hormonal systems, effectuate 
aforementioned processes.50
The approach to study this intangible process is ‘multidimensional’, reflected by the 
variety of levels, neurobiological to psychological, or characteristics on which sleep is 
measured.63 Sleep can be appreciated through e.g. subjective appraisal, lack of move-
ment, or slow-wave activity on electro-encephalography, all of which can estimate the 
same quantifiable characteristics such as total sleep time.63 In line with this multidimen-
sionality, we measured sleep using self-report, actigraphy in combination with diaries, 
or polysomnography, or a combination of these where deemed possible or appropriate.
Please note that our population-based measures were largely not designed to diagnose 




or deficient sleep versus ‘normal’ sleep (the ‘tip of the iceberg’ of sleep disturbances). 
Analogously, we studied sleep characteristics on a continuous scale, assuming that this 
conveyed information on subclinical but relevant abnormal sleep. Also, we assumed 
that our single measurements were to some extent stable over time and thus indicative 
of chronic exposure to a certain level of normal/abnormal, or good/poor, sleep.
Subjective versus objective measurements
Subjective measurements of sleep have been preferred in large-scale studies for their 
ease of administration and low costs. In general, subjective appraisal is inherently valu-
able as it expresses well-being. In sleep research, such measures are also relevant as 
they may drive seeking healthcare, and signal sleep problems that matter to individuals. 
Objectively measured sleep can only explain a part of the subjective appraisal of sleep’s 
quality.67,68 The role of subjective evaluation in sleep medicine, for example in insomnia 
diagnosis and treatment,69 is, and remains, important regardless of increasing techno-
logical advances.
Yet, subjective quantification of sleep characteristics such as total sleep time may sub-
stantially differ from those obtained by methods taking physiological measurements, 
e.g. actigraphy.6,70 This disagreement itself could of course be of interest, e.g. to assess 
insomnia severity.67 Nevertheless, disagreement between methods is not random and 
may introduce bias.6,71 If we are primarily interested in studying e.g. total sleep time, 
a characteristic best quantified physiologically, use of self-reported total sleep time 
means it will be misclassified and as such may introduce bias and hamper etiological 
inference. This issue is eloquently voiced by Bianchi and colleagues, who also highlight 
that using self-reported total sleep time increases the potential for confounding by 
unknown factors leading to systematically over- or underestimated total sleep time.5 
Especially cognition should be considered here. The importance of cognitive processes 
for reporting sleep is well illustrated by a study showing consistent differences for dif-
ferent constructs according to using a direct or indirect method of querying sleep.72 
Cognitive impairment may further reduce the validity of self-reporting sleep (see 
discussion of Chapter 3.1), possibly so that persons with lower cognitive functioning 
overstate their actigraphy-estimated sleep duration,6 and patients with Alzheimer’s 
disease underreport problematic sleeping in the face of evidently poor sleep estimated 
with actigraphy.10 Besides cognition, affective factors are also relevant, as self-reported 
total sleep time is inextricably linked to mood.6,73,74 Health-related factors as discussed 
by researchers from the Sleep Heart Health Study are also important to consider.75
We encountered inaccuracy in self-reporting time-related sleep characteristics in 
our meta-analysis (see Chapter 2.1), where up to 10% of individuals in some cohorts 
reported longer total sleep time than their time spent in bed. Moreover, this disagree-
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ment in methods determined the difference in findings with regard to dementia risk in 
this thesis (see Chapters 3.1 and 3.2).
Some researchers respond to these inherent limitations of self-reported sleep data by 
carefully discussing these challenges, while others advocate we radically stop querying 
self-reported total sleep time.5 We discussed possible biases and, where possible, used 
more objective methods to quantify sleep. Also, not knowing what determines these 
self-reported measures precludes actionable, preventive interventions to benefit public 
health when studying these measures (see paragraph “From sleep epidemiology to 
prevention”).76
Reverse causation
Alzheimer’s disease, the most common form of dementia, and Parkinson’s disease 
are degenerative diseases hypothesized to be present long before diagnosis can be 
made.52,53,77 Prospective cohort studies using structured repeated assessments show 
that subtle cognitive or motor deficits are already appreciable for up to a decade 
before the diagnosis in patients versus controls.78-80 Besides typical disease-related 
characteristics, more non-specific neuropsychiatric symptoms may also be present in 
this prediagnostic phase, such as depressive symptoms,78,81,82 or physical inactivity for 
Alzheimer’s disease.83,84 When such factors are investigated as potential risk factors 
for incident dementia in non-demented individuals followed up over time, they may 
temporally precede a dementia diagnosis and be labeled a risk factor when truly there 
is no causal relation. Instead, the temporal relation is causal but reversed, which can 
also be thought of as confounding by the underlying pathological processes. Sleep is 
also subject to this phenomenon. Neurodegenerative pathology may directly influence 
brain regions that generate or propagate sleep,36,85,86 or may affect sleep and 24-hour 
activity rhythms through other prodromal or non-specific symptoms or signs, e.g. physi-
cal inactivity, apathy, decreased light exposure.
We examined potential reverse causation by stratifying analyses on follow-up time, 
simulating premature study endings. We restricted follow-up to the first e.g. 2 years after 
baseline, censoring all at-risk participants, and then incrementally increased follow-up 
from 2 years towards the duration of the overall follow-up, simulating shorter-duration 
studies within our own study. We did not exclude the first years of follow-up, selecting 
persons on not getting the outcome for the first e.g. 2 years, which has been described 
to potentially lead to selection bias.87 We assumed that a decrease in strength of effect 
sizes with increasing follow-up time indicates preclinical or prodromal disease disturb-
ing sleep at baseline (see Chapter 3.3).
This analytical approach to reverse causation seems worthwhile to pursue in an 
individual-participant data framework on sleep and incident dementia, as done by oth-




stratifying existing studies on median total follow-up time as previously performed7,9 is 
a less sensible approach to examine potential reverse causation, as single risk estimates 
averaged over long study follow-up may still be driven only by a strong relation in the 
first few years of follow-up.
Please note that aforementioned approach to detect reverse causation only shows a 
temporal relation, and cannot prove reverse causation. This means that a typical pat-
tern indicating reverse causation does not prove the absence of any causal effect of 
the exposure on the outcome. The exposure may also be a step in a multistage process 
that harms only in a certain opportune window. Evidence for such a multistage process, 
requiring accumulation of several sequential pathological ‘hits’, may be found in inci-
dence data in prospective cohorts for dementia.88 Also, a temporal relation indicative of 
reverse causation does not exclude the possibility of confounding of the relation of the 
exposure and risk of the outcome by genuine, unknown risk factors.
From sleep epidemiology towards prevention or treatment
Epidemiological studies not only aim to provide quantifiable insight into the etiology of 
disease but also to contribute information to prevent disease. This second step should 
be highlighted to show that identifying risk factors does not necessarily allow taking 
preventive action.89 A difference between the two can be identified within the potential 
outcomes framework, or counterfactual framework, of causal inference.90 The difference 
is that the sleep exposures studied by epidemiologists may differ from what is reason-
ably intervened upon to change that exposure.
Take the following example: Reducing high BMI may seem like a reasonable objective 
in public health. Yet, different interventions to reduce BMI tackle different underlying 
biological processes. Examples include giving lifestyle advice, prescribing diets, per-
forming bariatric surgery, but also amputating a limb.91,92 Amputation seems effective to 
reduce BMI, yet everybody would agree it would not reduce risk of cardiovascular out-
comes or mortality. Why not? Clearly, the underlying biological substrates of increased 
BMI, its directly identifiable upstream causes, increase the risk, not necessarily BMI itself. 
Considering BMI as risk factor for mortality still lacks the actionable information needed 
to inform public health policies.
As discussed earlier, sleep is a process involving various neurobiological and neu-
rotransmitter systems, and is pragmatically measured across multiple dimensions. 
Analogous to the BMI example, this suggest a potential for a disconnect between 
observational exposures and potential interventions. Let’s pretend that we performed 
the perfect observational study on the relation of actigraphy-estimated sleep with de-
mentia risk, and found an association of short total sleep time with increased dementia 
risk. How do we then increase total sleep time, and will this reduce dementia incidence? 
Pharmacological interventions, typically sedative hypnotics, may not necessarily mimic 
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naturalistic sleep.93 Interventions such as cognitive behavioral therapies are designed 
to address dysfunctional thoughts or behaviors regarding sleep. This may renormalize a 
short total sleep time, yet problematic cognition or behavior may have not necessarily 
been the problem underlying short total sleep time. Moreover, behavioral changes to 
increase sleep, i.e. deciding to get more sleep, is only indirectly achieved by extending 
sleep opportunity in the hopes of getting more sleep.
Even if we studied an exposure that was more clearly defined in terms of the underly-
ing biology, e.g. slow-wave sleep, there may still be a disconnect between observational 
exposure and potential interventions. Pharmacological interventions that enhance 
slow-wave activity and therefore slow-wave sleep, may differ in other effects that differ-
entially relate to the outcome under study.94 Specifically enhancing slow-wave activity 
during sleep may also be achieved through waking activities (meditation, cognitive ac-
tivity, physical activity), sensory stimulation during sleep (acoustic, olfactory, vestibular 
stimuli), or non-invasive transcranial electromagnetic stimulation.95 Interestingly, these 
different interventions are also associated with a better performance on cognitive tasks,95 
even in older adults,96 supporting a key role for slow-wave activity or sleep in cognition 
and providing a basis for targeted treatment or prevention of cognitive impairments.
A more thorough understanding of the neurobiological determinants of sleep may 
help to design interventions towards preventative action. This does however not pre-
clude that appropriate interventions may have a different effect than what was derived 
from observational studies.97
Identifying a risk factor in observational studies is a process of reasonably excluding 
biases and chance and then accepting that whatever remains is the causal relation of 
that exposure with your outcome. Aforementioned example suggests that not only is 
short total sleep time not defined well enough in terms of its corresponding interven-
tion, but that this lack of specificity in its definition is hampering our ability to know to 
what extent our association is unconfounded.92 This principle seems to apply not only to 
total sleep time but to a number of sleep exposures in epidemiological studies, includ-
ing ours. It is therefore important to stress that current sleep epidemiological findings 
should be considered more an important first step than research efforts lacking action-
able information. Epidemiologists advocating the use of well-defined interventions in 
the potential outcomes framework are in my opinion advocating pragmatism, and as 
such may understand that current population-based studies pragmatically investigate 
sleep through feasible measures first. If no relation exists, valuable resources are better 
invested elsewhere.
Threats to validity of sleep findings
Several threats, or biases, may have affected the validity of the findings in this thesis. 




validity, and limited generalizability. We tried to account for these potential biases in the 
analysis phase, or discussed them, per chapter. Here, I want to briefly highlight the issues 
of confounding, and generalizability.
Confounding indicates that a third factor, a cause of both the exposure and outcome, 
distorts their relation.98 Confounding in observational research is ubiquitous. Recogniz-
ing the potential for confounding, trying to reduce confounding or at least discuss the 
potential for confounding based on someone’s expert knowledge is a prerequisite in any 
attempt to produce methodologically sound results.99 Selection of potential confound-
ers was informed on literature where possible.98 Further studies on what determines our 
population-based measures of sleep, especially brain determinants, seems important to 
improve adequate control for confounding in future.
The importance of recognizing potential confounding in observational sleep research 
is illustrated by an example focused on the rare, neurodegenerative disease Fatal Fa-
milial Insomnia (FFI). This disease involves abnormal folding of the brain’s own prion 
proteins, related to a specific genetic polymorphism in the gene encoding prion protein. 
It is characterized by a progressive, severe lack of sleep, and patients often die within a 
year of diagnosis. One thus observes a lack of sleep linked to a high mortality rate. While 
sleep disturbance can certainly impact health and well-being, and may contribute to an 
increased risk of dying, the apparent association of sleep disturbance in FFI with high 
mortality is likely confounded by the underlying neurodegenerative process. Sleep dis-
turbances in FFI are therefore not proof that a lack of sleep is life-threatening in humans.
As a rule of thumb, one should be very critical in interpreting observational associa-
tions as causal. This is especially important as aforementioned example may lead families 
of patients with FFI to believe that treating sleep disturbances may have prolonged the 
life of their loved one, for which currently no evidence exists. I find this an interesting 
example as it featured in the popular book on sleep “Why We Sleep” by Matthew Walker 
published in 2017,100 which evoked criticisms in the form of blogs on social media,101,102 
and a sportsman-like response by the author.103 It is also of personal interest as I have 
been in personal contact with patients with prion disease and their families, during my 
work as physician for the Dutch National Prion Registry. Having witnessed how espe-
cially family members deal with scarce information available on these severe disorders, 
I find it all the more important that the information on possible treatments is accurate.
Regarding generalizability, studies embedded in the Rotterdam Study were based on 
predominantly individuals from European descent, with a middle-to-high income.104 We 
found that subjective appraisal of sleep was poorer in the US compared to the Nether-
lands and the UK (see Chapter 2.1). Interestingly, meta-analyses on the relation of mostly 
self-reported sleep characteristics with dementia and Alzheimer’s disease risk showed 
that results obtained from European studies were similar to those from North-American 
studies.7,9 Nevertheless, cross-cultural heterogeneity in the social timing of sleep and 
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its role in daily life,105 especially in aged individuals studied in this thesis, may limit the 
generalizability of our findings.
IMPLICATIONS
Clinical
We aimed to study sleep’s role in the etiology of neurodegenerative disease, in a 
population-based setting, and studied sleep mostly in otherwise healthy individuals. 
Therefore, findings have limited implications for patients and healthcare professionals. 
Nevertheless, several points may be of clinical interest.
First, descriptive sleep data from our meta-analysis provides a data-driven view on ex-
tremes in sleep, e.g. through percentile curves, which may be used as an evidence-based 
starting point to actively screen for underlying sleep disorders. Cut-offs are applicable to 
the general population, and further evaluation of their accuracy and overall usefulness 
in more selected populations, e.g. patients visiting a general practitioner with a sleep 
complaint or something related, or visiting a sleep clinic, should be performed.
Our data show that sleep complaints are common, especially with increasing age in 
older adults, providing a potential target for sleep improvement at the population level. 
At the same time, the same data can be interpreted as sleep problems being something 
‘normal’. If indeed sleep complaints, after evaluation by a healthcare professional, are 
not in need of further diagnostic tests or therapeutic interventions, our data could be 
used to reassure individuals with sleep complaints that their problems are common.
Second, dementia patients and their families can be informed that poor sleep in late 
life is associated with an increased risk of dementia, or vice versa, that poor sleep may 
precede a diagnosis of dementia by years. This may not necessarily be reflected in sub-
jective appraisal of sleep, although we did not investigate whether in retrospect sleep 
problems may be recognized. Also, our results show that typical changes in 24-hour 
activity rhythms that may constitute prodromal dementia features are an advance in 
sleep phase and earlier bedtime. Explaining these disease-related changes to patients 
and loved ones may help them gain a sense of understanding of, and therefore perhaps 
control over, the very serious problems they are faced with.
Third, patients with Parkinson’s disease with questions regarding sleep could be 
informed that having more sleep complaints and reporting a shorter sleep duration are 
prodromal features of the disease that may occur on average at least two years before 
a diagnosis.
Although we could not reasonably show relations of sleep and incident outcomes 
that indicate a causal effect, optimizing sleep and circadian rhythms seem reasonably 




about perceived sleep problems seems warranted, for which Dutch healthcare profes-
sionals may find the structured NHG-standaard approach useful.106
Public health
Our meta-analysis results show what is ‘normal’ for different sleep characteristics, dif-
ferent from the expert recommendations of the US National Sleep Foundation about 
what constitutes ‘good’ sleep. This provides an alternative, more pragmatic benchmark 
for future sleep studies. Our findings show that sleep complaints are common and not 
necessarily explained by aberrant sleep times. An association of more insomnia symp-
toms with above-normal time in bed suggests a place for interventions to reduce the 
time in bed as used in insomnia disorder treatment, i.e. non-pharmacological, cognitive-
behavioral interventions. Education is a key part of such interventions, so large-scale 
education of the public seems at first glance a potentially efficacious route to try and 
shift the population distribution of insomnia symptoms. Debunking false myths about 
sleep that have public health sleep significance107 may be part of that approach. Pos-
sibly, as mentioned above, providing state-of-the-art cognitive behavioral therapy for 
insomnia via digital channels may provide a scalable alternative to effectively reduce 
insomnia complaints and related mental health problems.3,4
Important caveats that should be kept in mind is that digital health interventions may 
not reach elderly persons, especially the more vulnerable, cognitively impaired persons 
who are expected to have substantial benefit.108,109 Nevertheless, use of smartphone in 
elderly persons seems to be on the rise, at least in the Netherlands,110 and with it may 
come increased openness to engage with digital health solutions. Also, an important 
caveat in any attempt to communicate the importance of sleep to the general public is 
that attention to sleep equals worry about sleep, which is bad for sleep.
Future research
Designing future sleep research focused on etiology of neurodegenerative diseases may 
be well informed by thinking about the most optimal observational study, with infinite 
resources at our disposal, that may be performed to support causal claims.
Ideally, we would need a large-scale (10,000+ participants) cohort study, that from 
midlife onwards111 repeatedly measures sleep with polysomnography and actigraphy, 
measure state-of-the-art, disease-related brain markers (CSF, blood, non-invasive 
neuroimaging), combined with continuous follow-up to diagnose neurodegenerative 
disease. Imaging approaches may focus on specific sleep-regulatory nuclei such as the 
locus coeruleus,112-114 which shows Alzheimer’s disease-related tau pathology early in 
life,35,115 and may play a role in RBD, a sleep disorder specific to development of alpha-
synucleinopathies.116 Functional imaging approaches would need to ensure simulta-
neous vigilance/sleep measurement, e.g. by combining fMRI/EEG to properly assess 
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sleep’s role in functional changes of the brain across time.117 Measuring from mid-life 
onwards may help establish a potential window of opportunity for preventive action.118 
Polysomnography must include a screening approach to further evaluate persons with 
possible RBD. Data analysis may include implementing causal inference methods, e.g. 
g-methods to deal with unmeasured confounding and time-varying confounding,119 or 
a 4-way decomposition analysis to deconstruct the potential interaction and mediation 
of sleep with Alzheimer’s disease pathology on risk of dementia.120,121
Unfortunately, this sleep study will remain a dream. Until then, we need to investigate 
both determinants as well as consequences of sleep in the general middle-aged and 
elderly population. Important avenues to pursue are linking brain structure and func-
tion to objective sleep and 24-hour activity rhythm characteristics, and leverage genetic 
data to establish the biological basis of our sleep measures, for which there is increasing 
attention.122 Both approaches are probably best executed in collaboration, such as the 
ENIGMA consortium for sleep neuroimaging studies, or setting up new collaborations 
to achieve large sample sizes for much-anticipated genome-wide associations studies 
on objective sleep and 24-hour activity rhythm phenotypes. Understanding the link of 
sleep and dementia may also be better achieved by using Mendelian randomization,123 
or leveraging genetic risk scores, to assess the associations of genetic correlates of 
certain sleep characteristics with dementia risk and vice versa. Using repeated measures 
of sleep to investigate what determines trajectories of sleep in aging will help elucidate 
relevant underlying factors in the context of slowly progressive neurodegenerative dis-
eases. Yet, most importantly, one of the key first steps towards better understanding the 
potential causal role of sleep disturbances in dementia is to account for disease-related 
neuropathological factors. Our approach using plasma-based biomarkers is an example 
of a feasible design to study this in large, population-based samples.
Besides pragmatic studies on the risk of neurodegenerative disease and related neuro-
biological correlates, several assumptions regarding the relation of sleep and Alzheimer’s 
disease pathology should also be addressed. These mostly concern the translation of 
laboratory findings to a ‘real world’ setting. For example, it is unclear how effects of acute 
sleep deprivation on pathology relate to the often less severe but chronic disturbances 
observed in real-life. For example, a 5-day chronic sleep restriction regime differed from 
acute sleep deprivation in microglia activation in mice,44 and the history of sleep may be 
carried forward and help determine behavioral performance days later.124 It is therefore 
unclear if a) chronic disturbances equate repeated acute disturbances, i.e. repeatedly 
elevate beta-amyloid levels, and if b) this leads to higher rates of plaque deposition, and 
if c) this leads to accelerated cognitive and functional deterioration. Acute excesses of 
beta-amyloid may also be adequately removed from interstitial or cerebrospinal fluid 




elevate beta-amyloid isoforms or other biomarkers of detrimental processes in cerebro-
spinal fluid or plasma.126,127
Population-based studies may also provide insights into how sleep determines 
Alzheimer’s disease pathology over time. Yet, so far only one study determined lon-
gitudinal changes in amyloid deposition.128 Authors reported that excessive daytime 
sleepiness in non-demented individuals increased amyloid deposition over 2.2 years 
on average. Potential confounding was discussed but not yet taken into account in the 
analyses.
CONCLUSION
We conclude that sleep complaints are common in elderly persons, more so than an 
inadequate sleep duration. Poor sleep was associated with incident neurodegenerative 
disease. In the case of self-reported sleep quality and duration in relation with Parkinson’s 
disease, patterns of associations suggest that poor sleep is a prodromal feature of the 
disease, whereas in the case of actigraphy-estimated nighttime wakefulness preceding 
all-cause dementia and Alzheimer’s disease, the link seemed not explained by known 
potential confounders.
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“The bed is open; the toothbrush hangs on the wall,
Put your shoes at the door, sleep, prepare for life.”
The last twist of the knife. 












Sleep is a normal phenomenon, yet poorly understood. Emerging neurobiological in-
sight into sleep suggests it serves several vital functions for the brain. These imply that 
disturbed sleep may contribute to brain disease. Specifically a link of sleep disturbances 
with age-related neurodegenerative diseases seems interesting as sleep’s role in brain 
health overlaps with pathological processes of these diseases. In this thesis, I examined 
how sleep is related to risk of dementia, including Alzheimer’s disease, and Parkinson’s 
disease, and related neurobiological correlates.
First, we aimed to describe sleep in the general population (Chapter 2.1). We collected 
individual-level data from 36 Dutch sleep cohorts, as well as objective and subjective 
sleep data from different countries, and investigated potential determinants. Summa-
ries of basic sleep characteristics such as sleep duration per night were given across 
the lifespan in percentile curves. We found that, of the 200,358 individuals from Dutch 
population-based studies, most persons had a sleep duration within the “acceptable” 
range according to US guidelines. Clearly delineable groups with poorer sleep were 
teenagers, and women. Adults that reported spending 7-8 hours in bed report the least 
sleep problems, and problems seemed to differ whether time in bed is higher or lower 
than that. While self-reported sleep duration in adult populations from the Netherlands, 
UK and US is similar, insomnia symptoms are more prevalent in the US than in the Neth-
erlands.
Objective sleep estimates showed that while women report sleep as shorter or poorer, 
actigraphy estimates suggest that they actually sleep longer and more efficient than 
men. When using the self-report recommendations, actigraphy-estimated sleep dura-
tion is below the recommended level for over 80% of adults aged 40 years and over. 
Recommendations for actigraphy-estimated sleep are currently lacking. Consistent 
across studies and countries, poor sleep quality is a greater perceived problem than 
short sleep, a finding that calls for targeting sleep quality improvement
We also reviewed the relation of 24-hour activity rhythms, as a measure of circadian 
rhythm functioning, with various disease outcomes, including neurodegenerative dis-
ease (Chapter 2.2). An increasing number of studies uses actigraphy to study the circa-
dian rhythm, yet most studies are cross-sectional or are not performed in the setting of 
a prospective cohort, making it hard to draw temporal inference. Especially neurode-
generative diseases are commonly investigated, where the few longitudinal studies that 
were performed suggest that 24-hour activity rhythm disturbances precede dementia, 
which should be studied further (see chapter 3.2).
Based on previous studies suggesting a relation of disturbed sleep with incident 
dementia, we further investigated the relation of sleep, assessed both with question-




and Alzheimer’s disease. First, in chapter 3.1, we specifically focused on subjective sleep 
quality assessed with the Pittsburgh Sleep Quality Index (PSQI). We found no relation of 
the PSQI score, nor its components, with incident dementia or Alzheimer’s disease. In 
contrast, actigraphy-estimated poorer sleep was associated with a higher risk of demen-
tia, including Alzheimer’s disease.
In line with the knowledge gap identified in chapter 2.2, we also investigated the asso-
ciation of actigraphy-estimated 24-hour activity rhythm characteristics with dementia. 
Disturbed activity rhythms, based on its variability and stability, were not related to 
dementia risk. We found an association of an earlier ‘lights out’ with increased dementia 
risk, which was especially strong in the first 2 year of follow-up. Also, an earlier onset of 
the least 5 active hours of the day were associated with a higher risk of dementia in the 
first 2 years of follow-up, which may be congruent with an advance in activity rhythms, 
as marker of circadian disturbance, as a late prodromal feature of dementia.
Besides dementia, we also investigated Parkinson’s disease (Chapter 3.3). We de-
termined the relation of self-reported sleep duration and sleep quality, as well as the 
changes in these sleep characteristics over two measurements, with incident parkinson-
ism, including Parkinson’s disease. Poorer sleep quality and shorter sleep duration were 
associated with an increased risk of Parkinson’s disease in the first 2 years of follow-up, 
disappearing with increasing follow-up. Also, a shortening of sleep duration and a wors-
ening of sleep quality over repeated measurements were associated with an increased 
risk of Parkinson’s disease. Both observations were congruent with a progressive dete-
rioration of sleep towards the diagnosis of Parkinson’s disease, i.e. of a deterioration of 
sleep as a prodromal feature of Parkinson’s disease.
In chapter 4, we further investigated potential neurobiological correlates of sleep. We 
investigated the relations of questionnaire-assessed and actigraphy-estimated sleep 
with neurofilament light chain (NfL), and also beta-amyloid isoforms and total tau, as-
sessed in plasma. We found no association of sleep characteristics with these plasma 
biomarkers of neurodegenerative disease, except for an association of a longer self-rated 
time in bed with a higher NfL concentration. The lack of associations of sleep character-
istics with biomarkers of neurodegenerative disease suggest that these processes do 
not confound, or mediate, the association of poor sleep with incident dementia.
Sleep has been hypothesized to clear waste from the brain, enhancing fluid exchange 
across the ‘glymphatic’ system. We investigated the relation of sleep with enlarged peri-
vascular spaces on brain MRI as a potential marker of impaired waste clearance through 
the glymphatic system. We found an association of higher actigraphy-estimated sleep 
efficiency with higher perivascular space count in the centrum semiovale. The direc-
tion of this cross-sectional association contrast with previous clinical and population-
based studies in humans. We discuss the various explanations of this finding, including 
246
CHAPTER 6
a speculation that perivascular spaces may signal a physiological aspect of the brain 
beneficial to sleep.
In chapter 4.3, we investigated the brain’s functional connectivity through resting-
state functional MRI which may sensitively detect any relevant consequences poor 
sleep may have on the brain in middle-aged to elderly persons. We found that a longer 
polysomnography-derived total sleep time was associated with a lower signal ampli-
tude in especially (pre)frontal regions. This cross-sectional association may indicate that 
total sleep time affects the repertoire of brain activity in those regions, that regional 






Slaap is, voor een alledaags fenomeen, slecht begrepen. Nieuwe inzichten vanuit de 
neurobiologie geven aan dat slaap het brein op verschillende belangrijke manieren 
ondersteunt in zijn functioneren. Er wordt hierbij gesuggereerd dat verstoorde slaap 
bij kan dragen aan het ontstaan van hersenziekten. Specifiek is de invloed van slaap 
op veelvoorkomende neurodegeneratieve ziekte interessant, aangezien de biologische 
effecten van slaap op het brein volgens dezelfde processen zouden verlopen als de 
pathologische processen in deze ziekten. In dit proefschrift onderzoek ik de relatie tus-
sen slaap en het risico op dementie, waaronder het Alzheimer subtype, de ziekte van 
Parkinson, en andere aspecten van het brein die gerelateerd zijn aan deze ziekten.
Eerst beschreven we slaap op populatieniveau (hoofdstuk 2.1). We verzamelden 
slaapdata van personen uit 36 onderzoekscohorten in Nederland, en subjectieve en 
objectieve slaapdata uit andere landen ter vergelijking. We beschreven verschillen naar 
leeftijd en geslacht, en onderzochten de relatie van diverse andere factoren met slaap 
variabelen. We vatten de data van slaapduur samen met percentiel curves over leeftij-
den van 1 tot 100 jaar, van 200,358 Nederlanders. De meeste mensen rapporteerden 
een slaapduur die paste bij de aanbevolen slaapduur voor hun leeftijd. Adolescenten 
en ook vrouwen waren subgroepen die relatief vaak slechte slaap rapporteerden of 
een inadequate slaapduur aangaven. Volwassenen die een tijd in bed rapporteerden 
tussen de 7 en 8 uur klaagden het minst over hun slaap. Het type slaapproblemen leek 
te verschillen tussen mensen die te kort versus te lang in bed lagen. We vonden dat zelf-
gerapporteerde slaapduur vergelijkbaar is tussen Nederland, het Verenigd Koninkrijk en 
de Verenigde Staten (VS), maar dat klachten over de slaap vaker voorkomen in de VS 
dan in Nederland. Objectieve schattingen van slaap middels beweging gemeten met 
actigrafie lieten zien dat vrouwen juist iets beter slapen dan mannen, tegenovergesteld 
aan wat zij rapporteerden. Aanbevelingen voor slaap gemeten met actigrafie zijn er 
momenteel niet, maar is nodig aangezien de huidige, op vragenlijsten gebaseerde aan-
bevelingen, stellen dat de meeste volwassenen te weinig zouden slapen gebaseerd op 
actigrafie (80% van de populatie heeft dan een slaapduur korter dan aanbevolen voor 
de leeftijd). De belangrijkste bevinding van dit onderzoek lijkt dat klachten over de slaap 
meer voorkomen dan een afwijkende slaapduur, wat suggereert dat verbeteringen van 
de slaap op populatieniveau niet zozeer te bereiken zijn door mensen te adviseren over 
de juiste slaapduur. 
Naast deze grote beschrijvende studie maakten we ook een niet-systematisch over-
zicht van studies naar de relatie van 24-uurs activiteitsritmes, als maat van het circadiane 
ritme, met neurodegeneratieve ziekten en andere veelvoorkomende aandoeningen op 
oudere leeftijd. Het aantal studies naar 24-uurs activiteitsritmes neemt de afgelopen 
jaren duidelijk toe, maar voornamelijk nog met een dwarsdoorsnede studie opzet. 
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Longitudinale studies zijn nodig om een temporeel verband te vinden tussen versto-
ringen van activiteitsritmes met dementie en andere neurodegeneratieve ziekten. Daar 
maakten we werk van in hoofdstuk 3.2. 
Op basis van eerdere studies, die een verband tussen slechte slaap en het risico op 
dementie lieten zien, onderzochten we enkele specifieke aspecten van slechte slaap 
verder, zoals slaapkwaliteit. We vonden dat slaapkwaliteit, ingeschat met de Pittsburgh 
Sleep Quality Index (PSQI), niet was gerelateerd aan het risico op dementie, noch het 
Alzheimer subtype. Ook de componenten van deze (zelf-gerapporteerde) slaapkwaliteit, 
die door anderen als risico-verhogend waren aangewezen, waren in onze studie niet 
geassocieerd met een hoger risico op dementie. In tegenstelling tot deze bevindingen 
voor slaapkwaliteit vonden we wel een relatie tussen slechter slapen en hoger dementie 
risico als slaap was bepaald met actigrafie. Met alle andere studies op dit gebied in over-
weging genomen, is het niet onwaarschijnlijk dat slecht slapen inderdaad geassocieerd 
is met een hoger risico op het krijgen van dementie. Of dat verband causaal blijft echter 
de vraag.
In navolging van de in hoofdstuk 2.2 geïdentificeerde behoefte aan longitudinale stu-
dies onderzochten we ook de relatie van actigrafie-bepaalde 24-uurs activiteitsritmes 
met dementierisico. Verstoorde ritmes, dat wil zeggen variabele en onstabiele ritmes, 
waren niet gerelateerd aan dementierisico. Vroeger het licht uitdoen om te gaan slapen 
was wel geassocieerd met een hoger dementierisico. Ook als de meest inactieve 5 uur 
van de dag eerder viel, was er een associatie met dementie in de daaropvolgende 2 
jaar, maar niet daarna. Beide bevindingen zijn congruent met prodromale dementie die 
het activiteitsritme verstoren, en het totaal aan bevindingen is niet ondersteunend voor 
een temporeel, mogelijk causaal, verband van verstoorde 24-uurs activiteitsritmes op 
dementierisico.
Ook onderzochten we de relatie van zelf-gerapporteerde kwaliteit en duur van slaap 
met het krijgen van een diagnose van een hypo-kinetisch rigide syndroom, inclusief de 
ziekte van Parkinson. Slechtere kwaliteit en kortere duur van slaap waren geassocieerd 
met een verhoogd risico op de ziekte van Parkinson, maar alleen in de eerste 2 jaar van de 
studie dan wanneer we langere periodes van follow-up analyseerden. Daarnaast vonden 
we ook dat een achteruitgang in slaap over twee rapportages gemiddeld enkele jaren 
uiteen, i.e. een verslechtering van de slaapkwaliteit en een verkorting van de slaapduur, 
geassocieerd was met een hoger Parkinson-risico nadien. De slaap lijkt dus progressief 
te verslechteren naarmate de diagnose dichterbij komt, wat we interpreteerden als 
slaapverslechtering als vroegtijdig signaal van de ziekte van Parkinson. 
In hoofdstuk 4 onderzochten we  middel dwarsdoorsnede onderzoeken de relatie van 
slaap met breinmaten die gerelateerd zijn aan neurodegeneratieve ziekten. We bepaal-
den de relatie van slaap, gemeten met de PSQI en actigrafie, met eiwitten indicatief voor 




waren het ‘lichte-keten’ neurofilament (NfL), twee vormen van beta-amyloid, en de 
totaal hoeveelheid tau. We vonden geen relaties tussen verschillende slaapaspecten en 
deze biomarkers, behoudens een associatie van een langere zelf-gerapporteerde tijd 
in bed met een hogere concentratie NfL. Die laatste associatie wijst waarschijnlijk op 
onderliggende aandoeningen. Het gebrek aan associaties in deze studie lijkt belangrijk, 
want deze suggereert dat de neurodegeneratieve processen gemeten met de biomar-
kers niet een gemeenschappelijke oorzaak zijn, noch een mediërende factor, van de 
eerdergenoemde relatie tussen slecht slapen en het risico op dementie. 
Een hypothese over de functie van slaap is dat deze een nachtelijke ‘hersenspoeling’ 
faciliteert waarin toxische afbraakproducten verwijderd worden. Die verwijdering van 
brein-‘afval’ zou plaatsvinden over het zogenaamde ‘glymfatische’ systeem, een systeem 
analoog aan het lymfatisch stelsel in de rest van het lichaam. Wij onderzochten de 
relatie tussen slaap en verwijde perivasculaire ruimten op een MRI van de hersenen, 
die dysfunctie van voorgenoemd glymfatisch systeem zouden indiceren. We vonden 
een associatie van hogere, actigrafie-bepaalde slaap efficiëntie met meer perivasculaire 
ruimte in één hersengebied, het centrum semiovale. De richting van de associatie was 
tegengesteld aan wat we hadden verwacht op basis van eerdere studies in de mens. 
In het hoofdstuk bespreken we de diverse interpretaties van deze bevindingen. Eén 
speculatieve verklaring is dat verwijding van de perivasculaire ruimten iets zegt over de 
fysiologie van het brein dat van voordeel is voor de slaap. 
In hoofdstuk 4.3 onderzochten we de relatie van slaap met het functioneren van de 
hersenen, gemeten met functionele MRI opgenomen tijdens een zogenaamde ‘rust-
staat’. Zo’n functionele MRI kan erg gevoelig zijn voor subtiele hersenveranderingen 
die mogelijk optreden als het gevolg van slecht slapen. We vonden dat een langere 
slaapduur, gemeten met polysomnografie, geassocieerd was met een lagere amplitude 
van het fMRI-signaal, in met name (pre)frontale hersengebieden. Deze associatie kan 
erop wijzen dat de slaapduur het repertoire van hersenactiviteit bepaalt in specifieke 
gebieden, of, vice versa, dat activiteit in specifieke hersengebieden bepalend is voor hoe 
lang je slaapt. Een derde verklaring is dat de slaapduur en de lokale hersenactiviteit een 
gemeenschappelijke oorzaak hebben. 
Als je het niet ziet zitten, ga liggen.
Based on: Jiggy Djé featuring Pete Philly. Ik Heb Je. De 
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Voor het bijwonen van de openbare 
verdediging van het proefschrift
SLEEP AND 
THE RISK OF 
NEURODEGENERATIVE 
DISEASE
A population-based approach
Woensdag 24 juni
Des middags om 15:30
Ten gevolge van de maatregelen 
omtrent het coronavirus zal de 
ceremonie plaatsvinden op een 
digitaal platform waarvoor u te zijner 
tijd toegang wordt verschaft.
Er zal tot nadere berichtgeving geen 
receptie plaatsvinden 
Thom S. Lysen
Claes de Vrieselaan 52A-1
3021 JR Rotterdam
Paranimfen:
Silvan Licher
Frank J. Wolters
promotie.thomlysen@gmail.com 
